Compositions and methods for suppressing pathogenic bacteria

Abstract

The present invention provides compositions and methods for suppressing pathogenic bacteria. [Solution] A composition is provided comprising (1) one or more purified bacterial strains belonging to the phylum Firmicutes or Bacteroidetes, and (2) one or more purified bacterial strains selected from the group consisting of Escherichia and Fusobacterium species.

Description

[Technical Field]

[0001] Related applications This application claims the benefits under Section 119(e) of the United States Patent Act, as provided for in U.S. Patent Application No. 62 / 884,917 filed on 9 August 2019, U.S. Patent Application No. 62 / 901,206 filed on 16 September 2019, U.S. Patent Application No. 62 / 947,517 filed on 12 December 2019, and U.S. Patent Application No. 63 / 031,299 filed on 28 May 2020. The entire contents of each of these referenced applications are incorporated herein by reference.

[0002] Government support This invention was made with government support under Grant No. 4500003237 granted by the Assistant Secretary of State for Preparedness and Response (HHS / ASPR) of the U.S. Department of Health and Human Services. The government has certain rights to this invention.

[0003] Compositions and methods for suppressing pathogenic bacteria are provided herein. Compositions and methods for treating diseases or disorders associated with bacterial colonization, or diseases or disorders associated with immune responses induced by bacteria are also provided herein. Compositions and methods for inducing regulatory T cell and short-chain fatty acid production in response to pathogenic bacteria are also provided herein. [Background technology]

[0004] Multidrug-resistant bacteria (MDROs, or "superbugs"), microorganisms that have developed resistance to one or more classes of antimicrobial agents, such as antibiotics, are emerging as a serious global health threat. In the United States, it is estimated that more than 2 million people suffer from serious bacterial infections resistant to one or more antibiotics each year (CDC, Antibiotic Resistance Threats in the United States, 2013; Publication No. CS239559-B). Treatment options for MDROs are extremely limited, making transmission prevention crucial. The most important factors contributing to the generation and proliferation of MDROs are antibiotic use and overuse / misuse, and the problem is expected to worsen as more antibiotic-resistant pathogens emerge (CDC, 2013; WHO 2017). [Overview of the project]

[0005] In some embodiments, the disclosure provides a composition comprising one or more purified bacterial strains belonging to the phylum Firmicutes or Bacteroidetes, and one or more purified bacterial strains selected from the group consisting of Escherichia and Fusobacterium species.

[0006] In some embodiments, one or more purified bacterial strains belonging to the phylum Firmicutes are bacterial strains belonging to the family Clostridium. In some embodiments, one or more purified bacterial strains belonging to the phylum Firmicutes are bacterial strains belonging to Clostridium cluster IV and / or Clostridium cluster XIVa. In some embodiments, one or more purified bacterial strains belonging to the phylum Bacteroidetes are bacterial strains belonging to the family Bacteroidaceae.

[0007] In some embodiments, one or more purified bacterial strains belonging to the phylum Firmicutes or Bacteroidetes are strains that produce short-chain fatty acids. In some embodiments, the short-chain fatty acid is butyric acid.

[0008] In some embodiments, the disclosure includes purified bacterial strains belonging to the species Escherichia, purified bacterial strains belonging to the species Fusobacterium, and Bifidobacterium pseudocatenulatum, Bifidobacterium adolescentis, Bifidobacterium longum, Clostridium citroniae, Clostridium clostridioforme, Clostridium bifermentans, Clostridium sordelli, Clostridium innocuum, Erysipelatoclostridium ramosum, Erysipelotrichaceae bacterium 6_1_45, Eubacterium hallii, Eubacterium rectale, Anaerostipes caccae, Blautia obeum, Blautia producta, Coprococcus comes, Dorea longicatena, Agathobaculum butyriciproducens, and Phascolarctobacterium The present invention provides a composition comprising one or more purified bacterial strains selected from the group consisting of Faecis species.

[0009] In some embodiments, the present disclosure provides a composition comprising a purified bacterial strain belonging to the species Escherichia, a purified bacterial strain belonging to the species Fusobacterium, and one or more purified bacterial strains selected from the group consisting of Bacteroides ovatus, Bacteroides thetaiotamicron, Bacteroides xylanisolvens, Bacteroides caccae, Bacteroides cellulosilyticus, Bacteroides faecis, Bacteroides fragilis, Bacteroides uniformis, Bacteroides vulgatus, Odoribacter splanchnicus, Parabacteroides distasonis, Parabacteroides merdae, Alistipes putredinis, and Alistipes shahii.

[0010] In some embodiments, the present disclosure provides a composition comprising a purified bacterial strain belonging to the species Escherichia, a purified bacterial strain belonging to the species Fusobacterium, and one or more purified bacterial strains selected from the group consisting of Collinsella aerofaciens, Bifidobacterium longum, Bacteroides ovatus, Bacteroides vulgatus, Alistipes putredinis, Clostridium citroniae, Clostridium clostridioforme, Erysipelatoclostridium ramosum, Erysipelotrichaceae bacterium 6_1_45, Blautia obeum, Blautia producta, Dorea longicatena, and Phascolarctobacterium faecium.

[0011] In some embodiments, the disclosure provides compositions comprising Clostridium bolteae, Anaerotruncus colihominis, Sellimonas intestinalis, Clostridium symbiosum, Blautia producta, Dorea longicatena, Erysipelotrichaceae bacterium, Flavinofractor plautii, purified bacterial strains belonging to the Escherichia species, and purified bacterial strains belonging to the Fusobacterium species.

[0012] In some embodiments, the present disclosure provides compositions comprising Anaerotruncus colihominis, Sellimonas intestinalis, Clostridium symbiosum, Dorea longicatena, Erysipelotrichaceae bacterium, Flavinofractor plautii, purified bacterial strains belonging to the Escherichia species, and purified bacterial strains belonging to the Fusobacterium species.

[0013] In some embodiments, this disclosure includes Clostridium saccharogumia (Clostridium ramosum JCM 1298), Flavonifractor plautii (Pseudoflavonifractor capillosus ATCC 29799), Clostridium hathewayi (Clostridium saccharolyticum WM1), Blautia coccoides (Lachnospiraceae bacterium 6_1_63FAA), multiple Clostridium species (Clostridium bolteae ATCC BAA-613), cf.Clostridium species MLG055 (Erysipelotrichaceae bacterium 2_2_44A), Clostridium indolis (Anaerostipes caccae DSM 14662), Anaerotruncus colihominis (Anaerotruncus colihominis DSM 17241), Ruminococcus species ID8 (Lachnospiraceae bacterium 2_1_46FAA), Clostridium lavalense (Clostridium asparagiforme DSM 15981), Clostridium symbiosum (Clostridium symbiosum WAL-14163), Clostridium ramosum, Eubacterium contortum (Clostridium species D5), Clostridium scindens (Lachnospiraceae bacterium The present invention provides a composition containing purified bacterial strains belonging to the species Escherichia, and purified bacterial strains belonging to the species Fusobacterium.

[0014] In some embodiments, the Disclosure provides compositions comprising Clostridium bolteae, Anaerotruncus colihominis, Sellimonas intestinalis, Clostridium symbiosum, Blautia producta, Erysipelotrichaceae bacterium, Flavinofractor plautii, purified bacterial strains belonging to the Escherichia species, and purified bacterial strains belonging to the Fusobacterium species.

[0015] In some aspects, the present disclosure relates to Collinsella aerofaciens, Bacteroides ovatus, Bacteroides thetaiotamicron, Bacteroides xylanisolvens, Bacteroides caccae, Bacteroides cellulosilyticus, Bacteroides faecis, Bacteroides uniformis, Bacteroides vulgatus, Odoribacter splanchnicus, Parabacteroides distasonis, Parabacteroides merdae, Alistipes putredinis, Alistipes shahii, Bifidobacterium pseudocatenulatum, Bifidobacterium adolescentis, Bifidobacterium longum, Clostridium citroniae, Clostridium clostridioforme, Clostridium innocuum, Erysipelatoclostridium ramosum, Erysipelotrichaceae bacterium The present invention provides a composition comprising 6_1_45, Eubacterium hallii, Eubacterium rectale, Anaerostipes caccae, Blautia obeum, Blautia producta, Coprococcus comes, Dorea longicatena, Agathobaculum butyriciproducens, Phascolarctobacterium faecis, purified bacterial strains belonging to the Escherichia species, and purified bacterial strains belonging to the Fusobacterium species.

[0016] In some aspects, the present disclosure relates to Collinsella aerofaciens, Bacteroides ovatus, Bacteroides thetaiotamicron, Bacteroides xylanisolvens, Bacteroides cellulosilyticus, Bacteroides uniformis, Bacteroides vulgatus, Parabacteroides distasonis, Alistipes putredinis, Alistipes shahii, Bifidobacterium adolescentis, Bifidobacterium longum, Clostridium citroniae, Clostridium clostridioforme, Clostridium innocuum, Erysipelatoclostridium ramosum, Erysipelotrichaceae bacterium 6_1_45, Eubacterium rectale, Anaerostipes caccae, Blautia obeum, Blautia producta, Coprococcus comes, Dorea longicatena, Agathobaculum The present invention provides a composition comprising butyriciproducens, Phascolarctobacterium faecis, purified bacterial strains belonging to the Escherichia species, and purified bacterial strains belonging to the Fusobacterium species.

[0017] In some embodiments, the Disclosure provides compositions comprising Bacteroides ovatus, Bacteroides thetaiotamicron, Bacteroides xylanisolvens, Bacteroides caccae, Bacteroides cellulosilyticus, Bacteroides faecis, Bacteroides uniformis, Bacteroides vulgatus, Alistipes putredinis, Alistipes shahii, Clostridium citroniae, Clostridium clostridioforme, Clostridium innocuum, Erysipelatoclostridium ramosum, Erysipelotrichaceae bacterium 6_1_45, Eubacterium hallii, Eubacterium rectale, Blautia obeum, Blautia producta, Coprococcus comes, Dorea longicatena, purified bacterial strains belonging to the Escherichia species, and purified bacterial strains belonging to the Fusobacterium species.

[0018] In some embodiments, the present disclosure provides a composition comprising Blautia producta, Bifidobacterium longum, Bifidobacterium adolescentis, Paeniclostridium sordellii, Bifidobacterium pseudocatenulatum, Erysipelatoclostridium ramosum, Escherichia coli, Clostridium clostridioforme, Paraclostridium bifermentans, Clostridium citroniae, Clostridium innocuum, Agathobaculum butyriciproducens, Clostridium innocuum, Dorea longicatena, Collinsella aerofaciens, Eubacterium hallii, Bacteroides faecis, Clostridium bolteae, Anaerotruncus colihominis, Drancourtella massiliensis, Clostridium symbiosum, Blautia producta, Dorea longicatena, Erysipelotrichaceae bacterium, and Flavonifractor plautii.

[0019] In some embodiments, the present disclosure provides a composition comprising Bacteroides cellulosilyticus, Bacteroides ovatus, Bacteroides thetaiotaomicron, Bacteroides uniformis, Bacteroides vulgatus, Bifidobacterium adolescentis, Bifidobacterium longum, Blautia producta, Clostridium citroniae, Clostridium clostridioforme, Clostridium innocuum, Clostridium innocuum, Coprococcus comes, Dorea longicatena, Erysipelatoclostridium ramosum, Eubacterium rectale, Parabacteroides distasonis, Bacteroides xylanisolvens, Blautia obeum, Alistipes putredinis, Collinsella aerofaciens, Eubacterium hallii, Anaerostipes caccae, Phascolarctobacterium faecium, Agathobaculum butyriciproducens, Fusobacterium mortiferum, and Escherichia coli.

[0020] In some embodiments, the present disclosure provides a composition comprising Bacteroides caccae, Bacteroides cellulosilyticus, Bacteroides ovatus, Bacteroides thetaiotaomicron, Bacteroides uniformis, Bacteroides vulgatus, Bifidobacterium longum, Blautia producta, Clostridium clostridioforme, Clostridium innocuum, Coprococcus comes, Dorea longicatena, Erysipelatoclostridium ramosum, Clostridium citroniae, Odoribacter splanchnicus, Parabacteroides distasonis, Bacteroides xylanisolvens, Blautia obeum, Alistipes putredinis, Collinsella aerofaciens, Alistipes shahii, Anaerostipes caccae, Phascolarctobacterium faecium, Agathobaculum butyriciproducens, Bacteroides fragilis, Fusobacterium mortiferum, and Escherichia coli.

[0021] In some embodiments, the present disclosure provides a composition comprising Bacteroides ovatus, Bacteroides vulgatus, Bifidobacterium adolescentis, Bifidobacterium longum, Bifidobacterium pseudocatenulatum, Blautia producta, Clostridium citroniae, Clostridium clostridioforme, Clostridium innocuum, Clostridium innocuum, Paeniclostridium sordellii, Coprococcus comes, Dorea longicatena, Erysipelatoclostridium ramosum, Eubacterium rectale, Odoribacter splanchnicus, Parabacteroides distasonis, Parabacteroides merdae, Bacteroides xylanisolvens, Blautia obeum, Alistipes putredinis, Collinsella aerofaciens, Eubacterium hallii, Alistipes shahii, Anaerostipes caccae, Phascolarctobacterium faecium, Agathobaculum butyriciproducens, Fusobacterium mortiferum, Paraclostridium bifermentans, and Escherichia coli.

[0022] In some embodiments, the present disclosure provides a composition comprising Bacteroides ovatus, Bacteroides vulgatus, Bifidobacterium longum, Blautia producta, Clostridium citroniae, Clostridium clostridioforme, Clostridium innocuum, Coprococcus comes, Dorea longicatena, Erysipelatoclostridium ramosum, Odoribacter splanchnicus, Parabacteroides distasonis, Bacteroides xylanisolvens, Blautia obeum, Alistipes putredinis, Collinsella aerofaciens, Alistipes shahii, Anaerostipes caccae, Phascolarctobacterium faecium, Fusobacterium mortiferum, and Escherichia coli.

[0023] In some embodiments, the present disclosure provides a composition comprising Bacteroides faecis, Bacteroides ovatus, Bacteroides vulgatus, Bifidobacterium adolescentis, Bifidobacterium longum, Blautia producta, Clostridium citroniae, Clostridium clostridioforme, Clostridium innocuum, Clostridium innocuum, Paeniclostridium sordellii, Dorea longicatena, Erysipelatoclostridium ramosum, Odoribacter splanchnicus, Blautia obeum, Alistipes putredinis, Collinsella aerofaciens, Eubacterium hallii, Anaerostipes caccae, Phascolarctobacterium faecium, Agathobaculum butyriciproducens, Bacteroides fragilis, Fusobacterium mortiferum, Paraclostridium bifermentans, and Escherichia coli.

[0024] In some aspects, the present disclosure relates to Bacteroides faecis, Bacteroides ovatus, Bacteroides vulgatus, Bifidobacterium longum, Blautia producta, Clostridium citroniae, Clostridium clostridioforme, Clostridium innocuum, Dorea longicatena, Erysipelatoclostridium ramosum, Odoribacter Compositions are provided that include splanchnicus, Alistipes putredinis, Collinsella aerofaciens, Blautia obeum, Anaerostipes caccae, Phascolarctobacterium faecium, Agathobaculum butyriciproducens, Fusobacterium mortiferum, and Escherichia coli.

[0025] In some embodiments, the Disclosure provides a composition comprising Bacteroides vulgatus, Clostridium citroniae, and Phascolarctobacterium faecium, and one or more purified bacterial strains selected from the group consisting of Bacteroides faecis, Bacteroides ovatus, Bifidobacterium longum, Blautia producta, Clostridium clostridioforme, Clostridium innocuum, Dorea longicatena, Erysipelatoclostridium ramosum, Odoribacter splanchnicus, Alistipes putredinis, Collinsella aerofaciens, Blautia obeum, Anaerostipes caccae, Agathobaculum butyriciproducens, Fusobacterium mortiferum, and Escherichia coli.

[0026] In some embodiments, the present disclosure provides a composition comprising Blautia producta, Bifidobacterium longum, Bifidobacterium adolescentis, Paeniclostridium sordellii, Bifidobacterium pseudocatenulatum, Erysipelatoclostridium ramosum, Escherichia coli, Clostridium clostridioforme, Paraclostridium bifermentans, Clostridium citroniae, Anaerostipes caccae, Fusobacterium mortiferum, Clostridium clostridioforme, Blautia obeum, Clostridium innocuum, Agathobaculum butyriciproducens, Clostridium innocuum, Dorea longicatena, Collinsella aerofaciens, Eubacterium hallii, Bacteroides faecis, Clostridium bolteae, Anaerotruncus colihominis, Drancourtella massiliensis, Clostridium symbiosum, Blautia producta, Dorea longicatena, Erysipelotrichaceae bacterium, and Flavonifractor plautii.

[0027] In some embodiments, the present disclosure provides a composition comprising Blautia producta, Bifidobacterium longum, Bifidobacterium adolescentis, Paeniclostridium sordellii, Bifidobacterium pseudocatenulatum, Erysipelatoclostridium ramosum, Escherichia coli, Clostridium clostridioforme, Paraclostridium bifermentans, Clostridium citroniae, Anaerostipes caccae, Fusobacterium mortiferum, Blautia obeum, Clostridium innocuum, Agathobaculum butyriciproducens, Clostridium innocuum, Dorea longicatena, Collinsella aerofaciens, Eubacterium hallii, Bacteroides faecis, Odoribacter species, Bacteroides fragilis, Bacteroides ovatus, Clostridium bolteae, Anaerotruncus colihominis, Drancourtella massiliensis, Clostridium symbiosum, Blautia producta, Dorea longicatena, Erysipelotrichaceae bacterium, and Flavonifractor plautii.

[0028] In some embodiments, the present disclosure provides a composition comprising Blautia producta, Bifidobacterium longum, Bifidobacterium adolescentis, Paeniclostridium sordellii, Bifidobacterium pseudocatenulatum, Erysipelatoclostridium ramosum, Escherichia coli, Paraclostridium bifermentans, Clostridium citroniae, Anaerostipes caccae, Fusobacterium mortiferum, Blautia obeum, Clostridium innocuum, Agathobaculum butyriciproducens, Odoribacter species, Bacteroides fragilis, Bacteroides ovatus, Clostridium bolteae, Anaerotruncus colihominis, Drancourtella massiliensis, Clostridium symbiosum, Blautia producta, Dorea longicatena, Erysipelotrichaceae bacterium, and Flavonifractor plautii.

[0029] In some aspects, the present disclosure relates to Collinsella aerofaciens, Bifidobacterium longum, Bacteroides ovatus, Bacteroides faecis, Bacteroides vulgatus, Odoribacter splanchnicus, Alistipes putredinis, Clostridium citroniae, Clostridium clostridioforme, Erysipelatoclostridium ramosum, Erysipelotrichaceae bacterium 6_1_45, Anaerostipes caccae, Blautia obeum, Blautia producta, Dorea longicatena, Agathobaculum butyriciproducens, Phascolarctobacterium faecium, Escherichia coli, and Fusobacterium mortiferum.

[0030] In some embodiments, the Disclosure provides compositions comprising Collinsella aerofaciens, Bifidobacterium longum, Bacteroides ovatus, Bacteroides vulgatus, Parabacteroides distasonis, Alistipes putredinis, Clostridium citroniae, Clostridium clostridioforme, Erysipelatoclostridium ramosum, Erysipelotrichaceae bacterium 6145, Anaerostipes caccae, Blautia obeum, Blautia producta, Agathobaculum butyriciproducens, Phascolarctobacterium faecium, Escherichia coli, and Fusobacterium mortiferum.

[0031] In some embodiments, the present disclosure provides compositions comprising Collinsella aerofaciens, Bifidobacterium longum, Bacteroides ovatus, Bacteroides vulgatus, Alistipes putredinis, Clostridium citroniae, Clostridium clostridioforme, Erysipelatoclostridium ramosum, Erysipelotrichaceae bacterium 6145, Blautia obeum, Blautia producta, Dorea longicatena, Phascolarctobacterium faecium, Escherichia coli, and Fusobacterium mortiferum.

[0032] In some embodiments, the composition comprises at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, at least 10, at least 11, at least 12, at least 13, at least 14, at least 15, at least 16, at least 17, at least 18, at least 19, at least 20, at least 21, at least 22, at least 23, at least 24, at least 25, at least 26, at least 27, at least 28, at least 29, at least 30, at least 31, at least 32, at least 33, at least 34, or at least 35 purified bacterial strains.

[0033] In some embodiments, the Escherichia species is Escherichia coli. In some embodiments, Escherichia coli is Escherichia species 3_2_53 FAA. In some embodiments, the Fusobacterium species is Fusobacterium mortiferum.

[0034] In some embodiments, Escherichia coli encodes one or more genes associated with bacteriocin production. In some embodiments, Escherichia coli does not encode any genes associated with plasmid uptake.

[0035] In some embodiments, the bacterial strain includes bacterial strains originating from two or more human donors.

[0036] In some embodiments, the composition is effective in inhibiting the replication, survival, and / or establishment of one or more pathogens. In some embodiments, the composition is effective in treating pathogenic infections in a subject. In some embodiments, the pathogens are susceptible to antibiotics.

[0037] In some embodiments, the pathogen is resistant to one or more antibiotics. In some embodiments, the pathogen is multidrug-resistant. In some embodiments, the multidrug-resistant bacteria are vancomycin-resistant Enterococci (VRE), carbapenem-resistant Enterobacteriaceae (CRE), Neisseria gonorrheae, multidrug-resistant Acinetobacter, Campylobacter, extended-spectrum β-lactamase (ESBL)-producing Enterobacteriaceae, multidrug-resistant Pseudomonas aeruginosa, Salmonella, drug-resistant non-typhoid Salmonella, drug-resistant Salmonella Typhi, drug-resistant Shigella, methicillin-resistant Staphylococcus aureus, drug-resistant Streptococcus pneumoniae, drug-resistant Tuberculosis, vancomycin-resistant Staphylococcus aureus, erythromycin-resistant Group A Streptococcus, or clindamycin-resistant Group B Streptococcus.

[0038] In some embodiments, the composition is effective in inducing the production of regulatory T cells (Tregs) in the gut. In some embodiments, the composition is effective in inducing the production of short-chain fatty acids (SCFAs) in the gut. In some embodiments, the composition is effective in inhibiting the replication, survival, and / or colonization of the gut by one or more bacteria associated with the induction of the Th1 immune response. In some embodiments, the composition is effective in inhibiting the replication, survival, and / or colonization of the gut by one or more oral microbiota bacteria.

[0039] In some embodiments, the bacterial strains are freeze-dried. In some embodiments, the bacterial strains are spray-dried. In some embodiments, one or more bacterial strains are spore-forming. In some embodiments, each of the bacterial strains is spore-forming. In some embodiments, one or more bacterial strains are vegetative-forming. In some embodiments, each of the bacterial strains is vegetative-forming.

[0040] In one embodiment, the present disclosure provides a pharmaceutical composition comprising any of the compositions described herein. In some embodiments, the pharmaceutical composition further comprises pharmaceutically acceptable excipients. In some embodiments, the pharmaceutical composition is formulated for oral delivery. In some embodiments, the pharmaceutical composition is formulated for rectal delivery. In some embodiments, the pharmaceutical composition is formulated for delivery to the intestines. In some embodiments, the pharmaceutical composition is formulated for delivery to the colon.

[0041] In some embodiments, the pharmaceutical composition is administered as a single dose. In some embodiments, the pharmaceutical composition is administered as multiple doses. In some embodiments, each dose comprises the administration of multiple capsules.

[0042] In some embodiments, the Disclosure provides a method for suppressing infection by a pathogen in a subject, comprising administering a therapeutically effective amount of any of the compositions or foods described herein. In some embodiments, the Disclosure provides any of the compositions or foods described herein for use as a pharmaceutical. In some embodiments, the Disclosure provides any of the compositions or foods described herein for use in suppressing infection by a pathogen. In some embodiments, the Disclosure provides the use of any of the compositions or foods described herein in the preparation of a pharmaceutical for suppressing infection by a pathogen. In some embodiments, the pathogen is susceptible to antibiotics. In some embodiments, the pathogen is resistant to antibiotics. In some embodiments, the pathogen is Clostridium difficile. In some embodiments, the pathogen is multidrug-resistant.

[0043] In some embodiments, the pathogen is Klebsiella pneumoniae. In some embodiments, Klebsiella pneumoniae is multidrug resistant. In some embodiments, the multidrug resistant Klebsiella pneumoniae is carbapenem resistant Klebsiella pneumoniae.

[0044] In some embodiments, Klebsiella pneumoniae induces a Th1 response. In some embodiments, Klebsiella pneumoniae is strain BAA-2552, strain KP-1, strain 700721, strain 13882, strain 34E1, strain BAA-1705, strain 700603, or strain Kp-2H7. In some embodiments, the Klebsiella pneumoniae strain is Kp-2H7.

[0045] In some embodiments, the subject is human. In some embodiments, the composition is administered to the subject multiple times. In some embodiments, the composition is administered to the subject by oral administration. In some embodiments, the composition is administered to the subject by rectal administration.

[0046] In some embodiments, the administration inhibits the replication, survival, and / or establishment of the pathogen. In some embodiments, the pathogen is vancomycin-resistant Enterococci (VRE), carbapenem-resistant Enterobacteriaceae (CRE), Neisseria gonorrheae, multidrug-resistant Acinetobacter, Campylobacter, extended-spectrum β-lactamase (ESBL)-producing Enterobacteriaceae, multidrug-resistant Pseudomonas aeruginosa, Salmonella, drug-resistant non-typhoid Salmonella, drug-resistant Salmonella Typhi, drug-resistant Shigella, methicillin-resistant Staphylococcus aureus, drug-resistant Streptococcus pneumoniae, drug-resistant Tuberculosis, vancomycin-resistant Staphylococcus aureus, erythromycin-resistant Group A Streptococcus, or clindamycin-resistant Group B Streptococcus.

[0047] In some embodiments, the method further comprises administering one or more additional compositions containing bacteria. In some embodiments, no antibiotic is administered prior to the administration of the pharmaceutical composition. In some embodiments, no vancomycin is administered prior to the administration of the pharmaceutical composition. In some embodiments, the method further comprises administering an antibiotic to the target prior to the administration of the pharmaceutical composition. In some embodiments, the antibiotic is vancomycin.

[0048] In some embodiments, the Disclosure provides a method for treating a pathogenic infection in a subject, comprising administering a therapeutically effective amount of any of the compositions or foods described herein. In some embodiments, the Disclosure provides any of the compositions or foods described herein for use as a pharmaceutical. In some embodiments, the Disclosure provides any of the compositions or foods described herein for use in treating a pathogenic infection. In some embodiments, the Disclosure provides the use of any of the compositions or foods described herein in the preparation of a pharmaceutical for treating a pathogenic infection. In some embodiments, the pathogen is susceptible to antibiotics. In some embodiments, the pathogen is resistant to antibiotics. In some embodiments, the pathogen is Clostridium difficile. In some embodiments, the pathogen is multidrug-resistant.

[0049] In some embodiments, the pathogen is Klebsiella pneumoniae. In some embodiments, Klebsiella pneumoniae is multidrug resistant. In some embodiments, the multidrug resistant Klebsiella pneumoniae is carbapenem resistant Klebsiella pneumoniae.

[0050] In some embodiments, Klebsiella pneumoniae induces a Th1 response. In some embodiments, Klebsiella pneumoniae is strain BAA-2552, strain KP-1, strain 700721, strain 13882, strain 34E1, strain BAA-1705, strain 700603, or strain Kp-2H7. In some embodiments, the Klebsiella pneumoniae strain is Kp-2H7.

[0051] In some embodiments, the subject is human. In some embodiments, the composition is administered to the subject multiple times. In some embodiments, the composition is administered to the subject orally. In some embodiments, the composition is administered to the subject rectally.

[0052] In some embodiments, the administration inhibits the replication, survival, and / or establishment of the pathogen. In some embodiments, the pathogen is vancomycin-resistant Enterococci (VRE), carbapenem-resistant Enterobacteriaceae (CRE), Neisseria gonorrheae, multidrug-resistant Acinetobacter, Campylobacter, extended-spectrum β-lactamase (ESBL)-producing Enterobacteriaceae, multidrug-resistant Pseudomonas aeruginosa, Salmonella, drug-resistant non-typhoid Salmonella, drug-resistant Salmonella Typhi, drug-resistant Shigella, methicillin-resistant Staphylococcus aureus, drug-resistant Streptococcus pneumoniae, drug-resistant Tuberculosis, vancomycin-resistant Staphylococcus aureus, erythromycin-resistant Group A Streptococcus, or clindamycin-resistant Group B Streptococcus.

[0053] In some embodiments, the method further comprises administering one or more additional compositions containing bacteria. In some embodiments, no antibiotic is administered prior to the administration of the pharmaceutical composition. In some embodiments, no vancomycin is administered prior to the administration of the pharmaceutical composition. In some embodiments, the method further comprises administering an antibiotic to the target prior to the administration of the pharmaceutical composition. In some embodiments, the antibiotic is vancomycin.

[0054] In some embodiments, the Disclosure provides a method for treating a disease or disorder related to bacterial colonization in a subject, comprising administering a therapeutically effective amount of any of the compositions or pharmaceutical compositions described herein. In some embodiments, the Disclosure provides any of the compositions or foods described herein for use as a pharmaceutical. In some embodiments, the Disclosure provides any of the compositions or foods described herein for use in treating a disease or disorder related to bacterial colonization. In some embodiments, the Disclosure provides the use of any of the compositions or foods described herein in the preparation of a pharmaceutical for treating a disease or disorder related to bacterial colonization. In some embodiments, the pathogen is susceptible to antibiotics. In some embodiments, the pathogen is resistant to antibiotics. In some embodiments, the pathogen is Clostridium difficile. In some embodiments, the pathogen is multidrug-resistant.

[0055] In some embodiments, the pathogen is Klebsiella pneumoniae. In some embodiments, Klebsiella pneumoniae is multidrug resistant. In some embodiments, the multidrug resistant Klebsiella pneumoniae is carbapenem resistant Klebsiella pneumoniae.

[0056] In some embodiments, Klebsiella pneumoniae induces a Th1 response. In some embodiments, Klebsiella pneumoniae is strain BAA-2552, strain KP-1, strain 700721, strain 13882, strain 34E1, strain BAA-1705, strain 700603, or strain Kp-2H7. In some embodiments, the Klebsiella pneumoniae strain is Kp-2H7.

[0057] In some embodiments, the subject is human. In some embodiments, the composition is administered to the subject multiple times. In some embodiments, the composition is administered to the subject by oral administration. In some embodiments, the composition is administered to the subject by rectal administration.

[0058] In some embodiments, the administration inhibits the replication, survival, and / or establishment of the pathogen.

[0059] In some embodiments, the pathogen is vancomycin-resistant Enterococci (VRE), carbapenem-resistant Enterobacteriaceae (CRE), Neisseria gonorrheae, multidrug-resistant Acinetobacter, Campylobacter, extended-spectrum β-lactamase (ESBL)-producing Enterobacteriaceae, multidrug-resistant Pseudomonas aeruginosa, Salmonella, drug-resistant non-typhoid Salmonella, drug-resistant Salmonella Typhi, drug-resistant Shigella, methicillin-resistant Staphylococcus aureus, drug-resistant Streptococcus pneumoniae, drug-resistant Tuberculosis, vancomycin-resistant Staphylococcus aureus, erythromycin-resistant Group A Streptococcus, or clindamycin-resistant Group B Streptococcus.

[0060] In some embodiments, the method further comprises administering one or more additional compositions containing bacteria. In some embodiments, no antibiotic is administered prior to the administration of the pharmaceutical composition. In some embodiments, no vancomycin is administered prior to the administration of the pharmaceutical composition. In some embodiments, the method further comprises administering an antibiotic to the target prior to the administration of the pharmaceutical composition. In some embodiments, the antibiotic is vancomycin.

[0061] In some embodiments, the Disclosure provides a method for inhibiting the colonization of oral microbiota bacteria into the intestine, comprising administering a therapeutically effective amount of any of the compositions or foods described herein. In some embodiments, the Disclosure provides any of the compositions or foods described herein for use as a pharmaceutical. In some embodiments, the Disclosure provides any of the compositions or foods described herein for use in inhibiting the colonization of oral microbiota bacteria into the intestine of a target. In some embodiments, the Disclosure provides the use of any of the compositions or foods described herein in the preparation of a pharmaceutical for inhibiting the colonization of oral microbiota bacteria into the intestine of a target.

[0062] In some embodiments, oral microbiota bacteria are susceptible to antibiotics. In some embodiments, oral microbiota bacteria are resistant to antibiotics.

[0063] In some embodiments, the subject is human. In some embodiments, the composition is administered to the subject multiple times. In some embodiments, the composition is administered to the subject by oral administration. In some embodiments, the composition is administered to the subject by rectal administration.

[0064] In some embodiments, the administration inhibits the replication, survival, and / or colonization of oral microbiome bacteria.

[0065] In some embodiments, the method further comprises administering one or more additional compositions containing bacteria. In some embodiments, no antibiotic is administered prior to the administration of the pharmaceutical composition. In some embodiments, no vancomycin is administered prior to the administration of the pharmaceutical composition. In some embodiments, the method further comprises administering an antibiotic to the target prior to the administration of the pharmaceutical composition. In some embodiments, the antibiotic is vancomycin.

[0066] The attached drawings are not drawn to scale. These drawings are for illustrative purposes only and are not essential to enabling this disclosure. For clarity, not all components are labeled in all drawings. These are the drawings below. [Brief explanation of the drawing]

[0067] [Figure 1] This document presents a timeline of a mouse model used in an experiment to establish carbapenem-resistant Enterobacteriaceae ("CRE"). [Figure 2] This shows the CRE fixation (fixation units, "CFU") levels in mouse fecal samples 15 days after treatment. From left to right: control (PBS), composition of 36 bacterial strains ("36-mix" or "LBP-1"), 36-mix without E. coli ("36-Ec" or "LBP-2"), 36-mix without Fusobacterium mortiferum ("36-Fuso" or "LBP-3"), 36-mix without E. coli and Fusobacterium ("36-Ec&Fuso" or "LBP-4"), and fecal fractionation treatment ("SFL"). LoD is the limit of detection. [Figure 3A] This chart shows CRE colonization (CFU) levels in fecal samples from mice 15 days after treatment. From left to right: control (PBS), composition of 36 bacterial strains ("36-mix" or "LBP-1"), composition of 33 bacterial strains ("33-mixB" or "LBP-5"), composition of 32 bacterial strains ("32-mix" or "LBP-6"), composition of 27 bacterial strains ("27-mix" or "LBP-7"), composition of 23 bacterial strains ("23-mix" or "LBP-8"), and fecal fractionation treatment ("SFL"). LoD is the limit of detection. [Figure 3B]This table shows CRE colonization (CFU) levels in fecal samples from mice 15 days after treatment. From left to right: control (PBS), composition of 36 bacterial strains ("36-mix" or "LBP-1"), composition of 33 bacterial strains ("33-mixB" or "LBP-5"), composition of 32 bacterial strains ("32-mix" or "LBP-6"), composition of 27 bacterial strains ("27-mix" or "LBP-7"), composition of 23 bacterial strains ("23-mix" or "LBP-8"), and fecal fractionation treatment ("SFL"). LoD is the limit of detection. This table shows the bacterial strains of the indicated compositions and their corresponding anti-CRE efficacy. "+" indicates a bacterial strain included in the indicated composition. [Figure 4] This table shows the bacterial strains present in 36-mix or LBP-1, 27-mix or LBP-7, and 23-mix or LBP-8, as evaluated in Figure 3. [Figure 5] This table shows the bacterial strains present in 36-mix or LBP-1, 33-mixB or LBP-5, and 32-mix or LBP-6, as evaluated in Figure 3. [Figure 6]The results of in vitro competitive experiments using the indicated bacterial strains and Campylobacter jejuni 81-176 (C. jejuni) are shown. Cultures of C. jejuni were incubated in the presence of controls: Lactococcus species (JL17), Escherichia coli ATCC 25922 (Ec 25922), Campylobacter in thioglycolate broth (Campy thio), Campylobacter in thioglycolate broth supplemented with minced meat (Campy CM-thio), Campylobacter in thioglycolate broth + succinate (Campy thio+S), or the individual bacterial strains shown. Compared to the control, strains 8, 9, 18, and 19 were considered "active" in reducing the number of C. jejuni colony-forming units (CFU / mL), while strains 15, 27, and 36 were considered "weakly active." CFU is the colony-forming unit. (+) indicates an active strain (≥3 log decrease), (*) indicates a weakly active strain (1.5-2.9 log decrease), and (o) indicates a control. "Inactive" strains had a <1.5 log decrease. [Figure 7] The results of in vitro competitive experiments using the indicated bacterial strains and Campylobacter jejuni 81-176 (C. jejuni) are shown. C. jejuni cultures were incubated in the presence of controls: Lactococcus species (JL17), Escherichia coli ATCC 25922 (Ec 25922), strain 6, Campylobacter in thioglycolate broth (Campy thio), Campylobacter in thioglycolate broth supplemented with minced meat (Campy CM-thio), or the individual bacterial strains shown. Strain VE303 6 (VE303-06) was found to be active in reducing the number of C. jejuni colony-forming units (CFU / mL). CFU is the number of colony-forming units, (+) indicates an active strain (≥3 log decrease), (*) indicates a weakly active strain (1.5-2.9 log decrease), and (o) indicates a control. The "inactive" strains exhibited a <1.5 log decrease. [Figure 8]The results of in vitro competitive experiments using the indicated bacterial strains and Shigella flexneri 2457T (S. flexneri) are shown. S. flexneri cultures were incubated in the presence of controls: Lactococcus species (JL17), Escherichia coli ATCC 25922 (Ec 25922), Shigella in peptone-yeast-glucose medium (Shigella PYG), Shigella in minced meat with carbohydrate broth (Shigella CMC), Shigella in yeast casitonic fatty acids with carbohydrate broth (Shigella YCFAC), Shigella in peptone-yeast-glucose medium containing succinate (Shigella PYG+S), or the individual bacterial strains shown. Compared to the control, strains 8, 9, 11, 13, 16, 21, 35, and 36 were considered "active" in reducing S. flexneri colony-forming units (CFU / mL), while strains 12, 15, 25, 30, and 34 were considered "weakly active." CFU represents colony-forming units; (+) indicates an active strain (≥4 log decrease), (*) indicates a weakly active strain (2-3.9 log decrease), and (o) indicates a control. "Inactive" strains had a <2 log decrease. [Figure 9]The results of in vivo competitive experiments using the indicated bacterial strains and Shigella flexneri 2457T (S. flexneri) are shown. S. flexneri cultures were incubated in the presence of controls: Lactococcus species (JL17), Escherichia coli ATCC 25922 (Ec 25922), Shigella in peptone-yeast-glucose medium (Shigella PYG), Shigella in chopped meat with carbohydrate broth (Shigella CMC), strain 24, or the individual bacterial strains shown. VE303 strains 1 (VE303-01), 2 (VE303-02), 4 (VE303-04), and 5 (VE303-05) were "weakly active" in reducing S. flexneri colony-forming units (CFU / mL). CFU is the colony-forming unit. (+) indicates an active strain (≥4 log decrease), (*) indicates a weakly active strain (2-3.9 log decrease), and (o) indicates a control. "Inactive" strains had a <2 log decrease. [Figure 10] This table summarizes the pathogen-inhibiting activity of the indicated bacterial strains. [Figure 11] A workflow diagram for measuring the survival of Campylobacter jejuni strains 81-176 is shown. The figure on the right shows the oxygen concentration gradient used, indicating that facultative anaerobic, aerobic, microaerophilic, and anaerobic bacterial species are expected to grow in the thioglycolate broth. [Figure 12] This diagram shows a workflow for adapting a broth competition assay to measure the growth inhibition of Shigella flexneri 2457T strain (S.flexneri 2457T), enteric agglutinating Escherichia coli (EAEC), and Klebsiella pneumoniae ATCC BAA-2814 (CRE) strain. [Figure 13]The results of in vitro broth competition experiments using the indicated bacterial strains and Campylobacter jejuni 81-176 (C. jejuni) are shown. C. jejuni cultures were incubated in the presence of C. jejuni alone or in the presence of the individual indicated bacterial strains. VE303 strain 6 (VE303-06) was found to be active in reducing the number of C. jejuni colony-forming units (CFU / mL), while VE303 strains 1 and 7 (VE303-01 and VE303-07, respectively) were found to be weakly active. CFU represents colony-forming units; (+) indicates an active strain (≥3 log decrease), (*) indicates a weakly active strain (1.5-2.9 log decrease), and (o) indicates a control. Inactive strains had a <1.5 log decrease. [Figure 14] This diagram shows a workflow for adapting a soft agar overlay assay to measure pathogen killing and / or inhibition of Shigella, EAEC, CRE, and Campylobacter strains. [Figure 15] An exemplary photograph of the soft agar overlay assay is shown. The final activity of the strains was based on a consensus across all replicates. Strains considered "active" produced inhibitory zones in ≥66% of replicas, strains considered "weakly active" produced inhibitory zones in 34–65% of replicas, and strains considered "inactive" produced inhibitory zones in ≤33% of replicas. [Figure 16] This paper shows the number of active strains and their targets from broth competition assays and soft agar overlay assays to measure the inhibition and / or killing of growth of C. jejuni (Campylobacter), S. flexneri (Shigella), and EAEC strains. [Figure 17] This table summarizes the pathogen inhibitory activity of the indicated bacterial strains in broth competition assays and soft agar overlay assays against S. flexneri, EAEC, or C. jejuni. [Figure 18]This table summarizes the pathogen inhibitory activity of the indicated bacterial strains in broth competition assays and soft agar overlay assays against S. flexneri, EAEC, or C. jejuni. [Figure 19] This table summarizes the pathogen inhibitory activity of the indicated bacterial strains in broth competition assays and soft agar overlay assays against S. flexneri, EAEC, or C. jejuni. [Figure 20] This table summarizes the pathogen inhibitory activity of the indicated bacterial strains in broth competition assays and soft agar overlay assays against S. flexneri, EAEC, or C. jejuni. [Figure 21] This table summarizes the pathogen inhibitory activity of the indicated bacterial strains in broth competition assays and soft agar overlay assays against S. flexneri, EAEC, or C. jejuni. [Figure 22]The levels of CRE (colony-forming units, "CFU") in mouse fecal samples 15 days after treatment with the indicated viable bacterial compositions are shown. From left to right: control (PBS), composition of 36 bacterial strains ("LBP-1"), composition of 31 bacterial strains ("LBP-9"), composition of 33 bacterial strains ("LBP-10"), composition of 35 bacterial strains ("LBP-11"), composition of 35 bacterial strains ("LBP-12"), composition of 30 bacterial strains ("LBP-13"), composition of 21 bacterial strains ("LBP-14"), composition of 23 bacterial strains ("LBP-15"), composition of 26 bacterial strains ("LBP-16"), composition of 22 bacterial strains ("LBP-17"), composition of 21 bacterial strains ("LBP-18"), composition of 20 bacterial strains ("LBP-19"), composition of 34 bacterial strains ("LBP- Compositions of 20, 33 bacterial strains ("LBP-21"), 27 bacterial strains ("LBP-22"), 25 bacterial strains ("LBP-23"), 27 bacterial strains ("LBP-24"), 30 bacterial strains ("LBP-25"), 27 bacterial strains ("LBP-26"), 22 bacterial strains ("LBP-27"), 26 bacterial strains ("LBP-28"), 22 bacterial strains ("LBP-29"), 17 bacterial strains ("LBP-30"), 25 bacterial strains ("LBP-31"), 19 bacterial strains ("LBP-32"), and 17 bacterial strains ("LBP-33"). LoD is the limit of detection. The individual bacterial strain compositions of LBP can also be found in Figure 35. [Figure 23] The levels of CRE (colony-forming units, "CFU") in mouse fecal samples at day 0 (D0), day 8 (D8), day 15 (D15), and day 22 (D22) after treatment are shown. At each time point, the treatments, from left to right, correspond to the control (PBS), a composition of 30 bacterial strains ("30-mix"), and a composition of 36 bacterial strains ("36-mix"). The 36-mix corresponds to "LBP-1," and the 30-mix corresponds to "LBP-25." The Level of Detection (LoD) is the limit of detection. [Figure 24]This shows the evaluation of the exclusion of various strains in the decolonization of CRE (Klebsiella pneumoniae "Kpn"). A shows the CRE colonization (colony-forming unit, "CFU") level in mouse fecal samples 14-17 days after treatment (D14-17Tx). LoD is the limit of detection. B is a table showing the strains excluded from the indicated composition and the corresponding anti-CRE efficacy. "+" indicates a strain included in the indicated composition. [Figure 25A] This shows the evaluation of the exclusion of Bacteroides species in CRE disinfection. The table shows the bacterial species present in LBP-32(19-mix). "+" indicates a strain included in the indicated composition. [Figure 25B] This shows the evaluation of Bacteroides species exclusion in CRE eradication. The levels of CRE (Klebsiella pneumoniae "Kpn") colonization (colony-forming units, "CFU") in mouse fecal samples at day 0 (D0), day 3 (D3), day 8 (D8), day 14 (D14), day 17 (D17), and day 22 (D22) post-treatment are shown. At each time point, the treatments, from left to right, correspond to control (PBS), composition LBP-32 (19-mix), and composition LBP-1 (36-mix). LoD is the limit of detection. [Figure 26A] This document presents an evaluation of a modified version of the viable bacterial product LBP-32 (19-mix) in the eradication of CRE (Klebsiella pneumoniae "Kpn"). A is a table showing the bacterial species present in 19-mix ("LBP-32") and the modified 17-mix ("LBP-30"). "+" indicates a strain included in the indicated composition. Arrows indicate the exclusion of Bacteroides vulgatus, Clostridium citroniae, and Phascolarctobacterium faecis from 17-mix ("LBP-30"). [Figure 26B]This shows the evaluation of a modified version of the viable bacterial product LBP-32 (19-mix) in the eradication of CRE (Klebsiella pneumoniae "Kpn"). B shows the level of CRE colonization (colony-forming units, "CFU") in fecal samples from mice 15 days (D8 post-Tx) after treatment with the indicated viable bacterial product: LBP-30 (17-mix), LBP-32 (19-mix), LBP-24 (27-mix), LBP-1 (36-mix), or control (PBS). LoD is the limit of detection. [Figure 27] This shows the CRE colonization (colony-forming unit, "CFU") levels in small intestinal samples from mice 22 days after treatment with either the control (PBS) or the live bacterial product LBP-32 (19-mix) (post-Tx). The Level of Depletion (LoD) is the limit of detection. [Figure 28] This document presents optimization strategies for developing live bacterial products. Figure A shows a schematic of a single-model optimization strategy in which live biotherapeutic products ("LBPs") are administered to mice colonized with Klebsiella pneumoniae (CRE; "anti-CRE LBPs") or mice colonized with ESBL ("anti-ESBL LBPs"). Next, anti-CRE LBPs and anti-ESBL LBPs are combined and administered to mice colonized with CRE and ESBL to identify candidate LBPs. Figure B shows a schematic of a dual-model optimization strategy in which mouse models colonized with CRE and ESBL are administered with both anti-CRE-LBPs and anti-ESBL-LBPs to identify candidate LBPs. [Figure 29] This paper presents timelines of mouse models undergoing single-challenge or co-challenge experiments in establishing carbapenem-resistant Enterobacteriaceae ("CRE") or extended-spectrum β-lactamase ("ESBL")-producing Enterobacteriaceae. [Figure 30]Figure 29 shows the colonization levels of mice in mono-colonized or co-colonized challenge models. A shows the colonization (colony-forming units, "CFU") levels of extended-spectrum β-lactamase ("ESBL")-producing Enterobacteriaceae in fecal samples from mice 3 (D3), 6 (D6), 11 (D11), and 17 (D17) post-challenge. Mice were challenged with ESBL ("mono-colonized," light gray) or co-challenged with ESBL and CRE ("co-colonized," dark gray). B shows the colonization (colony-forming units, "CFU") levels of CRE in fecal samples from mice 3 (D3), 6 (D6), 11 (D11), and 17 (D17) post-challenge. Mice were challenged with CRE ("single-settlement," light gray) or co-challenged with CRE and ESBL ("co-settlement," dark gray). Each group of mice contained 8 mice. [Figure 31A] This section describes mouse colonization in single-challenge (single-colonization) or co-colonization challenge models. Timelines are presented for mouse models undergoing single-challenge or co-challenge CRE and ESBL colonization experiments in carbapenem-resistant Enterobacteriaceae ("CRE") or extended-spectrum β-lactamase ("ESBL")-producing Enterobacteriaceae colonization experiments from day 7 to day 3 after antibiotic administration. Next, 36-mix (LBP-1) or control ("PBS") was administered on day -2, day -1, and day 0. [Figure 31B]This shows the colonization of mice in single-challenge (mono-colonization) or co-colonization challenge models. Figure 31A shows the colonization levels of mice in single-challenge ("mono") or co-colonization ("co") challenge models. Mice were subjected to one of the following challenges: CRE ("CRE Mono"), ESBL ("ESBL Mono"), CRE and ESBL ("CRE Co"), or ESBL and CRE ("ESBL Co"). Colonization (colony-forming units, "CFU") levels in fecal samples are shown 14 days after treatment with 36-mix or control (PBS). [Figure 32] This table summarizes the pathogen inhibitory activity of the indicated bacterial strains in broth competition assays and soft agar overlay assays against S. flexneri, EAEC, or C. jejuni. [Figure 33] This table summarizes the pathogen inhibitory activity of the indicated bacterial strains in broth competition assays and soft agar overlay assays against S. flexneri, EAEC, or C. jejuni. [Figure 34A] This paper shows the number of active strains and their targets from broth competition assays and soft agar overlay assays to measure the inhibition and / or killing of growth of C. jejuni (Campylobacter), S. flexneri (Shigella), and EAEC strains. [Figure 34B] This paper shows the number of active strains and their targets from broth competition assays and soft agar overlay assays to measure the inhibition and / or killing of growth of C. jejuni (Campylobacter), S. flexneri (Shigella), and EAEC strains. [Figure 35-1]Figure 22 shows a table of bacterial strains present in each of the bacterial compositions evaluated: LBP-1, LBP-9, LBP-10, LBP-11, LBP-12, LBP-13, LBP-14, LBP-15, LBP-16, LBP-17, LBP-18, LBP-19, LBP-20, LBP-21, LBP-22, LBP-23, LBP-24, LBP-25, LBP-26, LBP-27, LBP-28, LBP-29, LBP-30, LBP-31, LBP-32, LBP-33, and LBP-34. The number of bacterial strains in each LBP composition is shown in parentheses. [Figure 35-2] Figure 22 shows a table of bacterial strains present in each of the bacterial compositions evaluated: LBP-1, LBP-9, LBP-10, LBP-11, LBP-12, LBP-13, LBP-14, LBP-15, LBP-16, LBP-17, LBP-18, LBP-19, LBP-20, LBP-21, LBP-22, LBP-23, LBP-24, LBP-25, LBP-26, LBP-27, LBP-28, LBP-29, LBP-30, LBP-31, LBP-32, LBP-33, and LBP-34. The number of bacterial strains in each LBP composition is shown in parentheses. [Figure 35-3] Figure 22 shows a table of bacterial strains present in each of the bacterial compositions evaluated: LBP-1, LBP-9, LBP-10, LBP-11, LBP-12, LBP-13, LBP-14, LBP-15, LBP-16, LBP-17, LBP-18, LBP-19, LBP-20, LBP-21, LBP-22, LBP-23, LBP-24, LBP-25, LBP-26, LBP-27, LBP-28, LBP-29, LBP-30, LBP-31, LBP-32, LBP-33, and LBP-34. The number of bacterial strains in each LBP composition is shown in parentheses. [Figure 36]The results of in vitro competitive experiments using the indicated bacterial strains and carbapenem-resistant Klebsiella pneumoniae ATCC BAA-2814 (CRE) are shown. CRE cultures were incubated in the presence of controls: Lactococcus species (JL17), Escherichia coli ATCC 25922 (Ec 25922), VE303 strain 6 (VE303-06), CRE alone, or the individual bacterial strains shown. Compared to the control, strains 16, 36, 9, 10, and 8 were considered "active" in reducing CRE colony-forming units (CFU / mL), while strains 11 and 34 were considered "weakly active." CFU is the colony-forming unit, (+) indicates an active strain (≥4 log decrease), (*) indicates a weakly active strain (2.0-3.9 log decrease), and (o) indicates the control. "Inactive" strains had a <2 log decrease. [Figure 37] The results of in vitro competitive experiments using the indicated bacterial strains and carbapenem-resistant Klebsiella pneumoniae ATCC BAA-2814 (CRE) are shown. CRE cultures were incubated in the presence of controls: Lactococcus species (JL17), Escherichia coli ATCC 25922 (Ec 25922), CRE alone, or the individual bacterial strains shown. VE303 strain 1 (VE303-01) and VE303 strain 4 (VE303-04) were found to be active in reducing the number of CRE colony-forming units (CFU / mL). CFU is a colony-forming unit, (+) indicates an active strain (≥4 log reduction), (*) indicates a weakly active strain (2.0-3.9 log reduction), and (o) indicates a control. "Inactive" strains had a <2 log reduction. [Figure 38] This table summarizes the pathogen inhibitory activity of the indicated bacterial strains in broth competition assays and soft agar overlay assays against CRE. [Figure 39]This shows the level of carbapenem-resistant Klebsiella pneumoniae (CRE) colonization (colony-forming units, "CFU") in samples from mice 14 days after treatment with control (PBS), the viable bacterial product LBP-32, or the viable bacterial product LBP-34 (post-Tx). The Level of Destruction (LoD) is the limit of detection. [Modes for carrying out the invention]

[0068] Suppressing or preventing undesirable bacteria in a target area, or inhibiting or preventing bacterial colonization in a specific area of ​​the body, can be difficult. Bacterial colonization can induce an immune response (local or systemic) in the target area, which can lead to serious illness. In particular, in the case of multidrug-resistant bacteria or microorganisms that have acquired antibiotic resistance, elimination using many conventional therapeutic agents, such as antibiotics, may be impossible due to resistance or tolerance to the drugs. In addition, it has recently been recognized that colonization of the gut by bacteria from the oral microbiome can affect the immune environment of the gut, such as by inducing a Th1-dominant immune response, leading to chronic inflammation and inflammatory states (see, for example, Atarashi et al. Science (2017) 358(359-365)). Normal bacterial colonization in various areas of the body, such as the oral cavity, can provide a reservoir for bacteria that can migrate and colonize other areas, such as the gut.

[0069] This specification provides compositions and methods for inhibiting colonization by pathogenic bacteria, such as multidrug-resistant bacteria. It also provides compositions and methods for inhibiting the colonization of oral microbiota bacteria in the target intestine. This specification provides compositions and methods for treating diseases or disorders related to bacterial colonization, or diseases or disorders related to immune responses induced by bacteria. It also provides compositions and methods for inducing regulatory T cell (Treg) production in response to pathogenic bacteria. Furthermore, it provides compositions and methods for inducing short-chain fatty acid (SCFA) production in response to pathogenic bacteria.

[0070] In some embodiments, one or more bacterial strains of the compositions provided herein colonize or re-colonize the target intestinal tract or a portion of the intestinal tract (e.g., the colon or cecum). Such colonization or re-colonization may also be referred to as transplantation. In some embodiments, one or more bacterial strains of the compositions re-colonize the target intestinal tract (e.g., the colon or cecum) after another microorganism or population of microorganisms has been partially or completely removed (e.g., by antibiotic treatment). In some embodiments, one or more bacterial strains of the compositions re-colonize the intestinal tract (e.g., the colon or cecum) after one or more pathogenic bacteria or other microorganisms (e.g., bacteria that induce an immune response) have been removed. In some embodiments, re-colonization of the intestinal tract or a portion of the intestinal tract by bacterial strains of the compositions described herein prevents or inhibits colonization by undesirable microorganisms (e.g., pathogenic bacteria, multidrug-resistant bacteria, oral microbiome bacteria, bacteria that induce an immune response, pathogenic symbionts, bacteria that reduce Treg production, bacteria that reduce SCFA production).

[0071] In some embodiments, one or more bacterial strains of the composition may grow faster than pathogens or undesirable bacteria such as pathogenic bacteria, multidrug-resistant bacteria, oral microbiome bacteria, bacteria that induce immune responses, bacteria that reduce Treg production, or bacteria that reduce SCFA production. Therefore, in some embodiments, if both pathogens or undesirable bacteria (e.g., pathogenic bacteria, multidrug-resistant organisms, oral microbiome bacteria, bacteria that induce immune responses that reduce Treg production, bacteria that reduce SCFA production) and one or more bacteria of the compositions provided herein are present in the intestinal tract (e.g., colon or cecum), one or more bacteria of the compositions provided herein may grow faster than the pathogens (e.g., have shorter doubling times), thereby preventing the pathogens from accumulating in the intestinal tract (e.g., colon or cecum). In some embodiments, one or more bacteria of the compositions provided herein may grow faster than pathogens in an otherwise intact or complete microbiome. In some embodiments, one or more bacteria of the compositions provided herein grow faster than pathogens in a depleted microbiome (e.g., after antibiotic treatment). In some embodiments, one or more bacteria of the compositions provided herein grow faster because they are well transplanted in the intestinal tract (e.g., colon or cecum). In some embodiments, one or more bacteria of the compositions provided herein grow faster because they are well metabolized with nutrients present in the intestinal tract (e.g., colon or cecum). In some embodiments, the bacterial strain compositions provided herein prevent or inhibit the replication of pathogens. In some embodiments, the bacterial strain compositions provided herein induce (kill) the death of pathogens. In some embodiments, the bacterial strains of the compositions provided herein can treat pathogenic infections due to synergistic effects between the bacterial strains.

[0072] In some embodiments, the bacterial compositions described herein prevent re-establishment by pathogens or undesirable bacteria (e.g., pathogenic bacteria, multidrug-resistant organisms, oral microbiome bacteria, immune response-inducing bacteria, pathogenic symbionts, bacteria that reduce Treg production, bacteria that reduce SCFA production). For example, in some embodiments, pathogens or undesirable bacteria are reduced or removed from the target, for example, using a first therapeutic agent (such as an antibiotic), and the bacterial compositions described herein are administered to prevent re-establishment of the target. In some embodiments, the bacterial compositions described herein reduce or remove pathogens or undesirable bacteria from the target and prevent re-establishment of the target.

[0073] In some embodiments, the bacterial strain combinations of the compositions provided herein are superior in nutrient utilization compared to pathogens or undesirable bacteria, thereby inhibiting the growth of pathogens or undesirable bacteria. In some embodiments, the bacterial strain combinations of the compositions provided herein are superior in transplantation compared to pathogens or undesirable bacteria, thereby inhibiting the growth of pathogens or undesirable bacteria. In some embodiments, the bacterial strain combinations of the compositions provided herein are superior in nutrient utilization and transplantation compared to pathogens or undesirable bacteria, thereby inhibiting the growth of pathogens or undesirable bacteria. In some embodiments, the bacterial strain combinations of the compositions provided herein inhibit the growth, survival, and / or establishment of pathogens or undesirable bacteria.

[0074] In some embodiments, the combination of bacterial strains of the compositions provided herein has antagonistic or inhibitory activity against pathogens or undesirable bacteria, thereby inhibiting the growth, survival, and / or establishment of pathogens or undesirable bacteria. In some embodiments, at least one bacterial strain of the compositions provided herein has antagonistic or inhibitory activity against pathogens or undesirable bacteria, thereby inhibiting the growth, survival, and / or establishment of pathogens or undesirable bacteria.

[0075] In some embodiments, the synergistic effect is brought about by the ability of this combination to settle in a specific niche in the intestinal tract (e.g., the colon or cecum). In some embodiments, the synergistic effect is brought about by the ability of this combination to metabolize specific nutrients. In some embodiments, the synergistic effect is brought about by the ability of this combination to provide specific metabolites to the environment.

[0076] The bacterial strains used in the compositions provided herein are generally isolated from the microbiome of healthy individuals. In some embodiments, the compositions include strains originating from a single individual. In some embodiments, the compositions include strains originating from multiple individuals. In some embodiments, bacterial strains are obtained from multiple individuals, isolated, and grown individually. The individually grown bacterial compositions may then be combined to provide the compositions of this disclosure. It should be understood that the origin of the bacterial strains of the compositions provided herein is not limited to the human microbiome from healthy individuals. In some embodiments, the bacterial strains originate from humans with an enterotoxemia microbiome. In some embodiments, the bacterial strains originate from non-human animals or the environment (e.g., soil or surface water). In some embodiments, the combination of bacterial strains provided herein originates from multiple sources (e.g., humans and non-human animals).

[0077] In some embodiments, the bacteria of the compositions provided herein are anaerobic bacteria. In some embodiments, the bacteria of the compositions provided herein are obligate anaerobic bacteria. In some embodiments, the bacteria of the compositions provided herein are Clostridia. Clostridia can be classified into phylogenetic clusters together with other closely related lineages and species. (See, for example, Rajilic-Stojanovic, M., and de Vos, WMFEMS Microbiol Rev 38, (2014) 996-1047.) Generally, Clostridia are classified as belonging to a particular cluster based on their 16S rRNA (or 16S rDNA) nucleic acid sequences. Methods for determining the identity of a particular bacterial species based on their 16S rRNA (or 16S rDNA) nucleic acid sequences are well known in the art (see, for example, Jumpstart Consortium Human Microbiome Project Data Generation Working, G. PLoS One (2012) 7, e39315).

[0078] In one embodiment, the disclosure provides a composition comprising one or more purified bacterial strains belonging to the phylum Firmicutes and one or more purified bacterial strains selected from the group consisting of Escherichia species (e.g., Escherichia species 3_2_53FAA) and Fusobacterium species (e.g., Fusobacterium mortiferum). In one embodiment, the Disclosure provides a composition comprising one or more purified bacterial strains belonging to the phylum Firmicutes and one or more purified bacterial strains selected from the group consisting of Escherichia species (e.g., Escherichia species 3_2_53FAA) and Fusobacterium species (e.g., Fusobacterium mortiferum). In some embodiments, as used herein, “comprising of” means a composition that does not contain any additional therapeutically active bacterial strains. In one embodiment, the Disclosure provides a composition comprising one or more purified bacterial strains belonging to the phylum Firmicutes and one or more purified bacterial strains selected from the group consisting of Escherichia species (e.g., Escherichia species 3_2_53FAA) and Fusobacterium species (e.g., Fusobacterium mortiferum).

[0079] In one embodiment, the disclosure provides a composition comprising one or more purified bacterial strains belonging to the phylum Firmicutes and one or more purified bacterial strains of an Escherichia species such as E. coli (e.g., Escherichia species 3_2_53FAA). In one embodiment, the disclosure provides a composition comprising one or more purified bacterial strains belonging to the phylum Firmicutes and one or more purified bacterial strains of an Escherichia species such as E. coli (e.g., Escherichia species 3_2_53FAA). In one embodiment, the disclosure provides a composition essentially comprising one or more purified bacterial strains belonging to the phylum Firmicutes and one or more purified bacterial strains of an Escherichia species such as E. coli (e.g., Escherichia species 3_2_53FAA).

[0080] In one embodiment, the disclosure provides a composition comprising one or more purified bacterial strains belonging to the phylum Firmicutes and one or more purified bacterial strains of the Fusobacterium species (e.g., Fusobacterium mortiferum). In one embodiment, the disclosure provides a composition comprising one or more purified bacterial strains belonging to the phylum Firmicutes and one or more purified bacterial strains of the Fusobacterium species (e.g., Fusobacterium mortiferum). In one embodiment, the disclosure provides a composition essentially comprising one or more purified bacterial strains belonging to the phylum Firmicutes and one or more purified bacterial strains of the Fusobacterium species (e.g., Fusobacterium mortiferum).

[0081] The phylum Firmicutes is characterized by DNA with low guanosine and cytosine content. Firmicutes constitute the largest portion of the mouse and human microbiome, and they are involved in energy absorption and the development of diabetes and obesity. Classes of Firmicute bacteria include Bacilli (e.g., Bacillales, Lactobacillales, Mollicutes, Erysipelotrichia) and Clostridia (e.g., Clostridiales, Halanaerobiales, Natranaerobiales, Thermoanaerobacteriales, and Negativicutes), as well as Thermolithobacteria.

[0082] In some embodiments, one or more bacterial strains of the phylum Firmicutes belong to the family Clostridiaceae. In some embodiments, the compositions described herein include one or more bacterial strains belonging to the genus Clostridium. In some embodiments, the compositions described herein include one or more bacterial strains belonging to Clostridium cluster IV and / or XIVa.

[0083] In some embodiments, one or more bacterial strains of the phylum Firmicutes produce short-chain fatty acids (SCFAs), such as any SCFA described herein. In some embodiments, one or more bacterial strains of the phylum Firmicutes produce butyrate. Butyrate is mainly produced by Firmicutes and Bacteroidetes in the gastrointestinal tract. In some embodiments, one or more bacterial strains belonging to Firmicutes are butyrate-producing strains such as Anaerotruncus colihominis, Sellimonas intestinalis (Ruminococcus torques), Clostridium symbiosum, Dorea longicatena, Erysipelotrichaceae bacterium, and Flavinofractor plautii (subdoligranulum species).

[0084] In one embodiment, the disclosure includes purified bacterial strains belonging to the Escherichia species such as E. coli (e.g., Escherichia species 3_2_53FAA), purified bacterial strains belonging to the Fusobacterium species (e.g., Fusobacterium mortiferum), and Bifidobacterium pseudocatenulatum, Bifidobacterium adolescentis, Bifidobacterium longum, Clostridium citroniae, Clostridium clostridioforme, Clostridium bifermentans, Clostridium sordelli, Clostridium innocuum, Erysipelatoclostridium ramosum, Erysipelotrichaceae bacterium 6_1_45, Eubacterium hallii, Eubacterium rectale, Anaerostipes caccae, Blautia obeum, Blautia producta, Coprococcus comes, Dorea The present invention provides a composition comprising one or more purified bacterial strains selected from the group consisting of longicatena, Agathobaculum butyriciproducens, and Phascolarctobacterium faecis.

[0085] In one embodiment, the disclosure includes purified bacterial strains belonging to the Escherichia species such as E. coli (e.g., Escherichia species 3_2_53FAA), purified bacterial strains belonging to the Fusobacterium species (e.g., Fusobacterium mortiferum), and Bifidobacterium pseudocatenulatum, Bifidobacterium adolescentis, Bifidobacterium longum, Clostridium citroniae, Clostridium clostridioforme, Clostridium bifermentans, Clostridium sordelli, Clostridium innocuum, Erysipelatoclostridium ramosum, Erysipelotrichaceae bacterium 6_1_45, Eubacterium hallii, Eubacterium rectale, Anaerostipes caccae, Blautia obeum, Blautia producta, Coprococcus comes, Dorea The present invention provides a composition comprising one or more purified bacterial strains selected from the group consisting of longicatena, Agathobaculum butyriciproducens, and Phascolarctobacterium faecis.

[0086] In one embodiment, the disclosure includes purified bacterial strains belonging to the Escherichia species such as E. coli (e.g., Escherichia species 3_2_53FAA), purified bacterial strains belonging to the Fusobacterium species (e.g., Fusobacterium mortiferum), and Bifidobacterium pseudocatenulatum, Bifidobacterium adolescentis, Bifidobacterium longum, Clostridium citroniae, Clostridium clostridioforme, Clostridium bifermentans, Clostridium sordelli, Clostridium innocuum, Erysipelatoclostridium ramosum, Erysipelotrichaceae bacterium 6_1_45, Eubacterium hallii, Eubacterium rectale, Anaerostipes caccae, Blautia obeum, Blautia producta, Coprococcus comes, Dorea The present invention provides a composition essentially consisting of one or more purified bacterial strains selected from the group comprising *Longicatena*, *Agathobaculum butyriciproducens*, and *Phascolarctobacterium faecis*. In some embodiments, as used herein, "essentially consisting of" refers to a composition that does not contain any additional therapeutically active bacterial strains.

[0087] In one embodiment, the bacterial composition comprises a purified bacterial strain containing a 16S rDNA sequence having at least 97% sequence identity with the nucleic acid sequence shown as Sequence ID No. 36, a purified bacterial strain containing a 16S rDNA sequence having at least 97% sequence identity with the nucleic acid sequence shown as Sequence ID No. 34, and one or more purified bacterial strains containing a 16S rDNA sequence having at least 97% sequence identity with the nucleic acid sequences shown as Sequence IDs No. 8-20, 25, 28, 30-32, and 35.

[0088] In one embodiment, the bacterial composition comprises a purified bacterial strain containing a 16S rDNA sequence having at least 97% sequence identity with the nucleic acid sequence shown as Sequence ID No. 36, a purified bacterial strain containing a 16S rDNA sequence having at least 97% sequence identity with the nucleic acid sequence shown as Sequence ID No. 34, and one or more purified bacterial strains containing a 16S rDNA sequence having at least 97% sequence identity with the nucleic acid sequences shown as Sequence IDs No. 8-20, 25, 28, 30-32, and 35.

[0089] In one embodiment, the bacterial composition essentially comprises a purified bacterial strain containing a 16S rDNA sequence having at least 97% sequence identity with the nucleic acid sequence shown as Sequence ID No. 36, a purified bacterial strain containing a 16S rDNA sequence having at least 97% sequence identity with the nucleic acid sequence shown as Sequence ID No. 34, and one or more purified bacterial strains containing a 16S rDNA sequence having at least 97% sequence identity with the nucleic acid sequences shown as Sequence IDs No. 8-20, 25, 28, 30-32, and 35.

[0090] In one embodiment, the disclosure includes purified bacterial strains belonging to the Escherichia species such as E. coli (e.g., Escherichia species 3_2_53FAA), and Bifidobacterium pseudocatenulatum, Bifidobacterium adolescentis, Bifidobacterium longum, Clostridium citroniae, Clostridium clostridioforme, Clostridium bifermentans, Clostridium sordelli, Clostridium innocuum, Erysipelatoclostridium ramosum, Erysipelotrichaceae bacterium 6_1_45, Eubacterium hallii, Eubacterium rectale, Anaerostipes caccae, Blautia obeum, Blautia producta, Coprococcus comes, Dorea longicatena, Agathobaculum butyriciproducens, and Phascolarctobacterium The present invention provides a composition comprising one or more purified bacterial strains selected from the group consisting of Faecis species.

[0091] In one embodiment, the disclosure includes purified bacterial strains belonging to the Escherichia species such as E. coli (e.g., Escherichia species 3_2_53FAA), and Bifidobacterium pseudocatenulatum, Bifidobacterium adolescentis, Bifidobacterium longum, Clostridium citroniae, Clostridium clostridioforme, Clostridium bifermentans, Clostridium sordelli, Clostridium innocuum, Erysipelatoclostridium ramosum, Erysipelotrichaceae bacterium 6_1_45, Eubacterium hallii, Eubacterium rectale, Anaerostipes caccae, Blautia obeum, Blautia producta, Coprococcus comes, Dorea longicatena, Agathobaculum butyriciproducens, and Phascolarctobacterium The present invention provides a composition comprising one or more purified bacterial strains selected from the group consisting of Faecis species.

[0092] In one embodiment, the disclosure includes purified bacterial strains belonging to the Escherichia species such as E. coli (e.g., Escherichia species 3_2_53FAA), and Bifidobacterium pseudocatenulatum, Bifidobacterium adolescentis, Bifidobacterium longum, Clostridium citroniae, Clostridium clostridioforme, Clostridium bifermentans, Clostridium sordelli, Clostridium innocuum, Erysipelatoclostridium ramosum, Erysipelotrichaceae bacterium 6_1_45, Eubacterium hallii, Eubacterium rectale, Anaerostipes caccae, Blautia obeum, Blautia producta, Coprococcus comes, Dorea longicatena, Agathobaculum butyriciproducens, and Phascolarctobacterium The present invention provides a composition comprising one or more purified bacterial strains selected from the group consisting of Faecis species. In some embodiments, as used herein, “essentially comprising” refers to a composition that does not contain any additional therapeutically active bacterial strains.

[0093] In one embodiment, the bacterial composition comprises a purified bacterial strain containing a 16S rDNA sequence having at least 97% sequence identity with the nucleic acid sequence shown as Sequence ID No. 36, and one or more purified bacterial strains containing a 16S rDNA sequence having at least 97% sequence identity with the nucleic acid sequences shown as Sequence ID Nos. 8-20, 25, 28, 30-32, and 35.

[0094] In one embodiment, the bacterial composition comprises a purified bacterial strain containing a 16S rDNA sequence having at least 97% sequence identity with the nucleic acid sequence shown as Sequence ID No. 36, and one or more purified bacterial strains containing a 16S rDNA sequence having at least 97% sequence identity with the nucleic acid sequences shown as Sequence ID Nos. 8-20, 25, 28, 30-32, and 35.

[0095] In one embodiment, the bacterial composition essentially consists of a purified bacterial strain containing a 16S rDNA sequence having at least 97% sequence identity with the nucleic acid sequence shown as Sequence ID No. 36, and one or more purified bacterial strains containing a 16S rDNA sequence having at least 97% sequence identity with the nucleic acid sequences shown as Sequence ID Nos. 8-20, 25, 28, 30-32, and 35.

[0096] In one aspect, the present disclosure provides purified bacterial strains belonging to the Fusobacterium species (e.g., Fusobacterium mortiferum) and Bifidobacterium pseudocatenulatum, Bifidobacterium adolescentis, Bifidobacterium longum, Clostridium citroniae, Clostridium clostridioforme, Clostridium bifermentans, Clostridium sordelli, Clostridium innocuum, Erysipelatoclostridium ramosum, Erysipelotrichaceae bacterium 6_1_45, Eubacterium hallii, Eubacterium rectale, Anaerostipes caccae, Blautia obeum, Blautia producta, Coprococcus comes, Dorea longicatena, Agathobaculum butyriciproducens, and Phascolarctobacterium The present invention provides a composition comprising one or more purified bacterial strains selected from the group consisting of Faecis species.

[0097] In one aspect, the present disclosure provides purified bacterial strains belonging to the Fusobacterium species (e.g., Fusobacterium mortiferum) and Bifidobacterium pseudocatenulatum, Bifidobacterium adolescentis, Bifidobacterium longum, Clostridium citroniae, Clostridium clostridioforme, Clostridium bifermentans, Clostridium sordelli, Clostridium innocuum, Erysipelatoclostridium ramosum, Erysipelotrichaceae bacterium 6_1_45, Eubacterium hallii, Eubacterium rectale, Anaerostipes caccae, Blautia obeum, Blautia producta, Coprococcus comes, Dorea longicatena, Agathobaculum butyriciproducens, and Phascolarctobacterium The present invention provides a composition comprising one or more purified bacterial strains selected from the group consisting of Faecis species.

[0098] In one aspect, the present disclosure provides purified bacterial strains belonging to the Fusobacterium species (e.g., Fusobacterium mortiferum) and Bifidobacterium pseudocatenulatum, Bifidobacterium adolescentis, Bifidobacterium longum, Clostridium citroniae, Clostridium clostridioforme, Clostridium bifermentans, Clostridium sordelli, Clostridium innocuum, Erysipelatoclostridium ramosum, Erysipelotrichaceae bacterium 6_1_45, Eubacterium hallii, Eubacterium rectale, Anaerostipes caccae, Blautia obeum, Blautia producta, Coprococcus comes, Dorea longicatena, Agathobaculum butyriciproducens, and Phascolarctobacterium The present invention provides a composition comprising one or more purified bacterial strains selected from the group consisting of Faecis species. In some embodiments, as used herein, “essentially comprising” refers to a composition that does not contain any additional therapeutically active bacterial strains.

[0099] In one embodiment, the bacterial composition comprises a purified bacterial strain containing a 16S rDNA sequence having at least 97% sequence identity with the nucleic acid sequence shown as Sequence ID No. 34, and one or more purified bacterial strains containing a 16S rDNA sequence having at least 97% sequence identity with the nucleic acid sequences shown as Sequence ID Nos. 8-20, 25, 28, 30-32, and 35.

[0100] In one embodiment, the bacterial composition comprises a purified bacterial strain containing a 16S rDNA sequence having at least 97% sequence identity with the nucleic acid sequence shown as Sequence ID No. 34, and one or more purified bacterial strains containing a 16S rDNA sequence having at least 97% sequence identity with the nucleic acid sequences shown as Sequence ID Nos. 8-20, 25, 28, 30-32, and 35.

[0101] In one embodiment, the bacterial composition essentially consists of a purified bacterial strain containing a 16S rDNA sequence having at least 97% sequence identity with the nucleic acid sequence shown as Sequence ID No. 34, and one or more purified bacterial strains containing a 16S rDNA sequence having at least 97% sequence identity with the nucleic acid sequences shown as Sequence ID Nos. 8-20, 25, 28, 30-32, and 35.

[0102] In one aspect, the present disclosure provides a method for the treatment of bacterial infections caused by the species Bacteroides caccae, Bacteroides intestinalis, Bacteroides faecis, Bacteroides ovatus, Bacteroides thetaiotaomicron, Bacteroides uniformis, Bacteroides vulgatus, Bifidobacterium adolescentis, Bifidobacterium longum, Bifidobacterium pseudocatenulatum, Blautia producta, Clostridium citroniae, Clostridium clostridioforme, Clostridium innocuum, Erysipelotrichaceae bacterium 6_1_45, Paeniclostridium sordellii, Coprococcus comes, Dorea longicatena, Erysipelatoclostridium ramosum, Eubacterium rectale, Odoribacter species UNK.MGS-12, Parabacteroides distasonis, Parabacteroides merdae, Bacteroides xylanisolvens, Blautia obeum, Alistipes putredinis, Collinsella aerofaciens, Eubacterium hallii, Alistipes shahii, Anaerostipes caccae, and Agathobaculum butyriciproducens

[0103] In one aspect, the present disclosure provides a method for the treatment of bacterial infections caused by the species Bacteroides caccae, Bacteroides intestinalis, Bacteroides faecis, Bacteroides ovatus, Bacteroides thetaiotaomicron, Bacteroides uniformis, Bacteroides vulgatus, Bifidobacterium adolescentis, Bifidobacterium longum, Bifidobacterium pseudocatenulatum, Blautia producta, Clostridium citroniae, Clostridium clostridioforme, Clostridium innocuum, Erysipelotrichaceae bacterium 6_1_45, Paeniclostridium sordellii, Coprococcus comes, Dorea longicatena, Erysipelatoclostridium ramosum, Eubacterium rectale, Odoribacter species UNK.MGS-12, Parabacteroides distasonis, Parabacteroides merdae, Bacteroides xylanisolvens, Blautia obeum, Alistipes putredinis, Collinsella aerofaciens, Eubacterium hallii, Alistipes shahii, Anaerostipes caccae, and Agathobaculum butyriciproducens

[0104] In one aspect, the present disclosure relates to the species Bacteroides caccae, Bacteroides intestinalis, Bacteroides faecis, Bacteroides ovatus, Bacteroides thetaiotaomicron, Bacteroides uniformis, Bacteroides vulgatus, Bifidobacterium adolescentis, Bifidobacterium longum, Bifidobacterium pseudocatenulatum, Blautia producta, Clostridium citroniae, Clostridium clostridioforme, Clostridium innocuum, Erysipelotrichaceae bacterium 6_1_45, Paeniclostridium sordellii, Coprococcus comes, Dorea longicatena, Erysipelatoclostridium ramosum, Eubacterium rectale, Odoribacter species UNK.MGS-12, Parabacteroides distasonis, Parabacteroides The present invention provides compositions essentially comprising bacterial strains of merdae, Bacteroides xylanisolvens, Blautia obeum, Alistipes putredinis, Collinsella aerofaciens, Eubacterium hallii, Alistipes shahii, Anaerostipes caccae, and Agathobaculum butyriciproducens. In some embodiments, as used herein, “essentially comprising” refers to compositions that do not contain any additional therapeutically active bacterial strains.

[0105] In one embodiment, the bacterial composition comprises a purified bacterial strain containing a 16S rDNA sequence having at least 97% sequence identity with the nucleic acid sequences shown as SEQ ID NOs: 1-30 and 32. In one embodiment, the bacterial composition comprises a purified bacterial strain containing a 16S rDNA sequence having at least 97% sequence identity with the nucleic acid sequences shown as SEQ ID NOs: 1-30 and 32. In one embodiment, the bacterial composition essentially consists of a purified bacterial strain containing a 16S rDNA sequence having at least 97% sequence identity with the nucleic acid sequences shown as SEQ ID NOs: 1-30 and 32.

[0106] In one aspect, the present disclosure relates to the species Bacteroides caccae, Bacteroides intestinalis, Bacteroides faecis, Bacteroides ovatus, Bacteroides thetaiotaomicron, Bacteroides uniformis, Bacteroides vulgatus, Bifidobacterium adolescentis, Bifidobacterium longum, Bifidobacterium pseudocatenulatum, Blautia producta, Clostridium citroniae, Clostridium clostridioforme, Clostridium innocuum, Erysipelotrichaceae bacterium 6_1_45, Paeniclostridium sordellii, Coprococcus comes, Dorea longicatena, Erysipelatoclostridium ramosum, Eubacterium rectale, Odoribacter species UNK.MGS-12, Parabacteroides distasonis, Parabacteroides merdae, Bacteroides xylanisolvens, Blautia obeum, Alistipes putredinis, Collinsella aerofaciens, Eubacterium hallii, Alistipes shahii, Bacteroides fragilis, Paraclostridium bifermentans, Escherichia coli, and Fusobacterium mortiferum.

[0107] In one aspect, the present disclosure relates to the species Bacteroides caccae, Bacteroides intestinalis, Bacteroides faecis, Bacteroides ovatus, Bacteroides thetaiotaomicron, Bacteroides uniformis, Bacteroides vulgatus, Bifidobacterium adolescentis, Bifidobacterium longum, Bifidobacterium pseudocatenulatum, Blautia producta, Clostridium citroniae, Clostridium clostridioforme, Clostridium innocuum, Erysipelotrichaceae bacterium 6_1_45, Paeniclostridium sordellii, Coprococcus comes, Dorea longicatena, Erysipelatoclostridium ramosum, Eubacterium rectale, Odoribacter species UNK.MGS-12, Parabacteroides distasonis, Parabacteroides merdae, Bacteroides xylanisolvens, Blautia obeum, Alistipes putredinis, Collinsella aerofaciens, Eubacterium hallii, Alistipes shahii, Bacteroides fragilis, Paraclostridium bifermentans, Escherichia coli, and Fusobacterium mortiferum.

[0108] In one aspect, the present disclosure relates to the species Bacteroides caccae, Bacteroides intestinalis, Bacteroides faecis, Bacteroides ovatus, Bacteroides thetaiotaomicron, Bacteroides uniformis, Bacteroides vulgatus, Bifidobacterium adolescentis, Bifidobacterium longum, Bifidobacterium pseudocatenulatum, Blautia producta, Clostridium citroniae, Clostridium clostridioforme, Clostridium innocuum, Erysipelotrichaceae bacterium 6_1_45, Paeniclostridium sordellii, Coprococcus comes, Dorea longicatena, Erysipelatoclostridium ramosum, Eubacterium rectale, Odoribacter species UNK.MGS-12, Parabacteroides distasonis, Parabacteroides The present invention provides compositions essentially comprising bacterial strains of merdae, Bacteroides xylanisolvens, Blautia obeum, Alistipes putredinis, Collinsella aerofaciens, Eubacterium hallii, Alistipes shahii, Bacteroides fragilis, Paraclostridium bifermentans, Escherichia coli, and Fusobacterium mortiferum. In some embodiments, as used herein, “essentially comprising” refers to compositions that do not contain any additional therapeutically active bacterial strains.

[0109] In one embodiment, the bacterial composition comprises a purified bacterial strain containing a 16S rDNA sequence having at least 97% sequence identity with the nucleic acid sequences shown as SEQ ID NOs: 1-29 and 33-36. In one embodiment, the bacterial composition comprises a purified bacterial strain containing a 16S rDNA sequence having at least 97% sequence identity with the nucleic acid sequences shown as SEQ ID NOs: 1-29 and 33-36. In one embodiment, the bacterial composition essentially consists of a purified bacterial strain containing a 16S rDNA sequence having at least 97% sequence identity with the nucleic acid sequences shown as SEQ ID NOs: 1-29 and 33-36.

[0110] In one aspect, the present disclosure provides a method for the preparation of a bacterial culture for the following species: Bacteroides caccae, Bacteroides intestinalis, Bacteroides faecis, Bacteroides ovatus, Bacteroides thetaiotaomicron, Bacteroides uniformis, Bacteroides vulgatus, Bifidobacterium adolescentis, Bifidobacterium longum, Bifidobacterium pseudocatenulatum, Blautia producta, Clostridium citroniae, Clostridium clostridioforme, Clostridium innocuum, Erysipelotrichaceae bacterium 6_1_45, Paeniclostridium sordellii, Coprococcus comes, Dorea longicatena, Erysipelatoclostridium ramosum, Eubacterium rectale, Odoribacter species UNK.MGS-12, Parabacteroides distasonis, Parabacteroides merdae, Bacteroides xylanisolvens, Blautia obeum, Alistipes putredinis, Collinsella aerofaciens, Eubacterium hallii, Alistipes shahii, Anaerostipes caccae, Phascolarctobacterium faecium, Agathobaculum butyriciproducens, Bacteroides fragilis, Fusobacterium mortiferum, and Paraclostridium bifermentans.

[0111] In one aspect, the present disclosure provides a method for the preparation of a bacterial culture for the following species: Bacteroides caccae, Bacteroides intestinalis, Bacteroides faecis, Bacteroides ovatus, Bacteroides thetaiotaomicron, Bacteroides uniformis, Bacteroides vulgatus, Bifidobacterium adolescentis, Bifidobacterium longum, Bifidobacterium pseudocatenulatum, Blautia producta, Clostridium citroniae, Clostridium clostridioforme, Clostridium innocuum, Erysipelotrichaceae bacterium 6_1_45, Paeniclostridium sordellii, Coprococcus comes, Dorea longicatena, Erysipelatoclostridium ramosum, Eubacterium rectale, Odoribacter species UNK.MGS-12, Parabacteroides distasonis, Parabacteroides merdae, Bacteroides xylanisolvens, Blautia obeum, Alistipes putredinis, Collinsella aerofaciens, Eubacterium hallii, Alistipes shahii, Anaerostipes caccae, Phascolarctobacterium faecium, Agathobaculum butyriciproducens, Bacteroides fragilis, Fusobacterium mortiferum, and Paraclostridium bifermentans.

[0112] In one aspect, the present disclosure relates to the species Bacteroides caccae, Bacteroides intestinalis, Bacteroides faecis, Bacteroides ovatus, Bacteroides thetaiotaomicron, Bacteroides uniformis, Bacteroides vulgatus, Bifidobacterium adolescentis, Bifidobacterium longum, Bifidobacterium pseudocatenulatum, Blautia producta, Clostridium citroniae, Clostridium clostridioforme, Clostridium innocuum, Erysipelotrichaceae bacterium 6_1_45, Paeniclostridium sordellii, Coprococcus comes, Dorea longicatena, Erysipelatoclostridium ramosum, Eubacterium rectale, Odoribacter species UNK.MGS-12, Parabacteroides distasonis, Parabacteroides The present invention provides compositions essentially comprising bacterial strains of merdae, Bacteroides xylanisolvens, Blautia obeum, Alistipes putredinis, Collinsella aerofaciens, Eubacterium hallii, Alistipes shahii, Anaerostipes caccae, Phascolarctobacterium faecium, Agathobaculum butyriciproducens, Bacteroides fragilis, Fusobacterium mortiferum, and Paraclostridium bifermentans. In some embodiments, as used herein, “essentially comprising” refers to compositions that do not contain any additional therapeutically active bacterial strains.

[0113] In one embodiment, the bacterial composition comprises a purified bacterial strain containing a 16S rDNA sequence having at least 97% sequence identity with the nucleic acid sequences shown as SEQ ID NOs: 1 to 35. In one embodiment, the bacterial composition comprises a purified bacterial strain containing a 16S rDNA sequence having at least 97% sequence identity with the nucleic acid sequences shown as SEQ ID NOs: 1 to 35. In one embodiment, the bacterial composition essentially consists of a purified bacterial strain containing a 16S rDNA sequence having at least 97% sequence identity with the nucleic acid sequences shown as SEQ ID NOs: 1 to 35.

[0114] In one aspect, the present disclosure provides a method for the preparation of a bacterial culture for the following species: Bacteroides caccae, Bacteroides intestinalis, Bacteroides faecis, Bacteroides ovatus, Bacteroides thetaiotaomicron, Bacteroides uniformis, Bacteroides vulgatus, Bifidobacterium adolescentis, Bifidobacterium longum, Bifidobacterium pseudocatenulatum, Blautia producta, Clostridium citroniae, Clostridium clostridioforme, Clostridium innocuum, Erysipelotrichaceae bacterium 6_1_45, Paeniclostridium sordellii, Coprococcus comes, Dorea longicatena, Erysipelatoclostridium ramosum, Eubacterium rectale, Odoribacter species UNK.MGS-12, Parabacteroides distasonis, Parabacteroides merdae, Bacteroides xylanisolvens, Blautia obeum, Alistipes putredinis, Collinsella aerofaciens, Eubacterium hallii, Alistipes shahii, Phascolarctobacterium faecium, Anaerostipes caccae, Agathobaculum butyriciproducens, Bacteroides fragilis, Paraclostridium bifermentans, and E. coli.

[0115] In one aspect, the present disclosure provides a method for the preparation of a bacterial culture for the following species: Bacteroides caccae, Bacteroides intestinalis, Bacteroides faecis, Bacteroides ovatus, Bacteroides thetaiotaomicron, Bacteroides uniformis, Bacteroides vulgatus, Bifidobacterium adolescentis, Bifidobacterium longum, Bifidobacterium pseudocatenulatum, Blautia producta, Clostridium citroniae, Clostridium clostridioforme, Clostridium innocuum, Erysipelotrichaceae bacterium 6_1_45, Paeniclostridium sordellii, Coprococcus comes, Dorea longicatena, Erysipelatoclostridium ramosum, Eubacterium rectale, Odoribacter species UNK.MGS-12, Parabacteroides distasonis, Parabacteroides merdae, Bacteroides xylanisolvens, Blautia obeum, Alistipes putredinis, Collinsella aerofaciens, Eubacterium hallii, Alistipes shahii, Phascolarctobacterium faecium, Anaerostipes caccae, Agathobaculum butyriciproducens, Bacteroides fragilis, Paraclostridium bifermentans, and E. coli.

[0116] In one aspect, the present disclosure relates to the species Bacteroides caccae, Bacteroides intestinalis, Bacteroides faecis, Bacteroides ovatus, Bacteroides thetaiotaomicron, Bacteroides uniformis, Bacteroides vulgatus, Bifidobacterium adolescentis, Bifidobacterium longum, Bifidobacterium pseudocatenulatum, Blautia producta, Clostridium citroniae, Clostridium clostridioforme, Clostridium innocuum, Erysipelotrichaceae bacterium 6_1_45, Paeniclostridium sordellii, Coprococcus comes, Dorea longicatena, Erysipelatoclostridium ramosum, Eubacterium rectale, Odoribacter species UNK.MGS-12, Parabacteroides distasonis, Parabacteroides The present invention provides compositions essentially comprising bacterial strains of merdae, Bacteroides xylanisolvens, Blautia obeum, Alistipes putredinis, Collinsella aerofaciens, Eubacterium hallii, Alistipes shahii, Phascolarctobacterium faecium, Anaerostipes caccae, Agathobaculum butyriciproducens, Bacteroides fragilis, Paraclostridium bifermentans, and E. coli. In some embodiments, as used herein, “essentially comprising” means compositions that do not contain any additional therapeutically active bacterial strains.

[0117] In one embodiment, the bacterial composition comprises a purified bacterial strain containing a 16S rDNA sequence having at least 97% sequence identity with the nucleic acid sequences shown as SEQ ID NOs: 1-33, 35, and 36. In one embodiment, the bacterial composition comprises a purified bacterial strain containing a 16S rDNA sequence having at least 97% sequence identity with the nucleic acid sequences shown as SEQ ID NOs: 1-33, 35, and 36. In one embodiment, the bacterial composition essentially consists of a purified bacterial strain containing a 16S rDNA sequence having at least 97% sequence identity with the nucleic acid sequences shown as SEQ ID NOs: 1-33, 35, and 36.

[0118] In one aspect, the present disclosure provides a composition comprising bacterial strains of the species Bacteroides caccae, Bacteroides intestinalis, Bacteroides faecis, Bacteroides ovatus, Bacteroides thetaiotaomicron, Bacteroides uniformis, Bacteroides vulgatus, Bifidobacterium adolescentis, Bifidobacterium longum, Bifidobacterium pseudocatenulatum, Blautia producta, Clostridium citroniae, Clostridium clostridioforme, Clostridium innocuum, Erysipelotrichaceae bacterium 6_1_45, Coprococcus comes, Dorea longicatena, Erysipelatoclostridium ramosum, Eubacterium rectale, Odoribacter species UNK.MGS-12, Parabacteroides distasonis, Parabacteroides merdae, Bacteroides xylanisolvens, Blautia obeum, Alistipes putredinis, Collinsella aerofaciens, Eubacterium hallii, Alistipes shahii, Fusobacterium mortiferum, and E. coli.

[0119] In one aspect, the present disclosure provides a composition comprising bacterial strains of the species Bacteroides caccae, Bacteroides intestinalis, Bacteroides faecis, Bacteroides ovatus, Bacteroides thetaiotaomicron, Bacteroides uniformis, Bacteroides vulgatus, Bifidobacterium adolescentis, Bifidobacterium longum, Bifidobacterium pseudocatenulatum, Blautia producta, Clostridium citroniae, Clostridium clostridioforme, Clostridium innocuum, Erysipelotrichaceae bacterium 6_1_45, Coprococcus comes, Dorea longicatena, Erysipelatoclostridium ramosum, Eubacterium rectale, Odoribacter species UNK.MGS-12, Parabacteroides distasonis, Parabacteroides merdae, Bacteroides xylanisolvens, Blautia obeum, Alistipes putredinis, Collinsella aerofaciens, Eubacterium hallii, Alistipes shahii, Fusobacterium mortiferum, and E. coli.

[0120] In one aspect, the present disclosure relates to the species Bacteroides caccae, Bacteroides intestinalis, Bacteroides faecis, Bacteroides ovatus, Bacteroides thetaiotaomicron, Bacteroides uniformis, Bacteroides vulgatus, Bifidobacterium adolescentis, Bifidobacterium longum, Bifidobacterium pseudocatenulatum, Blautia producta, Clostridium citroniae, Clostridium clostridioforme, Clostridium innocuum, Erysipelotrichaceae bacterium 6_1_45, Coprococcus comes, Dorea longicatena, Erysipelatoclostridium ramosum, Eubacterium rectale, Odoribacter species UNK.MGS-12, Parabacteroides distasonis, Parabacteroides merdae, Bacteroides The present invention provides compositions essentially comprising bacterial strains of xylanisolvens, Blautia obeum, Alistipes putredinis, Collinsella aerofaciens, Eubacterium hallii, Alistipes shahii, Fusobacterium mortiferum, and E. coli. In some embodiments, as used herein, “essentially comprising” refers to compositions that do not contain any additional therapeutically active bacterial strains.

[0121] In one embodiment, the bacterial composition comprises a purified bacterial strain containing a 16S rDNA sequence having at least 97% sequence identity with the nucleic acid sequences shown as SEQ ID NOs: 1-15, 17-29, 34, and 36. In one embodiment, the bacterial composition comprises a purified bacterial strain containing a 16S rDNA sequence having at least 97% sequence identity with the nucleic acid sequences shown as SEQ ID NOs: 1-15, 17-29, 34, and 36. In one embodiment, the bacterial composition essentially consists of a purified bacterial strain containing a 16S rDNA sequence having at least 97% sequence identity with the nucleic acid sequences shown as SEQ ID NOs: 1-15, 17-29, 34, and 36.

[0122] In one aspect, the present disclosure relates to the species Bacteroides intestinalis, Bacteroides faecis, Bacteroides ovatus, Bacteroides uniformis, Bacteroides vulgatus, Bifidobacterium longum, Blautia producta, Clostridium citroniae, Clostridium clostridioforme, Erysipelotrichaceae bacterium 6_1_45, Coprococcus comes, Dorea Compositions are provided that include bacterial strains of E. longicatena, Erysipelatoclostridium ramosum, Eubacterium rectale, Odoribacter sp.

[0123] In one aspect, the present disclosure provides a composition comprising bacterial strains of the species Bacteroides intestinalis, Bacteroides faecis, Bacteroides ovatus, Bacteroides uniformis, Bacteroides vulgatus, Bifidobacterium longum, Blautia producta, Clostridium citroniae, Clostridium clostridioforme, Erysipelotrichaceae bacterium 6_1_45, Coprococcus comes, Dorea longicatena, Erysipelatoclostridium ramosum, Eubacterium rectale, Odoribacterium species UNK.MGS-12, Parabacteroides distasonis, Bacteroides xylanisolvens, Blautia obeum, Alistipes putredinis, Eubacterium hallii, Fusobacterium mortiferum, and E. coli.

[0124] In one embodiment, the present disclosure provides a composition essentially consisting of bacterial strains of the species Bacteroides intestinalis, Bacteroides faecis, Bacteroides ovatus, Bacteroides uniformis, Bacteroides vulgatus, Bifidobacterium longum, Blautia producta, Clostridium citroniae, Clostridium clostridioforme, Erysipelotrichaceae bacterium 6_1_45, Coprococcus comes, Dorea longicatena, Erysipelatoclostridium ramosum, Eubacterium rectale, Odoribacter species UNK.MGS-12, Parabacteroides distasonis, Bacteroides xylanisolvens, Blautia obeum, Alistipes putredinis, Eubacterium hallii, Fusobacterium mortiferum, and E. coli. In some embodiments, as used herein, “essentially consisting of” refers to a composition that does not contain any additional therapeutically active bacterial strains.

[0125] In one embodiment, the bacterial composition comprises a purified bacterial strain containing a 16S rDNA sequence having at least 97% sequence identity with the nucleic acid sequences shown as SEQ ID NOs: 2-4, 6, 7, 9, 11-13, 15, 18-22, 24-26, 28, 34, and 36. In one embodiment, the bacterial composition comprises a purified bacterial strain containing a 16S rDNA sequence having at least 97% sequence identity with the nucleic acid sequences shown as SEQ ID NOs: 2-4, 6, 7, 9, 11-13, 15, 18-22, 24-26, 28, 34, and 36. In one embodiment, the bacterial composition essentially consists of a purified bacterial strain containing a 16S rDNA sequence having at least 97% sequence identity with the nucleic acid sequences shown as SEQ ID NOs: 2-4, 6, 7, 9, 11-13, 15, 18-22, 24-26, 28, 34, and 36.

[0126] In one aspect, the present disclosure provides a composition comprising a bacterial strain of the species Bacteroides caccae, Bacteroides intestinalis, Bacteroides faecis, Bacteroides thetaiotaomicron, Bacteroides uniformis, Bacteroides vulgatus, Bacteroides ovatus, Blautia producta, Clostridium citroniae, Clostridium clostridioforme, Clostridium innocuum, Erysipelotrichaceae bacterium 6_1_45, Coprococcus comes, Dorea longicatena, Erysipelatoclostridium ramosum, Eubacterium rectale, Bacteroides xylanisolvens, Blautia obeum, Alistipes putredinis, Eubacterium hallii, Alistipes shahii, Fusobacterium mortiferum, and E. coli.

[0127] In one aspect, the present disclosure provides a composition comprising bacterial strains of the species Bacteroides caccae, Bacteroides intestinalis, Bacteroides faecis, Bacteroides thetaiotaomicron, Bacteroides uniformis, Bacteroides vulgatus, Bacteroides ovatus, Blautia producta, Clostridium citroniae, Clostridium clostridioforme, Clostridium innocuum, Erysipelotrichaceae bacterium 6_1_45, Coprococcus comes, Dorea longicatena, Erysipelatoclostridium ramosum, Eubacterium rectale, Bacteroides xylanisolvens, Blautia obeum, Alistipes putredinis, Eubacterium hallii, Alistipes shahii, Fusobacterium mortiferum, and E. coli.

[0128] In one embodiment, the present disclosure provides a composition essentially comprising bacterial strains of the species Bacteroides caccae, Bacteroides intestinalis, Bacteroides faecis, Bacteroides thetaiotaomicron, Bacteroides uniformis, Bacteroides vulgatus, Bacteroides ovatus, Blautia producta, Clostridium citroniae, Clostridium clostridioforme, Clostridium innocuum, Erysipelotrichaceae bacterium 6_1_45, Coprococcus comes, Dorea longicatena, Erysipelatoclostridium ramosum, Eubacterium rectale, Bacteroides xylanisolvens, Blautia obeum, Alistipes putredinis, Eubacterium hallii, Alistipes shahii, Fusobacterium mortiferum, and E. coli. In some embodiments, as used herein, “essentially consisting of” refers to a composition that does not contain any additional therapeutically active bacterial strains.

[0129] In one embodiment, the bacterial composition comprises a purified bacterial strain containing a 16S rDNA sequence having at least 97% sequence identity with the nucleic acid sequences shown as SEQ ID NOs: 1-3, 5-8, 11-15, 17-20, 24-26, 28, 29, 34, and 36. In one embodiment, the bacterial composition comprises a purified bacterial strain containing a 16S rDNA sequence having at least 97% sequence identity with the nucleic acid sequences shown as SEQ ID NOs: 1-3, 5-8, 11-15, 17-20, 24-26, 28, 29, 34, and 36. In one embodiment, the bacterial composition essentially consists of a purified bacterial strain containing a 16S rDNA sequence having at least 97% sequence identity with the nucleic acid sequences shown as SEQ ID NOs: 1-3, 5-8, 11-15, 17-20, 24-26, 28, 29, 34, and 36.

[0130] In one aspect, the present disclosure provides a composition comprising a bacterial strain of the species Bacteroides caccae, Bacteroides intestinalis, Bacteroides faecis, Bacteroides ovatus, Bacteroides thetaiotaomicron, Bacteroides uniformis, Bacteroides vulgatus, Bifidobacterium adolescentis, Bifidobacterium longum, Bifidobacterium pseudocatenulatum, Clostridium innocuum, Erysipelotrichaceae bacterium 6_1_45, Paeniclostridium sordellii, Erysipelatoclostridium ramosum, Odoribacter species UNK.MGS-12, Parabacteroides distasonis, Parabacteroides merdae, Bacteroides xylanisolvens, Alistipes putredinis, Collinsella aerofaciens, Alistipes shahii, Phascolarctobacterium faecium, Bacteroides fragilis, Paraclostridium bifermentans, Fusobacterium mortiferum, and E. coli.

[0131] In one aspect, the present disclosure provides a composition comprising bacterial strains of the species Bacteroides caccae, Bacteroides intestinalis, Bacteroides faecis, Bacteroides ovatus, Bacteroides thetaiotaomicron, Bacteroides uniformis, Bacteroides vulgatus, Bifidobacterium adolescentis, Bifidobacterium longum, Bifidobacterium pseudocatenulatum, Clostridium innocuum, Erysipelotrichaceae bacterium 6_1_45, Paeniclostridium sordellii, Erysipelatoclostridium ramosum, Odoribacter species UNK.MGS-12, Parabacteroides distasonis, Parabacteroides merdae, Bacteroides xylanisolvens, Alistipes putredinis, Collinsella aerofaciens, Alistipes shahii, Phascolarctobacterium faecium, Bacteroides fragilis, Paraclostridium bifermentans, Fusobacterium mortiferum, and E. coli.

[0132] In one aspect, the present disclosure relates to the species Bacteroides caccae, Bacteroides intestinalis, Bacteroides faecis, Bacteroides ovatus, Bacteroides thetaiotaomicron, Bacteroides uniformis, Bacteroides vulgatus, Bifidobacterium adolescentis, Bifidobacterium longum, Bifidobacterium pseudocatenulatum, Clostridium innocuum, Erysipelotrichaceae bacterium 6_1_45, Paeniclostridium sordellii, Erysipelatoclostridium ramosum, Odoribacter species UNK.MGS-12, Parabacteroides distasonis, Parabacteroides merdae, Bacteroides xylanisolvens, Alistipes putredinis, Collinsella aerofaciens, Alistipes shahii, Phascolarctobacterium The present invention provides compositions essentially consisting of bacterial strains of faecium, Bacteroides fragilis, Paraclostridium bifermentans, Fusobacterium mortiferum, and E. coli. In some embodiments, as used herein, “essentially consisting of” refers to compositions that do not contain any additional therapeutically active bacterial strains.

[0133] In one embodiment, the bacterial composition comprises a purified bacterial strain containing a 16S rDNA sequence having at least 97% sequence identity with the nucleic acid sequences shown as SEQ ID NOs: 1-10, 14-16, 19, 21-27, 29, 31, and 33-36. In one embodiment, the bacterial composition comprises a purified bacterial strain containing a 16S rDNA sequence having at least 97% sequence identity with the nucleic acid sequences shown as SEQ ID NOs: 1-10, 14-16, 19, 21-27, 29, 31, and 33-36. In one embodiment, the bacterial composition essentially consists of a purified bacterial strain containing a 16S rDNA sequence having at least 97% sequence identity with the nucleic acid sequences shown as SEQ ID NOs: 1-10, 14-16, 19, 21-27, 29, 31, and 33-36.

[0134] In one aspect, the present disclosure relates to the species Bacteroides caccae, Bacteroides intestinalis, Bacteroides faecis, Bacteroides ovatus, Bacteroides thetaiotaomicron, Bacteroides uniformis, Bacteroides vulgatus, Blautia producta, Clostridium citroniae, Clostridium clostridioforme, Clostridium innocuum, Erysipelotrichaceae Compositions are provided that include bacterial strains of bacterium 6_1_45, Coprococcus comes, Dorea longicatena, Erysipelatoclostridium ramosum, Eubacterium rectale, Bacteroides xylanisolvens, Blautia obeum, Alistipes putredinis, Eubacterium hallii, Alistipes shahii, and E. coli.

[0135] Bacteroides caccae, Bacteroides intestinalis, Bacteroides faecis, Bacteroides ovatus, Bacteroides thetaiotaomicron, Bacteroides uniformis, and Bacteroides vulgatus rectal, Bacteroides xylanisolvens, Blautia obeum, Alistipes putredinis, Eubacterium hallii, and Alistipes shahii.

[0136] In one embodiment, the present disclosure provides a composition essentially consisting of bacterial strains of the species Bacteroides caccae, Bacteroides intestinalis, Bacteroides faecis, Bacteroides ovatus, Bacteroides thetaiotaomicron, Bacteroides uniformis, Bacteroides vulgatus, Blautia producta, Clostridium citroniae, Clostridium clostridioforme, Clostridium innocuum, Erysipelotrichaceae bacterium 6_1_45, Coprococcus comes, Dorea longicatena, Erysipelatoclostridium ramosum, Eubacterium rectale, Bacteroides xylanisolvens, Blautia obeum, Alistipes putredinis, Eubacterium hallii, Alistipes shahii, and E. coli. In some embodiments, as used herein, “essentially consisting of” refers to a composition that does not contain any additional therapeutically active bacterial strains.

[0137] In one embodiment, the bacterial composition comprises a purified bacterial strain containing a 16S rDNA sequence having at least 97% sequence identity with the nucleic acid sequences shown as SEQ ID NOs: 1-7, 11-15, 17-20, 24-26, 28, 29, and 36. In one embodiment, the bacterial composition comprises a purified bacterial strain containing a 16S rDNA sequence having at least 97% sequence identity with the nucleic acid sequences shown as SEQ ID NOs: 1-7, 11-15, 17-20, 24-26, 28, 29, and 36. In one embodiment, the bacterial composition essentially consists of a purified bacterial strain containing a 16S rDNA sequence having at least 97% sequence identity with the nucleic acid sequences shown as SEQ ID NOs: 1-7, 11-15, 17-20, 24-26, 28, 29, and 36.

[0138] In one embodiment, the present disclosure provides a composition comprising bacterial strains of the species Bacteroides caccae, Bacteroides intestinalis, Bacteroides faecis, Bacteroides ovatus, Bacteroides thetaiotaomicron, Bacteroides uniformis, Bacteroides vulgatus, Blautia producta, Clostridium citroniae, Clostridium clostridioforme, Clostridium innocuum, Erysipelotrichaceae bacterium 6_1_45, Coprococcus comes, Dorea longicatena, Erysipelatoclostridium ramosum, Eubacterium rectale, Bacteroides xylanisolvens, Blautia obeum, Alistipes putredinis, Eubacterium hallii, and Alistipes shahii.

[0139] In one embodiment, the present disclosure provides bacterial strains comprising bacterial strains of the species Bacteroides caccae, Bacteroides intestinalis, Bacteroides faecis, Bacteroides ovatus, Bacteroides thetaiotaomicron, Bacteroides uniformis, Bacteroides vulgatus, Blautia producta, Clostridium citroniae, Clostridium clostridioforme, Clostridium innocuum, Erysipelotrichaceae bacterium 6_1_45, Coprococcus comes, Dorea longicatena, Erysipelatoclostridium ramosum, Eubacterium rectale, Bacteroides xylanisolvens, Blautia obeum, Alistipes putredinis, Eubacterium hallii, and Alistipes shahii.

[0140] In one embodiment, the present disclosure provides compositions essentially comprising bacterial strains of the species Bacteroides caccae, Bacteroides intestinalis, Bacteroides faecis, Bacteroides ovatus, Bacteroides thetaiotaomicron, Bacteroides uniformis, Bacteroides vulgatus, Blautia producta, Clostridium citroniae, Clostridium clostridioforme, Clostridium innocuum, Erysipelotrichaceae bacterium 6_1_45, Coprococcus comes, Dorea longicatena, Erysipelatoclostridium ramosum, Eubacterium rectale, Bacteroides xylanisolvens, Blautia obeum, Alistipes putredinis, Eubacterium hallii, and Alistipes shahii. In some embodiments, as used herein, “essentially comprising” means compositions that do not contain any additional therapeutically active bacterial strains.

[0141] In one embodiment, the bacterial composition comprises a purified bacterial strain containing a 16S rDNA sequence having at least 97% sequence identity with the nucleic acid sequences shown as SEQ ID NOs: 1-7, 11-15, 17-20, 24-26, 28, and 29. In one embodiment, the bacterial composition comprises a purified bacterial strain containing a 16S rDNA sequence having at least 97% sequence identity with the nucleic acid sequences shown as SEQ ID NOs: 1-7, 11, 13-15, 17, 19, 24-26, 28, 29, 34, and 36. In one embodiment, the bacterial composition essentially consists of a purified bacterial strain containing a 16S rDNA sequence having at least 97% sequence identity with the nucleic acid sequences shown as SEQ ID NOs: 1-7, 11, 13-15, 17, 19, 24-26, 28, 29, 34, and 36.

[0142] Bacteroides caccae, Bacteroides intestinalis, Bacteroides faecis, Bacteroides ovatus, Bacteroides thetaiotaomicron, Bacteroides uniformis, and Bacteroides vulgatus、Blautia producta、Clostridium clostridioforme、Clostridium innocuum、Erysipelotrichaceae bacterium 6_1_45、Coprococcus comes、Erysipelatoclostridium ramosum putredinis, Eubacterium hallii, Alistipes shahii, and Fusobacterium mortiferum, respectively.

[0143] Bacteroides caccae, Bacteroides intestinalis, Bacteroides faecis, Bacteroides ovatus, Bacteroides thetaiotaomicron, Bacteroides uniformis, and Bacteroides vulgatus、Blautia producta、Clostridium clostridioforme、Clostridium innocuum、Erysipelotrichaceae bacterium 6_1_45、Coprococcus comes、Erysipelatoclostridium ramosum putredinis, Eubacterium hallii, Alistipes shahii, and Fusobacterium mortiferum, respectively.

[0144] In one embodiment, the present disclosure provides compositions essentially comprising bacterial strains of the species Bacteroides caccae, Bacteroides intestinalis, Bacteroides faecis, Bacteroides ovatus, Bacteroides thetaiotaomicron, Bacteroides uniformis, Bacteroides vulgatus, Blautia producta, Clostridium clostridioforme, Clostridium innocuum, Erysipelotrichaceae bacterium 6_1_45, Coprococcus comes, Erysipelatoclostridium ramosum, Bacteroides xylanisolvens, Blautia obeum, Alistipes putredinis, Eubacterium hallii, Alistipes shahii, Fusobacterium mortiferum, and E. coli. In some embodiments, as used herein, “essentially comprising” means compositions that do not contain any additional therapeutically active bacterial strains.

[0145] In one embodiment, the bacterial composition comprises a purified bacterial strain containing a 16S rDNA sequence having at least 97% sequence identity with the nucleic acid sequences shown as SEQ ID NOs: 1-7, 11, 13-15, 17, 19, 24-26, 28, 29, 34, and 36. In one embodiment, the bacterial composition comprises a purified bacterial strain containing a 16S rDNA sequence having at least 97% sequence identity with the nucleic acid sequences shown as SEQ ID NOs: 1-7, 11, 13-15, 17, 19, 24-26, 28, 29, 34, and 36. In one embodiment, the bacterial composition essentially consists of a purified bacterial strain containing a 16S rDNA sequence having at least 97% sequence identity with the nucleic acid sequences shown as SEQ ID NOs: 1-7, 11, 13-15, 17, 19, 24-26, 28, 29, 34, and 36.

[0146] In one aspect, the present disclosure provides a method for the preparation of a bacterial culture for the following species: Bacteroides caccae, Bacteroides intestinalis, Bacteroides faecis, Bacteroides ovatus, Bacteroides thetaiotaomicron, Bacteroides uniformis, Bacteroides vulgatus, Bifidobacterium adolescentis, Bifidobacterium longum, Bifidobacterium pseudocatenulatum, Blautia producta, Clostridium citroniae, Clostridium clostridioforme, Clostridium innocuum, Erysipelotrichaceae bacterium 6_1_45, Paeniclostridium sordellii, Coprococcus comes, Dorea longicatena, Erysipelatoclostridium ramosum, Eubacterium rectale, Odoribacter species UNK.MGS-12, Parabacteroides distasonis, Parabacteroides merdae, Bacteroides xylanisolvens, Blautia obeum, Alistipes putredinis, Collinsella aerofaciens, Eubacterium hallii, Alistipes shahii, Anaerostipes caccae, Phascolarctobacterium faecium, Agathobaculum butyriciproducens, Bacteroides fragilis, and Paraclostridium bifermentans.

[0147] In one aspect, the present disclosure provides a method for the preparation of a bacterial culture for the following species: Bacteroides caccae, Bacteroides intestinalis, Bacteroides faecis, Bacteroides ovatus, Bacteroides thetaiotaomicron, Bacteroides uniformis, Bacteroides vulgatus, Bifidobacterium adolescentis, Bifidobacterium longum, Bifidobacterium pseudocatenulatum, Blautia producta, Clostridium citroniae, Clostridium clostridioforme, Clostridium innocuum, Erysipelotrichaceae bacterium 6_1_45, Paeniclostridium sordellii, Coprococcus comes, Dorea longicatena, Erysipelatoclostridium ramosum, Eubacterium rectale, Odoribacter species UNK.MGS-12, Parabacteroides distasonis, Parabacteroides merdae, Bacteroides xylanisolvens, Blautia obeum, Alistipes putredinis, Collinsella aerofaciens, Eubacterium hallii, Alistipes shahii, Anaerostipes caccae, Phascolarctobacterium faecium, Agathobaculum butyriciproducens, Bacteroides fragilis, and Paraclostridium bifermentans.

[0148] In one aspect, the present disclosure relates to the species Bacteroides caccae, Bacteroides intestinalis, Bacteroides faecis, Bacteroides ovatus, Bacteroides thetaiotaomicron, Bacteroides uniformis, Bacteroides vulgatus, Bifidobacterium adolescentis, Bifidobacterium longum, Bifidobacterium pseudocatenulatum, Blautia producta, Clostridium citroniae, Clostridium clostridioforme, Clostridium innocuum, Erysipelotrichaceae bacterium 6_1_45, Paeniclostridium sordellii, Coprococcus comes, Dorea longicatena, Erysipelatoclostridium ramosum, Eubacterium rectale, Odoribacter species UNK.MGS-12, Parabacteroides distasonis, Parabacteroides The present invention provides compositions essentially comprising bacterial strains of merdae, Bacteroides xylanisolvens, Blautia obeum, Alistipes putredinis, Collinsella aerofaciens, Eubacterium hallii, Alistipes shahii, Anaerostipes caccae, Phascolarctobacterium faecium, Agathobaculum butyriciproducens, Bacteroides fragilis, and Paraclostridium bifermentans. In some embodiments, as used herein, “essentially comprising” refers to compositions that do not contain any additional therapeutically active bacterial strains.

[0149] In one embodiment, the bacterial composition comprises a purified bacterial strain containing a 16S rDNA sequence having at least 97% sequence identity with the nucleic acid sequences shown as SEQ ID NOs: 1-33 and 35. In one embodiment, the bacterial composition comprises a purified bacterial strain containing a 16S rDNA sequence having at least 97% sequence identity with the nucleic acid sequences shown as SEQ ID NOs: 1-33 and 35. In one embodiment, the bacterial composition essentially consists of a purified bacterial strain containing a 16S rDNA sequence having at least 97% sequence identity with the nucleic acid sequences shown as SEQ ID NOs: 1-33 and 35.

[0150] In one aspect, the present disclosure relates to the species Bacteroides intestinalis, Bacteroides ovatus, Bacteroides thetaiotaomicron, Bacteroides uniformis, Bacteroides vulgatus, Bifidobacterium adolescentis, Bifidobacterium longum, Blautia producta, Clostridium citroniae, Clostridium clostridioforme, Clostridium innocuum, Erysipelotrichaceae bacterium 6_1_45, Coprococcus comes, Dorea longicatena, Erysipelatoclostridium ramosum, Eubacterium rectale, Parabacteroides distasonis, Bacteroides xylanisolvens, Blautia obeum, Alistipes putredinis, Collinsella aerofaciens, Eubacterium hallii, Anaerostipes The present invention provides a composition containing bacterial strains of caccae, Phascolarctobacterium faecium, Agathobaculum butyriciproducens, Fusobacterium mortiferum, and E. coli.

[0151] In one aspect, the present disclosure provides a bacterial strain comprising a bacterial strain of the species Bacteroides intestinalis, Bacteroides ovatus, Bacteroides thetaiotaomicron, Bacteroides uniformis, Bacteroides vulgatus, Bifidobacterium adolescentis, Bifidobacterium longum, Blautia producta, Clostridium citroniae, Clostridium clostridioforme, Clostridium innocuum, Erysipelotrichaceae bacterium 6_1_45, Coprococcus comes, Dorea longicatena, Erysipelatoclostridium ramosum, Eubacterium rectale, Parabacteroides distasonis, Bacteroides xylanisolvens, Blautia obeum, Alistipes putredinis, Collinsella aerofaciens, Eubacterium hallii, Anaerostipes caccae, Phascolarctobacterium faecium, Agathobaculum butyriciproducens, Fusobacterium mortiferum, and E. coli.

[0152] In one aspect, the present disclosure relates to the species Bacteroides intestinalis, Bacteroides ovatus, Bacteroides thetaiotaomicron, Bacteroides uniformis, Bacteroides vulgatus, Bifidobacterium adolescentis, Bifidobacterium longum, Blautia producta, Clostridium citroniae, Clostridium clostridioforme, Clostridium innocuum, Erysipelotrichaceae bacterium 6_1_45, Coprococcus comes, Dorea longicatena, Erysipelatoclostridium ramosum, Eubacterium rectale, Parabacteroides distasonis, Bacteroides xylanisolvens, Blautia obeum, Alistipes putredinis, Collinsella aerofaciens, Eubacterium hallii, Anaerostipes The present invention provides compositions essentially consisting of bacterial strains of *E. coli*, *Phascolarctobacterium faecium*, *Agathobaculum butyriciproducens*, *Fusobacterium mortiferum*, and *E. coli*. In some embodiments, as used herein, "essentially consisting of" refers to compositions that do not contain any additional therapeutically active bacterial strains.

[0153] In one embodiment, the bacterial composition comprises a purified bacterial strain containing a 16S rDNA sequence having at least 97% sequence identity with the nucleic acid sequences shown as SEQ ID NOs: 2, 4-9, 11-15, 17-20, 22, 24-28, 30-32, 34, and 36. In one embodiment, the bacterial composition comprises a purified bacterial strain containing a 16S rDNA sequence having at least 97% sequence identity with the nucleic acid sequences shown as SEQ ID NOs: 2, 4-9, 11-15, 17-20, 22, 24-28, 30-32, 34, and 36. In one embodiment, the bacterial composition essentially consists of a purified bacterial strain containing a 16S rDNA sequence having at least 97% sequence identity with the nucleic acid sequences shown as SEQ ID NOs: 2, 4-9, 11-15, 17-20, 22, 24-28, 30-32, 34, and 36.

[0154] In one aspect, the present disclosure relates to the species Bacteroides intestinalis, Bacteroides ovatus, Bacteroides thetaiotaomicron, Bacteroides uniformis, Bacteroides vulgatus, Bifidobacterium longum, Blautia producta, Clostridium clostridioforme, Clostridium innocuum, Erysipelotrichaceae bacterium 6_1_45, Dorea longicatena, Erysipelatoclostridium ramosum, Clostridium citroniae, Parabacteroides distasonis, Bacteroides xylanisolvens, Blautia obeum, Alistipes putredinis, Collinsella aerofaciens, Eubacterium hallii, Anaerostipes caccae, Phascolarctobacterium faecium, Agathobaculum butyriciproducens, Fusobacterium The present invention provides compositions containing bacterial strains of Mortiferum and E. coli.

[0155] In one aspect, the present disclosure provides a composition comprising bacterial strains of the species Bacteroides intestinalis, Bacteroides ovatus, Bacteroides thetaiotaomicron, Bacteroides uniformis, Bacteroides vulgatus, Bifidobacterium longum, Blautia producta, Clostridium clostridioforme, Clostridium innocuum, Erysipelotrichaceae bacterium 6_1_45, Dorea longicatena, Erysipelatoclostridium ramosum, Clostridium citoniae, Parabacteroides distasonis, Bacteroides xylanisolvens, Blautia obeum, Alistipes putredinis, Collinsella aerofaciens, Eubacterium hallii, Anaerostipes caccae, Phascolarctobacterium faecium, Agathobaculum butyriciproducens, Fusobacterium mortiferum, and E. coli.

[0156] In one aspect, the present disclosure relates to the species Bacteroides intestinalis, Bacteroides ovatus, Bacteroides thetaiotaomicron, Bacteroides uniformis, Bacteroides vulgatus, Bifidobacterium longum, Blautia producta, Clostridium clostridioforme, Clostridium innocuum, Erysipelotrichaceae bacterium 6_1_45, Dorea longicatena, Erysipelatoclostridium ramosum, Clostridium citroniae, Parabacteroides distasonis, Bacteroides xylanisolvens, Blautia obeum, Alistipes putredinis, Collinsella aerofaciens, Eubacterium hallii, Anaerostipes caccae, Phascolarctobacterium faecium, Agathobaculum butyriciproducens, Fusobacterium The present invention provides compositions essentially derived from bacterial strains of Mortiferum and E. coli. In some embodiments, as used herein, “essentially derived from” refers to compositions that do not contain any additional therapeutically active bacterial strains.

[0157] In one embodiment, the bacterial composition comprises a purified bacterial strain containing a 16S rDNA sequence having at least 97% sequence identity with the nucleic acid sequences shown as SEQ ID NOs: 2, 4-7, 9, 11, 13-15, 18-20, 22, 24-28, 30-32, 34, and 36. In one embodiment, the bacterial composition comprises a purified bacterial strain containing a 16S rDNA sequence having at least 97% sequence identity with the nucleic acid sequences shown as SEQ ID NOs: 2, 4-7, 9, 11, 13-15, 18-20, 22, 24-28, 30-32, 34, and 36. In one embodiment, the bacterial composition essentially consists of a purified bacterial strain containing a 16S rDNA sequence having at least 97% sequence identity with the nucleic acid sequences shown as SEQ ID NOs: 2, 4-7, 9, 11, 13-15, 18-20, 22, 24-28, 30-32, 34, and 36.

[0158] In one aspect, the present disclosure provides a composition comprising bacterial strains of the species Bacteroides caccae, Bacteroides intestinalis, Bacteroides ovatus, Bacteroides thetaiotaomicron, Bacteroides uniformis, Bacteroides vulgatus, Bifidobacterium longum, Blautia producta, Clostridium clostridioforme, Clostridium innocuum, Coprococcus comes, Dorea longicatena, Erysipelatoclostridium ramosum, Clostridium citroniae, Odoribacter species UNK.MGS-12, Parabacteroides distasonis, Bacteroides xylanisolvens, Blautia obeum, Alistipes putredinis, Collinsella aerofaciens, Alistipes shahii, Anaerostipes caccae, Phascolarctobacterium faecium, Agathobaculum butyriciproducens, Bacteroides fragilis, Fusobacterium mortiferum, and E. coli.

[0159] In one aspect, the present disclosure provides a composition comprising bacterial strains of the species Bacteroides caccae, Bacteroides intestinalis, Bacteroides ovatus, Bacteroides thetaiotaomicron, Bacteroides uniformis, Bacteroides vulgatus, Bifidobacterium longum, Blautia producta, Clostridium clostridioforme, Clostridium innocuum, Coprococcus comes, Dorea longicatena, Erysipelatoclostridium ramosum, Clostridium citroniae, Odoribacter species UNK.MGS-12, Parabacteroides distasonis, Bacteroides xylanisolvens, Blautia obeum, Alistipes putredinis, Collinsella aerofaciens, Alistipes shahii, Anaerostipes caccae, Phascolarctobacterium faecium, Agathobaculum butyriciproducens, Bacteroides fragilis, Fusobacterium mortiferum, and E. coli.

[0160] In one aspect, the disclosure relates to the species Bacteroides caccae, Bacteroides intestinalis, Bacteroides ovatus, Bacteroides thetaiotaomicron, Bacteroides uniformis, Bacteroides vulgatus, Bifidobacterium longum, Blautia producta, Clostridium clostridioforme, Clostridium innocuum, Coprococcus comes, Dorea longicatena, Erysipelatoclostridium ramosum, Clostridium citroniae, Odoribacter species UNK.MGS-12, Parabacteroides distasonis, Bacteroides xylanisolvens, Blautia obeum, Alistipes putredinis, Collinsella aerofaciens, Alistipes shahii, Anaerostipes caccae, Phascolarctobacterium faecium, Agathobaculum The present invention provides compositions essentially consisting of bacterial strains of butyriciproducens, Bacteroides fragilis, Fusobacterium mortiferum, and E. coli. In some embodiments, as used herein, “essentially consisting of” refers to compositions that do not contain any additional therapeutically active bacterial strains.

[0161] In one embodiment, the bacterial composition comprises a purified bacterial strain containing a 16S rDNA sequence having at least 97% sequence identity with the nucleic acid sequence shown as SEQ ID NOs: 1, 2, 4-7, 9, 11, 13, 14, 17-22, 24-27, 29-34, and 36. In one embodiment, the bacterial composition comprises a purified bacterial strain containing a 16S rDNA sequence having at least 97% sequence identity with the nucleic acid sequence shown as SEQ ID NOs: 1, 2, 4-7, 9, 11, 13, 14, 17-22, 24-27, 29-34, and 36. In one embodiment, the bacterial composition essentially consists of a purified bacterial strain containing a 16S rDNA sequence having at least 97% sequence identity with the nucleic acid sequence shown as SEQ ID NOs: 1, 2, 4-7, 9, 11, 13, 14, 17-22, 24-27, 29-34, and 36.

[0162] In one aspect, the present disclosure provides a composition comprising a bacterial strain of the species Bacteroides ovatus, Bacteroides vulgatus, Bifidobacterium adolescentis, Bifidobacterium longum, Bifidobacterium pseudocatenulatum, Blautia producta, Clostridium citroniae, Clostridium clostridioforme, Clostridium innocuum, Erysipelotrichaceae bacterium 6_1_45, Paeniclostridium sordellii, Coprococcus comes, Dorea longicatena, Erysipelatoclostridium ramosum, Eubacterium rectale, Odoribacter species UNK.MGS-12, Parabacteroides distasonis, Parabacteroides merdae, Bacteroides xylanisolvens, Blautia obeum, Alistipes putredinis, Collinsella aerofaciens, Eubacterium hallii, Alistipes shahii, Anaerostipes caccae, Phascolarctobacterium faecium, Agathobaculum butyriciproducens, Paraclostridium bifermentans, Fusobacterium mortiferum, and E. coli.

[0163] In one aspect, the present disclosure provides a composition comprising bacterial strains of the species Bacteroides ovatus, Bacteroides vulgatus, Bifidobacterium adolescentis, Bifidobacterium longum, Bifidobacterium pseudocatenulatum, Blautia producta, Clostridium citroniae, Clostridium clostridioforme, Clostridium innocuum, Erysipelotrichaceae bacterium 6_1_45, Paeniclostridium sordellii, Coprococcus comes, Dorea longicatena, Erysipelatoclostridium ramosum, Eubacterium rectale, Odoribacter species UNK.MGS-12, Parabacteroides distasonis, Parabacteroides merdae, Bacteroides xylanisolvens, Blautia obeum, Alistipes putredinis, Collinsella aerofaciens, Eubacterium hallii, Alistipes shahii, Anaerostipes caccae, Phascolarctobacterium faecium, Agathobaculum butyriciproducens, Paraclostridium bifermentans, Fusobacterium mortiferum, and E. coli.

[0164] In one aspect, the present disclosure relates to the species Bacteroides ovatus, Bacteroides vulgatus, Bifidobacterium adolescentis, Bifidobacterium longum, Bifidobacterium pseudocatenulatum, Blautia producta, Clostridium citroniae, Clostridium clostridioforme, Clostridium innocuum, Erysipelotrichaceae bacterium 6_1_45, Paeniclostridium sordellii, Coprococcus comes, Dorea longicatena, Erysipelatoclostridium ramosum, Eubacterium rectale, Odoribacter species UNK.MGS-12, Parabacteroides distasonis, Parabacteroides merdae, Bacteroides xylanisolvens, Blautia obeum, Alistipes putredinis, Collinsella The present invention provides compositions essentially comprising bacterial strains of E. coli, including E. aerofaciens, Eubacterium hallii, Alistipes shahii, Anaerostipes caccae, Phascolarctobacterium faecium, Agathobaculum butyriciproducens, Paraclostridium bifermentans, Fusobacterium mortiferum, and E. coli. In some embodiments, as used herein, “essentially comprising” refers to compositions that do not contain any additional therapeutically active bacterial strains.

[0165] In one embodiment, the bacterial composition comprises a purified bacterial strain containing a 16S rDNA sequence having at least 97% sequence identity with the nucleic acid sequences shown as SEQ ID NOs: 4, 7-32, and 34-36. In one embodiment, the bacterial composition comprises a purified bacterial strain containing a 16S rDNA sequence having at least 97% sequence identity with the nucleic acid sequences shown as SEQ ID NOs: 4, 7-32, and 34-36. In one embodiment, the bacterial composition essentially consists of a purified bacterial strain containing a 16S rDNA sequence having at least 97% sequence identity with the nucleic acid sequences shown as SEQ ID NOs: 4, 7-32, and 34-36.

[0166] In one aspect, the present disclosure provides a composition comprising a bacterial strain of the species Bacteroides caccae, Bacteroides intestinalis, Bacteroides faecis, Bacteroides ovatus, Bacteroides thetaiotaomicron, Bacteroides uniformis, Bacteroides vulgatus, Bifidobacterium longum, Blautia producta, Clostridium clostridioforme, Clostridium innocuum, Erysipelotrichaceae bacterium 6_1_45, Paeniclostridium sordellii, Dorea longicatena, Erysipelatoclostridium ramosum, Clostridium citoniae, Parabacteroides distasonis, Parabacteroides merdae, Bacteroides xylanisolvens, Blautia obeum, Alistipes putredinis, Alistipes shahii, Anaerostipes caccae, Phascolarctobacterium faecium, Agathobaculum butyriciproducens, Bacteroides fragilis, Paraclostridium bifermentans, Fusobacterium mortiferum, and E. coli.

[0167] In one aspect, the present disclosure provides a composition comprising bacterial strains of the species Bacteroides caccae, Bacteroides intestinalis, Bacteroides faecis, Bacteroides ovatus, Bacteroides thetaiotaomicron, Bacteroides uniformis, Bacteroides vulgatus, Bifidobacterium longum, Blautia producta, Clostridium clostridioforme, Clostridium innocuum, Erysipelotrichaceae bacterium 6_1_45, Paeniclostridium sordellii, Dorea longicatena, Erysipelatoclostridium ramosum, Clostridium citoniae, Parabacteroides distasonis, Parabacteroides merdae, Bacteroides xylanisolvens, Blautia obeum, Alistipes putredinis, Alistipes shahii, Anaerostipes caccae, Phascolarctobacterium faecium, Agathobaculum butyriciproducens, Bacteroides fragilis, Paraclostridium bifermentans, Fusobacterium mortiferum, and E. coli.

[0168] In one aspect, the present disclosure relates to the species Bacteroides caccae, Bacteroides intestinalis, Bacteroides faecis, Bacteroides ovatus, Bacteroides thetaiotaomicron, Bacteroides uniformis, Bacteroides vulgatus, Bifidobacterium longum, Blautia producta, Clostridium clostridioforme, Clostridium innocuum, Erysipelotrichaceae bacterium 6_1_45, Paeniclostridium sordellii, Dorea longicatena, Erysipelatoclostridium ramosum, Clostridium citroniae, Parabacteroides distasonis, Parabacteroides merdae, Bacteroides xylanisolvens, Blautia obeum, Alistipes putredinis, Alistipes shahii, Anaerostipes The present invention provides compositions essentially comprising bacterial strains of *E. coli*, *Phascolarctobacterium faecium*, *Agathobaculum butyriciproducens*, *Bacteroides fragilis*, *Paraclostridium bifermentans*, *Fusobacterium mortiferum*, and *E. coli*. In some embodiments, as used herein, "essentially comprising" refers to compositions that do not contain any additional therapeutically active bacterial strains.

[0169] In one embodiment, the bacterial composition comprises a purified bacterial strain containing a 16S rDNA sequence having at least 97% sequence identity with the nucleic acid sequences shown as SEQ ID NOs: 1-7, 9, 11, 13-16, 18-20, 22-26, and 29-36. In one embodiment, the bacterial composition comprises a purified bacterial strain containing a 16S rDNA sequence having at least 97% sequence identity with the nucleic acid sequences shown as SEQ ID NOs: 1-7, 9, 11, 13-16, 18-20, 22-26, and 29-36. In one embodiment, the bacterial composition essentially consists of a purified bacterial strain containing a 16S rDNA sequence having at least 97% sequence identity with the nucleic acid sequences shown as SEQ ID NOs: 1-7, 9, 11, 13-16, 18-20, 22-26, and 29-36.

[0170] In one aspect, the disclosure relates to the species Bacteroides caccae, Bacteroides ovatus, Bacteroides vulgatus, Bifidobacterium longum, Blautia producta, Clostridium citroniae, Clostridium clostridioforme, Clostridium innocuum, Coprococcus comes, Dorea longicatena, Erysipelatoclostridium ramosum, Odoribacter spp. Compositions are provided that include bacterial strains of UNK.MGS-12, Parabacteroides distasonis, Bacteroides xylanisolvens, Blautia obeum, Alistipes putredinis, Alistipes shahii, Anaerostipes caccae, Phascolarctobacterium faecium, Agathobaculum butyriciproducens, Fusobacterium mortiferum, and E. coli.

[0171] In one aspect, the present disclosure provides a composition comprising bacterial strains of the species Bacteroides caccae, Bacteroides ovatus, Bacteroides vulgatus, Bifidobacterium longum, Blautia producta, Clostridium citroniae, Clostridium clostridioforme, Clostridium innocuum, Coprococcus comes, Dorea longicatena, Erysipelatoclostridium ramosum, Odoribacter species UNK.MGS-12, Parabacteroides distasonis, Bacteroides xylanisolvens, Blautia obeum, Alistipes putredinis, Alistipes shahii, Anaerostipes caccae, Phascolarctobacterium faecium, Agathobaculum butyriciproducens, Fusobacterium mortiferum, and E. coli.

[0172] In one embodiment, the present disclosure provides a composition essentially consisting of bacterial strains of the species Bacteroides caccae, Bacteroides ovatus, Bacteroides vulgatus, Bifidobacterium longum, Blautia producta, Clostridium citroniae, Clostridium clostridioforme, Clostridium innocuum, Coprococcus comes, Dorea longicatena, Erysipelatoclostridium ramosum, Odoribacter species UNK.MGS-12, Parabacteroides distasonis, Bacteroides xylanisolvens, Blautia obeum, Alistipes putredinis, Alistipes shahii, Anaerostipes caccae, Phascolarctobacterium faecium, Agathobaculum butyriciproducens, Fusobacterium mortiferum, and E. coli. In some embodiments, as used herein, “essentially consisting of” refers to a composition that does not contain any additional therapeutically active bacterial strains.

[0173] In one embodiment, the bacterial composition comprises a purified bacterial strain containing a 16S rDNA sequence having at least 97% sequence identity with the nucleic acid sequence shown as SEQ ID NOs: 1, 4, 7, 9, 11-14, 17-19, 21, 22, 24-26, 29-32, 34, and 36. In one embodiment, the bacterial composition comprises a purified bacterial strain containing a 16S rDNA sequence having at least 97% sequence identity with the nucleic acid sequence shown as SEQ ID NOs: 1, 4, 7, 9, 11-14, 17-19, 21, 22, 24-26, 29-32, 34, and 36. In one embodiment, the bacterial composition essentially consists of a purified bacterial strain containing a 16S rDNA sequence having at least 97% sequence identity with the nucleic acid sequence shown as SEQ ID NOs: 1, 4, 7, 9, 11-14, 17-19, 21, 22, 24-26, 29-32, 34, and 36.

[0174] In one aspect, the present disclosure provides a composition comprising bacterial strains of the species Bacteroides caccae, Bacteroides intestinalis, Bacteroides ovatus, Bacteroides thetaiotaomicron, Bacteroides uniformis, Bacteroides vulgatus, Bifidobacterium longum, Blautia producta, Clostridium citroniae, Clostridium clostridioforme, Clostridium innocuum, Coprococcus comes, Dorea longicatena, Erysipelatoclostridium ramosum, Odoribacter species UNK.MGS-12, Parabacteroides distasonis, Bacteroides xylanisolvens, Blautia obeum, Alistipes putredinis, Collinsella aerofaciens, Alistipes shahii, Anaerostipes caccae, Phascolarctobacterium faecium, Agathobaculum butyriciproducens, Fusobacterium mortiferum, and E. coli.

[0175] In one aspect, the present disclosure provides a composition comprising bacterial strains of the species Bacteroides caccae, Bacteroides intestinalis, Bacteroides ovatus, Bacteroides thetaiotaomicron, Bacteroides uniformis, Bacteroides vulgatus, Bifidobacterium longum, Blautia producta, Clostridium citroniae, Clostridium clostridioforme, Clostridium innocuum, Coprococcus comes, Dorea longicatena, Erysipelatoclostridium ramosum, Odoribacter species UNK.MGS-12, Parabacteroides distasonis, Bacteroides xylanisolvens, Blautia obeum, Alistipes putredinis, Collinsella aerofaciens, Alistipes shahii, Anaerostipes caccae, Phascolarctobacterium faecium, Agathobaculum butyriciproducens, Fusobacterium mortiferum, and E. coli.

[0176] In one aspect, the present disclosure relates to the species Bacteroides caccae, Bacteroides intestinalis, Bacteroides ovatus, Bacteroides thetaiotaomicron, Bacteroides uniformis, Bacteroides vulgatus, Bifidobacterium longum, Blautia producta, Clostridium citroniae, Clostridium clostridioforme, Clostridium innocuum, Coprococcus comes, Dorea longicatena, Erysipelatoclostridium ramosum, Odoribacter species UNK.MGS-12, Parabacteroides distasonis, Bacteroides xylanisolvens, Blautia obeum, Alistipes putredinis, Collinsella aerofaciens, Alistipes shahii, Anaerostipes caccae, Phascolarctobacterium faecium, Agathobaculum The present invention provides compositions essentially consisting of bacterial strains of butyriciproducens, Fusobacterium mortiferum, and E. coli. In some embodiments, as used herein, “essentially consisting of” refers to compositions that do not contain any additional therapeutically active bacterial strains.

[0177] In one embodiment, the bacterial composition comprises a purified bacterial strain containing a 16S rDNA sequence having at least 97% sequence identity with the nucleic acid sequences represented as SEQ ID NOs: 1, 2, 4-7, 9, 11-14, 17-19, 21, 22, 24-27, 29-32, 34, and 36. In one embodiment, the bacterial composition comprises a purified bacterial strain containing a 16S rDNA sequence having at least 97% sequence identity with the nucleic acid sequences represented as SEQ ID NOs: 1, 2, 4-7, 9, 11-14, 17-19, 21, 22, 24-27, 29-32, 34, and 36. In one embodiment, the bacterial composition essentially consists of a purified bacterial strain containing a 16S rDNA sequence having at least 97% sequence identity with the nucleic acid sequences shown as SEQ ID NOs: 1, 2, 4-7, 9, 11-14, 17-19, 21, 22, 24-27, 29-32, 34, and 36.

[0178] In one embodiment, the present disclosure provides a composition comprising bacterial strains of the species Bacteroides ovatus, Bacteroides vulgatus, Bifidobacterium longum, Blautia producta, Clostridium citroniae, Clostridium clostridioforme, Clostridium innocuum, Coprococcus comes, Dorea longicatena, Erysipelatoclostridium ramosum, Odoribacter species UNK.MGS-12, Parabacteroides distasonis, Bacteroides xylanisolvens, Blautia obeum, Alistipes putredinis, Collinsella aerofaciens, Alistipes shahii, Anaerostipes caccae, Phascolarctobacterium faecium, Fusobacterium mortiferum, and E. coli.

[0179] In one embodiment, the present disclosure provides a composition comprising bacterial strains of the species Bacteroides ovatus, Bacteroides vulgatus, Bifidobacterium longum, Blautia producta, Clostridium citroniae, Clostridium clostridioforme, Clostridium innocuum, Coprococcus comes, Dorea longicatena, Erysipelatoclostridium ramosum, Odoribacter species UNK.MGS-12, Parabacteroides distasonis, Bacteroides xylanisolvens, Blautia obeum, Alistipes putredinis, Collinsella aerofaciens, Alistipes shahii, Anaerostipes caccae, Phascolarctobacterium faecium, Fusobacterium mortiferum, and E. coli.

[0180] In one embodiment, the present disclosure provides a composition essentially consisting of bacterial strains of the species Bacteroides ovatus, Bacteroides vulgatus, Bifidobacterium longum, Blautia producta, Clostridium citroniae, Clostridium clostridioforme, Clostridium innocuum, Coprococcus comes, Dorea longicatena, Erysipelatoclostridium ramosum, Odoribacter species UNK.MGS-12, Parabacteroides distasonis, Bacteroides xylanisolvens, Blautia obeum, Alistipes putredinis, Collinsella aerofaciens, Alistipes shahii, Anaerostipes caccae, Phascolarctobacterium faecium, Fusobacterium mortiferum, and E. coli. In some embodiments, as used herein, “essentially consisting of” refers to a composition that does not contain any additional therapeutically active bacterial strains.

[0181] In one embodiment, the bacterial composition comprises a purified bacterial strain containing a 16S rDNA sequence having at least 97% sequence identity with the nucleic acid sequences shown as SEQ ID NOs: 4, 7, 9, 11-14, 17-19, 21, 22, 24-27, 29-32, 34, and 36. In one embodiment, the bacterial composition comprises a purified bacterial strain containing a 16S rDNA sequence having at least 97% sequence identity with the nucleic acid sequences shown as SEQ ID NOs: 4, 7, 9, 11-14, 17-19, 21, 22, 24-27, 29-32, 34, and 36. In one embodiment, the bacterial composition essentially consists of a purified bacterial strain containing a 16S rDNA sequence having at least 97% sequence identity with the nucleic acid sequences shown as SEQ ID NOs: 4, 7, 9, 11-14, 17-19, 21, 22, 24-27, 29-32, 34, and 36.

[0182] In one embodiment, the present disclosure provides a composition comprising bacterial strains of the species Bacteroides ovatus, Bifidobacterium longum, Blautia producta, Clostridium clostridioforme, Clostridium innocuum, Coprococcus comes, Dorea longicatena, Erysipelatoclostridium ramosum, Odoribacter species UNK.MGS-12, Bacteroides xylanisolvens, Alistipes putredinis, Collinsella aerofaciens, Blautia obeum, Anaerostipes caccae, Agathobaculum butyriciproducens, Fusobacterium mortiferum, and E. coli.

[0183] In one embodiment, the present disclosure provides a composition comprising bacterial strains of the species Bacteroides ovatus, Bifidobacterium longum, Blautia producta, Clostridium clostridioforme, Clostridium innocuum, Coprococcus comes, Dorea longicatena, Erysipelatoclostridium ramosum, Odoribacter species UNK.MGS-12, Bacteroides xylanisolvens, Alistipes putredinis, Collinsella aerofaciens, Blautia obeum, Anaerostipes caccae, Agathobaculum butyriciproducens, Fusobacterium mortiferum, and E. coli.

[0184] In one embodiment, the present disclosure provides compositions essentially comprising bacterial strains of the species Bacteroides ovatus, Bifidobacterium longum, Blautia producta, Clostridium clostridioforme, Clostridium innocuum, Coprococcus comes, Dorea longicatena, Erysipelatoclostridium ramosum, Odoribacter species UNK.MGS-12, Bacteroides xylanisolvens, Alistipes putredinis, Collinsella aerofaciens, Blautia obeum, Anaerostipes caccae, Agathobaculum butyriciproducens, Fusobacterium mortiferum, and E. coli. In some embodiments, as used herein, “essentially comprising” means compositions that do not contain any additional therapeutically active bacterial strains.

[0185] In one embodiment, the bacterial composition comprises a purified bacterial strain containing a 16S rDNA sequence having at least 97% sequence identity with the nucleic acid sequences indicated as SEQ ID NOs: 4, 9, 11, 13, 14, 17-19, 21, 24, 26, 27, 29, 30, 32, 34, and 36. In one embodiment, the bacterial composition comprises a purified bacterial strain containing a 16S rDNA sequence having at least 97% sequence identity with the nucleic acid sequences indicated as SEQ ID NOs: 4, 9, 11, 13, 14, 17-19, 21, 24, 26, 27, 29, 30, 32, 34, and 36. In one embodiment, the bacterial composition essentially consists of a purified bacterial strain containing a 16S rDNA sequence having at least 97% sequence identity with the nucleic acid sequences shown as SEQ ID NOs: 4, 9, 11, 13, 14, 17-19, 21, 24, 26, 27, 29, 30, 32, 34, and 36.

[0186] In one aspect, the present disclosure provides a composition comprising a bacterial strain of the species Bacteroides faecis, Bacteroides ovatus, Bacteroides vulgatus, Bifidobacterium adolescentis, Bifidobacterium longum, Blautia producta, Clostridium citroniae, Clostridium clostridioforme, Clostridium innocuum, Erysipelotrichaceae bacterium 6_1_45, Paeniclostridium sordellii, Dorea longicatena, Erysipelatoclostridium ramosum, Odoribacter species UNK.MGS-12, Blautia obeum, Alistipes putredinis, Collinsella aerofaciens, Eubacterium hallii, Anaerostipes caccae, Phascolarctobacterium faecium, Agathobaculum butyriciproducens, Bacteroides fragilis, Paraclostridium bifermentans, Fusobacterium mortiferum, and E. coli.

[0187] In one aspect, the present disclosure provides a composition comprising bacterial strains of the species Bacteroides faecis, Bacteroides ovatus, Bacteroides vulgatus, Bifidobacterium adolescentis, Bifidobacterium longum, Blautia producta, Clostridium citroniae, Clostridium clostridioforme, Clostridium innocuum, Erysipelotrichaceae bacterium 6_1_45, Paeniclostridium sordellii, Dorea longicatena, Erysipelatoclostridium ramosum, Odoribacter species UNK.MGS-12, Blautia obeum, Alistipes putredinis, Collinsella aerofaciens, Eubacterium hallii, Anaerostipes caccae, Phascolarctobacterium faecium, Agathobaculum butyriciproducens, Bacteroides fragilis, Paraclostridium bifermentans, Fusobacterium mortiferum, and E. coli.

[0188] In one aspect, the present disclosure relates to the species Bacteroides faecis, Bacteroides ovatus, Bacteroides vulgatus, Bifidobacterium adolescentis, Bifidobacterium longum, Blautia producta, Clostridium citroniae, Clostridium clostridioforme, Clostridium innocuum, Erysipelotrichaceae bacterium 6_1_45, Paeniclostridium sordellii, Dorea longicatena, Erysipelatoclostridium ramosum, Odoribacter species UNK.MGS-12, Blautia obeum, Alistipes putredinis, Collinsella aerofaciens, Eubacterium hallii, Anaerostipes caccae, Phascolarctobacterium faecium, Agathobaculum butyriciproducens, Bacteroides The present invention provides compositions essentially consisting of bacterial strains of *E. fragilis*, *Paraclostridium bifermentans*, *Fusobacterium mortiferum*, and *E. coli*. In some embodiments, as used herein, "essentially consisting of" refers to compositions that do not contain any additional therapeutically active bacterial strains.

[0189] In one embodiment, the bacterial composition comprises a purified bacterial strain containing a 16S rDNA sequence having at least 97% sequence identity with the nucleic acid sequences shown as SEQ ID NOs: 3, 4, 7-9, 11-16, 18, 19, 21, 25-28, and 30-36. In one embodiment, the bacterial composition comprises a purified bacterial strain containing a 16S rDNA sequence having at least 97% sequence identity with the nucleic acid sequences shown as SEQ ID NOs: 3, 4, 7-9, 11-16, 18, 19, 21, 25-28, and 30-36. In one embodiment, the bacterial composition essentially consists of a purified bacterial strain containing a 16S rDNA sequence having at least 97% sequence identity with the nucleic acid sequences shown as SEQ ID NOs: 3, 4, 7-9, 11-16, 18, 19, 21, 25-28, and 30-36.

[0190] In one embodiment, the present disclosure provides a composition comprising bacterial strains of the species Bacteroides faecis, Bacteroides ovatus, Bacteroides vulgatus, Bifidobacterium longum, Blautia producta, Clostridium citroniae, Clostridium clostridioforme, Clostridium innocuum, Dorea longicatena, Erysipelatoclostridium ramosum, Odoribacter species UNK.MGS-12, Alistipes putredinis, Collinsella aerofaciens, Blautia obeum, Anaerostipes caccae, Phascolarctobacterium faecium, Agathobaculum butyriciproducens, Fusobacterium mortiferum, and E. coli.

[0191] In one embodiment, the present disclosure provides a composition comprising bacterial strains of the species Bacteroides faecis, Bacteroides ovatus, Bacteroides vulgatus, Bifidobacterium longum, Blautia producta, Clostridium citroniae, Clostridium clostridioforme, Clostridium innocuum, Dorea longicatena, Erysipelatoclostridium ramosum, Odoribacter species UNK.MGS-12, Alistipes putredinis, Collinsella aerofaciens, Blautia obeum, Anaerostipes caccae, Phascolarctobacterium faecium, Agathobaculum butyriciproducens, Fusobacterium mortiferum, and E. coli.

[0192] In one embodiment, the present disclosure provides compositions essentially comprising bacterial strains of the species Bacteroides faecis, Bacteroides ovatus, Bacteroides vulgatus, Bifidobacterium longum, Blautia producta, Clostridium citroniae, Clostridium clostridioforme, Clostridium innocuum, Dorea longicatena, Erysipelatoclostridium ramosum, Odoribacter species UNK.MGS-12, Alistipes putredinis, Collinsella aerofaciens, Blautia obeum, Anaerostipes caccae, Phascolarctobacterium faecium, Agathobaculum butyriciproducens, Fusobacterium mortiferum, and E. coli. In some embodiments, as used herein, “essentially comprising” means compositions that do not contain any additional therapeutically active bacterial strains.

[0193] In one embodiment, the bacterial composition comprises a purified bacterial strain containing a 16S rDNA sequence having at least 97% sequence identity with the nucleic acid sequence shown as SEQ ID NOs: 3, 4, 7, 9, 11-14, 18, 19, 21, 26, 27, 29-32, 34, and 36. In one embodiment, the bacterial composition comprises a purified bacterial strain containing a 16S rDNA sequence having at least 97% sequence identity with the nucleic acid sequence shown as SEQ ID NOs: 3, 4, 7, 9, 11-14, 18, 19, 21, 26, 27, 29-32, 34, and 36. In one embodiment, the bacterial composition essentially consists of a purified bacterial strain containing a 16S rDNA sequence having at least 97% sequence identity with the nucleic acid sequence shown as SEQ ID NOs: 3, 4, 7, 9, 11-14, 18, 19, 21, 26, 27, 29-32, 34, and 36.

[0194] In one embodiment, the present disclosure provides a composition comprising purified bacterial strains relating to the following species: Bacteroides ovatus, Bacteroides vulgatus, Bifidobacterium longum, Blautia producta, Clostridium citroniae, Clostridium clostridioforme, Clostridium innocuum, Erysipelatoclostridium ramosum, Parabacteroides distasonis, Alistipes putredinis, Collinsella aerofaciens, Blautia obeum, Anaerostipes caccae, Phascolarctobacterium faecium, Agathobaculum butyriciproducens, Fusobacterium mortiferum, and E. coli.

[0195] In one embodiment, the present disclosure provides a composition comprising purified bacterial strains relating to the following species: Bacteroides ovatus, Bacteroides vulgatus, Bifidobacterium longum, Blautia producta, Clostridium citroniae, Clostridium clostridioforme, Clostridium innocuum, Erysipelatoclostridium ramosum, Parabacteroides distasonis, Alistipes putredinis, Collinsella aerofaciens, Blautia obeum, Anaerostipes caccae, Phascolarctobacterium faecium, Agathobaculum butyriciproducens, Fusobacterium mortiferum, and E. coli.

[0196] In one embodiment, the present disclosure provides compositions essentially consisting of purified bacterial strains relating to the following species: Bacteroides ovatus, Bacteroides vulgatus, Bifidobacterium longum, Blautia producta, Clostridium citroniae, Clostridium clostridioforme, Clostridium innocuum, Erysipelatoclostridium ramosum, Parabacteroides distasonis, Alistipes putredinis, Collinsella aerofaciens, Blautia obeum, Anaerostipes caccae, Phascolarctobacterium faecium, Agathobaculum butyriciproducens, Fusobacterium mortiferum, and E. coli. In some embodiments, as used herein, “essentially consisting of” means compositions that do not contain any additional therapeutically active bacterial strains.

[0197] In one embodiment, the bacterial composition comprises a purified bacterial strain containing a 16S rDNA sequence having at least 97% sequence identity with the nucleic acid sequence shown as SEQ ID NOs: 4, 7, 9, 11-14, 19, 22, 26, 27, 29-32, 34, and 36. In one embodiment, the bacterial composition comprises a purified bacterial strain containing a 16S rDNA sequence having at least 97% sequence identity with the nucleic acid sequence shown as SEQ ID NOs: 4, 7, 9, 11-14, 19, 22, 26, 27, 29-32, 34, and 36. In one embodiment, the bacterial composition essentially consists of a purified bacterial strain containing a 16S rDNA sequence having at least 97% sequence identity with the nucleic acid sequence shown as SEQ ID NOs: 4, 7, 9, 11-14, 19, 22, 26, 27, 29-32, 34, and 36.

[0198] In one embodiment, the present disclosure provides a composition comprising purified bacterial strains relating to the following species: Bacteroides ovatus, Bacteroides vulgatus, Bifidobacterium longum, Blautia producta, Clostridium citroniae, Clostridium clostridioforme, Erysipelotrichaceae bacterium 6_1_45, Dorea longicatena, Erysipelatoclostridium ramosum, Blautia obeum, Alistipes putredinis, Collinsella aerofaciens, Phascolarctobacterium faecium, Fusobacterium mortiferum, and E. coli.

[0199] In one embodiment, the present disclosure provides a composition comprising purified bacterial strains relating to the following species: Bacteroides ovatus, Bacteroides vulgatus, Bifidobacterium longum, Blautia producta, Clostridium citroniae, Clostridium clostridioforme, Erysipelotrichaceae bacterium 6_1_45, Dorea longicatena, Erysipelatoclostridium ramosum, Blautia obeum, Alistipes putredinis, Collinsella aerofaciens, Phascolarctobacterium faecium, Fusobacterium mortiferum, and E. coli.

[0200] In one embodiment, the present disclosure provides compositions essentially consisting of purified bacterial strains relating to the following species: Bacteroides ovatus, Bacteroides vulgatus, Bifidobacterium longum, Blautia producta, Clostridium citroniae, Clostridium clostridioforme, Erysipelotrichaceae bacterium 6_1_45, Dorea longicatena, Erysipelatoclostridium ramosum, Blautia obeum, Alistipes putredinis, Collinsella aerofaciens, Phascolarctobacterium faecium, Fusobacterium mortiferum, and E. coli. In some embodiments, as used herein, “essentially consisting of” means compositions that do not contain any additional therapeutically active bacterial strains.

[0201] In one embodiment, the bacterial composition comprises a purified bacterial strain containing a 16S rDNA sequence having at least 97% sequence identity with the nucleic acid sequence shown as SEQ ID NOs: 4, 7, 9, 11-13, 15, 18, 19, 25-27, 31, 34, and 36. In one embodiment, the bacterial composition comprises a purified bacterial strain containing a 16S rDNA sequence having at least 97% sequence identity with the nucleic acid sequence shown as SEQ ID NOs: 4, 7, 9, 11-13, 15, 18, 19, 25-27, 31, 34, and 36. In one embodiment, the bacterial composition essentially consists of a purified bacterial strain containing a 16S rDNA sequence having at least 97% sequence identity with the nucleic acid sequence shown as SEQ ID NOs: 4, 7, 9, 11-13, 15, 18, 19, 25-27, 31, 34, and 36.

[0202] In one aspect, the present disclosure provides a method for treating bacterial infections caused by the following species: Collinsella aerofaciens, Bifidobacterium pseudocatenulatum, Bifidobacterium adolescentis, Bifidobacterium longum, Bacteroides ovatus, Bacteroides thetaiotaomicron, Bacteroides xylanisolvens, Bacteroides caccae, Bacteroides cellulosilyticus, Bacteroides faecis, Bacteroides fragilis, Bacteroides uniformis, Bacteroides vulgatus, Odoribacter splanchnicus, Parabacteroides distasonis, Parabacteroides merdae, Alistipes putredinis, Alistipes shahii, Clostridium citroniae, Clostridium clostridioforme, Clostridium bifermentans, Clostridium sordellii, Clostridium innocuum, Erysipelatoclostridium ramosum, Erysipelotrichaceae bacterium 6_1_45, Eubacterium hallii, Eubacterium rectale, Anaerostipes caccae, Blautia obeum, Blautia producta, Coprococcus comes, Dorea longicatena, Agathobaculum butyriciproducens, Phascolarctobacterium faecium, Escherichia coli, and Fusobacterium mortiferum, related to purified bacteria.

[0203] In one aspect, the present disclosure provides a method for treating bacterial infections caused by the following species: Collinsella aerofaciens, Bifidobacterium pseudocatenulatum, Bifidobacterium adolescentis, Bifidobacterium longum, Bacteroides ovatus, Bacteroides thetaiotaomicron, Bacteroides xylanisolvens, Bacteroides caccae, Bacteroides cellulosilyticus, Bacteroides faecis, Bacteroides fragilis, Bacteroides uniformis, Bacteroides vulgatus, Odoribacter splanchnicus, Parabacteroides distasonis, Parabacteroides merdae, Alistipes putredinis, Alistipes shahii, Clostridium citroniae, Clostridium clostridioforme, Clostridium bifermentans, Clostridium sordellii, Clostridium innocuum, Erysipelatoclostridium ramosum, Erysipelotrichaceae bacterium 6_1_45, Eubacterium hallii, Eubacterium rectale, Anaerostipes caccae, Blautia obeum, Blautia producta, Coprococcus comes, Dorea longicatena, Agathobaculum butyriciproducens, Phascolarctobacterium faecium, Escherichia coli, and Fusobacterium mortiferum related to the composition of purified bacteria.

[0204] In one aspect, the present disclosure relates to the following species Collinsella aerofaciens, Bifidobacterium pseudocatenulatum, Bifidobacterium adolescentis, Bifidobacterium longum, Bacteroides ovatus, Bacteroides thetaiotaomicron, Bacteroides xylanisolvens, Bacteroides caccae, Bacteroides cellulosilyticus, Bacteroides faecis, Bacteroides fragilis, Bacteroides uniformis, Bacteroides vulgatus, Odoribacter splanchnicus, Parabacteroides distasonis, Parabacteroides merdae, Alistipes putredinis, Alistipes shahii, Clostridium citroniae, Clostridium clostridioforme, Clostridium bifermentans, Clostridium sordellii, Clostridium The present invention provides compositions essentially consisting of purified bacterial strains related to innocuum, Erysipelatoclostridium ramosum, Erysipelotrichaceae bacterium 6145, Eubacterium hallii, Eubacterium rectale, Anaerostipes caccae, Blautia obeum, Blautia producta, Coprococcus comes, Dorea longicatena, Agathobaculum butyriciproducens, Phascolarctobacterium faecium, Escherichia coli, and Fusobacterium mortiferum. In some embodiments, as used herein, “essentially consisting of” refers to compositions that do not contain any additional therapeutically active bacterial strains.

[0205] In one embodiment, the bacterial composition comprises a purified bacterial strain containing a 16S rDNA sequence having at least 97% sequence identity with the nucleic acid sequences represented as SEQ ID NOs: 27, 10, 8, 9, 4, 5, 24, 1, 2, 3, 33, 6, 7, 21, 22, 23, 26, 29, 12, 13, 35, 16, 14, 19, 15, 28, 20, 30, 25, 11, 17, 18, 32, 31, 36, and 34. In one embodiment, the bacterial composition comprises a purified bacterial strain containing a 16S rDNA sequence having at least 97% sequence identity with the nucleic acid sequences represented as SEQ ID NOs: 27, 10, 8, 9, 4, 5, 24, 1, 2, 3, 33, 6, 7, 21, 22, 23, 26, 29, 12, 13, 35, 16, 14, 19, 15, 28, 20, 30, 25, 11, 17, 18, 32, 31, 36, and 34. In one embodiment, the bacterial composition essentially consists of a purified bacterial strain containing a 16S rDNA sequence having at least 97% sequence identity with the nucleic acid sequences shown as SEQ ID NOs: 27, 10, 8, 9, 4, 5, 24, 1, 2, 3, 33, 6, 7, 21, 22, 23, 26, 29, 12, 13, 35, 16, 14, 19, 15, 28, 20, 30, 25, 11, 17, 18, 32, 31, 36, and 34. In one embodiment, the bacterial consortium is LBP-1 (see, for example, Figure 35).

[0206] In one aspect, the present disclosure provides a composition comprising purified bacterial strains associated with the following species: Collinsella aerofaciens, Bifidobacterium pseudocatenulatum, Bifidobacterium adolescentis, Bifidobacterium longum, Bacteroides ovatus, Bacteroides thetaiotaomicron, Bacteroides xylanisolvens, Bacteroides caccae, Bacteroides cellulosilyticus, Bacteroides faecis, Bacteroides uniformis, Bacteroides vulgatus, Odoribacter splanchnicus, Parabacteroides distasonis, Parabacteroides merdae, Alistipes putredinis, Alistipes shahii, Clostridium citroniae, Clostridium clostridioforme, Clostridium sordellii, Clostridium innocuum, Erysipelatoclostridium ramosum, Erysipelotrichaceae bacterium 6_1_45, Eubacterium hallii, Eubacterium rectale, Anaerostipes caccae, Blautia obeum, Blautia producta, Coprococcus comes, Dorea longicatena, and Agathobaculum butyriciproducens.

[0207] In one aspect, the present disclosure provides a composition comprising purified bacterial strains associated with the following species: Collinsella aerofaciens, Bifidobacterium pseudocatenulatum, Bifidobacterium adolescentis, Bifidobacterium longum, Bacteroides ovatus, Bacteroides thetaiotaomicron, Bacteroides xylanisolvens, Bacteroides caccae, Bacteroides cellulosilyticus, Bacteroides faecis, Bacteroides uniformis, Bacteroides vulgatus, Odoribacter splanchnicus, Parabacteroides distasonis, Parabacteroides merdae, Alistipes putredinis, Alistipes shahii, Clostridium citroniae, Clostridium clostridioforme, Clostridium sordellii, Clostridium innocuum, Erysipelatoclostridium ramosum, Erysipelotrichaceae bacterium 6_1_45, Eubacterium hallii, Eubacterium rectale, Anaerostipes caccae, Blautia obeum, Blautia producta, Coprococcus comes, Dorea longicatena, and Agathobaculum butyriciproducens.

[0208] In one aspect, the present disclosure relates to the following species Collinsella aerofaciens, Bifidobacterium pseudocatenulatum, Bifidobacterium adolescentis, Bifidobacterium longum, Bacteroides ovatus, Bacteroides thetaiotaomicron, Bacteroides xylanisolvens, Bacteroides caccae, Bacteroides cellulosilyticus, Bacteroides faecis, Bacteroides uniformis, Bacteroides vulgatus, Odoribacter splanchnicus, Parabacteroides distasonis, Parabacteroides merdae, Alistipes putredinis, Alistipes shahii, Clostridium citroniae, Clostridium clostridioforme, Clostridium sordellii, Clostridium innocuum, Erysipelatoclostridium ramosum, Erysipelotrichaceae The present invention provides compositions essentially consisting of purified bacterial strains related to bacterium 6_1_45, Eubacterium hallii, Eubacterium rectale, Anaerostipes caccae, Blautia obeum, Blautia producta, Coprococcus comes, Dorea longicatena, and Agathobaculum butyriciproducens. In some embodiments, as used herein, “essentially consisting of” refers to compositions that do not contain any additional therapeutically active bacterial strains.

[0209] In one embodiment, the bacterial composition comprises a purified bacterial strain containing a 16S rDNA sequence having at least 97% sequence identity with the nucleic acid sequences shown as SEQ ID NOs: 27, 10, 8, 9, 4, 5, 24, 1, 2, 3, 6, 7, 21, 22, 23, 26, 29, 1, 2, 3, 6, 7, 21, 22, 23, 26, 29, 12, 13, 16, 14, 19, 15, 28, 20, 30, 25, 11, 17, 18, and 32. In one embodiment, the bacterial composition essentially consists of a purified bacterial strain containing a 16S rDNA sequence having at least 97% sequence identity with the nucleic acid sequence shown as SEQ ID NOs: 27, 10, 8, 9, 4, 5, 24, 1, 2, 3, 6, 7, 21, 22, 23, 26, 29, 12, 13, 16, 14, 19, 15, 28, 20, 30, 25, 11, 17, 18, and 32. In one embodiment, the bacterial consortium is LBP-9 (see, for example, Figure 35).

[0210] In one aspect, the present disclosure provides a method for producing a bacterial culture of the following species: Collinsella aerofaciens, Bifidobacterium pseudocatenulatum, Bifidobacterium adolescentis, Bifidobacterium longum, Bacteroides ovatus, Bacteroides thetaiotaomicron, Bacteroides xylanisolvens, Bacteroides caccae, Bacteroides cellulosilyticus, Bacteroides faecis, Bacteroides fragilis, Bacteroides uniformis, Bacteroides vulgatus, Odoribacter splanchnicus, Parabacteroides distasonis, Parabacteroides merdae, Alistipes putredinis, Alistipes shahii, Clostridium citroniae, Clostridium clostridioforme, Clostridium bifermentans, Clostridium sordellii, Clostridium innocuum, Erysipelatoclostridium ramosum, Erysipelotrichaceae bacterium 6_1_45, Eubacterium hallii, Eubacterium rectale, Blautia obeum, Blautia producta, Coprococcus comes, Dorea longicatena, Escherichia coli, and Fusobacterium provide a composition containing purified bacteria strains related to the deadly

[0211] In one aspect, the present disclosure provides a method for producing a bacterial culture of the following species: Collinsella aerofaciens, Bifidobacterium pseudocatenulatum, Bifidobacterium adolescentis, Bifidobacterium longum, Bacteroides ovatus, Bacteroides thetaiotaomicron, Bacteroides xylanisolvens, Bacteroides caccae, Bacteroides cellulosilyticus, Bacteroides faecis, Bacteroides fragilis, Bacteroides uniformis, Bacteroides vulgatus, Odoribacter splanchnicus, Parabacteroides distasonis, Parabacteroides merdae, Alistipes putredinis, Alistipes shahii, Clostridium citroniae, Clostridium clostridioforme, Clostridium bifermentans, Clostridium sordellii, Clostridium innocuum, Erysipelatoclostridium ramosum, Erysipelotrichaceae bacterium 6_1_45, Eubacterium hallii, Eubacterium rectale, Blautia obeum, Blautia producta, Coprococcus comes, Dorea longicatena, Escherichia coli, and Fusobacterium provide a composition consisting of purified bacteria strains related to the deadly

[0212] In one aspect, the present disclosure relates to the following species Collinsella aerofaciens, Bifidobacterium pseudocatenulatum, Bifidobacterium adolescentis, Bifidobacterium longum, Bacteroides ovatus, Bacteroides thetaiotaomicron, Bacteroides xylanisolvens, Bacteroides caccae, Bacteroides cellulosilyticus, Bacteroides faecis, Bacteroides fragilis, Bacteroides uniformis, Bacteroides vulgatus, Odoribacter splanchnicus, Parabacteroides distasonis, Parabacteroides merdae, Alistipes putredinis, Alistipes shahii, Clostridium citroniae, Clostridium clostridioforme, Clostridium bifermentans, Clostridium sordellii, Clostridium The present invention provides compositions essentially consisting of purified bacterial strains related to innocuum, Erysipelatoclostridium ramosum, Erysipelotrichaceae bacterium 6145, Eubacterium hallii, Eubacterium rectale, Blautia obeum, Blautia producta, Coprococcus comes, Dorea longicatena, Escherichia coli, and Fusobacterium mortiferum. In some embodiments, as used herein, “essentially consisting of” refers to compositions that do not contain any additional therapeutically active bacterial strains.

[0213] In one embodiment, the bacterial composition comprises a purified bacterial strain containing a 16S rDNA sequence having at least 97% sequence identity with the nucleic acid sequences represented as SEQ ID NOs: 27, 10, 8, 9, 4, 5, 24, 1, 2, 3, 33, 6, 7, 21, 22, 23, 26, 29, 12, 13, 35, 16, 14, 19, 15, 28, 20, 25, 11, 17, 18, 36, and 34. In one embodiment, the bacterial composition comprises a purified bacterial strain containing a 16S rDNA sequence having at least 97% sequence identity with the nucleic acid sequences represented as SEQ ID NOs: 27, 10, 8, 9, 4, 5, 24, 1, 2, 3, 33, 6, 7, 21, 22, 23, 26, 29, 12, 13, 35, 16, 14, 19, 15, 28, 20, 25, 11, 17, 18, 36, and 34. In one embodiment, the bacterial composition essentially consists of a purified bacterial strain containing a 16S rDNA sequence having at least 97% sequence identity with the nucleic acid sequences shown as SEQ ID NOs: 27, 10, 8, 9, 4, 5, 24, 1, 2, 3, 33, 6, 7, 21, 22, 23, 26, 29, 12, 13, 35, 16, 14, 19, 15, 28, 20, 25, 11, 17, 18, 36, and 34. In one embodiment, the bacterial consortium is LBP-10 (see, for example, Figure 35).

[0214] In one aspect, the present disclosure provides a method for treating bacterial infections caused by the following species: Collinsella aerofaciens, Bifidobacterium pseudocatenulatum, Bifidobacterium adolescentis, Bifidobacterium longum, Bacteroides ovatus, Bacteroides thetaiotaomicron, Bacteroides xylanisolvens, Bacteroides caccae, Bacteroides cellulosilyticus, Bacteroides faecis, Bacteroides fragilis, Bacteroides uniformis, Bacteroides vulgatus, Odoribacter splanchnicus, Parabacteroides distasonis, Parabacteroides merdae, Alistipes putredinis, Alistipes shahii, Clostridium citroniae, Clostridium clostridioforme, Clostridium bifermentans, Clostridium sordellii, Clostridium innocuum, Erysipelatoclostridium ramosum, Erysipelotrichaceae bacterium 6_1_45, Eubacterium hallii, Eubacterium rectale, Anaerostipes caccae, Blautia obeum, Blautia producta, Coprococcus comes, Dorea longicatena, Agathobaculum butyriciproducens, Phascolarctobacterium faecium, and Fusobacterium mortiferum, related to purified bacteria.

[0215] In one aspect, the present disclosure provides a method for treating bacterial infections caused by the following species: Collinsella aerofaciens, Bifidobacterium pseudocatenulatum, Bifidobacterium adolescentis, Bifidobacterium longum, Bacteroides ovatus, Bacteroides thetaiotaomicron, Bacteroides xylanisolvens, Bacteroides caccae, Bacteroides cellulosilyticus, Bacteroides faecis, Bacteroides fragilis, Bacteroides uniformis, Bacteroides vulgatus, Odoribacter splanchnicus, Parabacteroides distasonis, Parabacteroides merdae, Alistipes putredinis, Alistipes shahii, Clostridium citroniae, Clostridium clostridioforme, Clostridium bifermentans, Clostridium sordellii, Clostridium innocuum, Erysipelatoclostridium ramosum, Erysipelotrichaceae bacterium 6_1_45, Eubacterium hallii, Eubacterium rectale, Anaerostipes caccae, Blautia obeum, Blautia producta, Coprococcus comes, Dorea longicatena, Agathobaculum butyriciproducens, Phascolarctobacterium faecium, and Fusobacterium mortiferum, related to the purified bacterial strain.

[0216] In one aspect, the present disclosure relates to the following species Collinsella aerofaciens, Bifidobacterium pseudocatenulatum, Bifidobacterium adolescentis, Bifidobacterium longum, Bacteroides ovatus, Bacteroides thetaiotaomicron, Bacteroides xylanisolvens, Bacteroides caccae, Bacteroides cellulosilyticus, Bacteroides faecis, Bacteroides fragilis, Bacteroides uniformis, Bacteroides vulgatus, Odoribacter splanchnicus, Parabacteroides distasonis, Parabacteroides merdae, Alistipes putredinis, Alistipes shahii, Clostridium citroniae, Clostridium clostridioforme, Clostridium bifermentans, Clostridium sordellii, Clostridium The present invention provides compositions essentially consisting of purified bacterial strains related to innocuum, Erysipelatoclostridium ramosum, Erysipelotrichaceae bacterium 6145, Eubacterium hallii, Eubacterium rectale, Anaerostipes caccae, Blautia obeum, Blautia producta, Coprococcus comes, Dorea longicatena, Agathobaculum butyriciproducens, Phascolarctobacterium faecium, and Fusobacterium mortiferum. In some embodiments, as used herein, “essentially consisting of” refers to compositions that do not contain any additional therapeutically active bacterial strains.

[0217] In one embodiment, the bacterial composition comprises a purified bacterial strain containing a 16S rDNA sequence having at least 97% sequence identity with the nucleic acid sequences represented as SEQ ID NOs: 27, 10, 8, 9, 4, 5, 24, 1, 2, 3, 33, 6, 7, 21, 22, 23, 26, 29, 12, 13, 35, 16, 14, 19, 15, 28, 20, 30, 25, 11, 17, 18, 32, 31, and 34. In one embodiment, the bacterial composition consists of a purified bacterial strain containing a 16S rDNA sequence having at least 97% sequence identity with the nucleic acid sequences represented as SEQ ID NOs: 27, 10, 8, 9, 4, 5, 24, 1, 2, 3, 33, 6, 7, 21, 22, 23, 26, 29, 12, 13, 35, 16, 14, 19, 15, 28, 20, 30, 25, 11, 17, 18, 32, 31, and 34. In one embodiment, the bacterial composition essentially consists of a purified bacterial strain containing a 16S rDNA sequence having at least 97% sequence identity with the nucleic acid sequences shown as SEQ ID NOs: 27, 10, 8, 9, 4, 5, 24, 1, 2, 3, 33, 6, 7, 21, 22, 23, 26, 29, 12, 13, 35, 16, 14, 19, 15, 28, 20, 30, 25, 11, 17, 18, 32, 31, and 34. In one embodiment, the bacterial consortium is LBP-11 (see, for example, Figure 35).

[0218] In one aspect, the present disclosure provides a method for treating bacterial infections caused by the following species: Collinsella aerofaciens, Bifidobacterium pseudocatenulatum, Bifidobacterium adolescentis, Bifidobacterium longum, Bacteroides ovatus, Bacteroides thetaiotaomicron, Bacteroides xylanisolvens, Bacteroides caccae, Bacteroides cellulosilyticus, Bacteroides faecis, Bacteroides fragilis, Bacteroides uniformis, Bacteroides vulgatus, Odoribacter splanchnicus, Parabacteroides distasonis, Parabacteroides merdae, Alistipes putredinis, Alistipes shahii, Clostridium citroniae, Clostridium clostridioforme, Clostridium bifermentans, Clostridium sordellii, Clostridium innocuum, Erysipelatoclostridium ramosum, Erysipelotrichaceae bacterium 6_1_45, Eubacterium hallii, Eubacterium rectale, Anaerostipes caccae, Blautia obeum, Blautia producta, Coprococcus comes, Dorea longicatena, Agathobaculum butyriciproducens, Phascolarctobacterium faecium, and Escherichia coli related to the purified bacteria.

[0219] In one aspect, the present disclosure provides a method for treating bacterial infections caused by the following species: Collinsella aerofaciens, Bifidobacterium pseudocatenulatum, Bifidobacterium adolescentis, Bifidobacterium longum, Bacteroides ovatus, Bacteroides thetaiotaomicron, Bacteroides xylanisolvens, Bacteroides caccae, Bacteroides cellulosilyticus, Bacteroides faecis, Bacteroides fragilis, Bacteroides uniformis, Bacteroides vulgatus, Odoribacter splanchnicus, Parabacteroides distasonis, Parabacteroides merdae, Alistipes putredinis, Alistipes shahii, Clostridium citroniae, Clostridium clostridioforme, Clostridium bifermentans, Clostridium sordellii, Clostridium innocuum, Erysipelatoclostridium ramosum, Erysipelotrichaceae bacterium 6_1_45, Eubacterium hallii, Eubacterium rectale, Anaerostipes caccae, Blautia obeum, Blautia producta, Coprococcus comes, Dorea longicatena, Agathobaculum butyriciproducens, Phascolarctobacterium faecium, and Escherichia coli.

[0220] In one aspect, the present disclosure relates to the following species Collinsella aerofaciens, Bifidobacterium pseudocatenulatum, Bifidobacterium adolescentis, Bifidobacterium longum, Bacteroides ovatus, Bacteroides thetaiotaomicron, Bacteroides xylanisolvens, Bacteroides caccae, Bacteroides cellulosilyticus, Bacteroides faecis, Bacteroides fragilis, Bacteroides uniformis, Bacteroides vulgatus, Odoribacter splanchnicus, Parabacteroides distasonis, Parabacteroides merdae, Alistipes putredinis, Alistipes shahii, Clostridium citroniae, Clostridium clostridioforme, Clostridium bifermentans, Clostridium sordellii, Clostridium The present invention provides compositions essentially consisting of purified bacterial strains related to innocuum, Erysipelatoclostridium ramosum, Erysipelotrichaceae bacterium 6145, Eubacterium hallii, Eubacterium rectale, Anaerostipes caccae, Blautia obeum, Blautia producta, Coprococcus comes, Dorea longicatena, Agathobaculum butyriciproducens, Phascolarctobacterium faecium, and Escherichia coli. In some embodiments, as used herein, “essentially consisting of” refers to compositions that do not contain any additional therapeutically active bacterial strains.

[0221] In one embodiment, the bacterial composition comprises a purified bacterial strain containing a 16S rDNA sequence having at least 97% sequence identity with the nucleic acid sequences represented as SEQ ID NOs: 27, 10, 8, 9, 4, 5, 24, 1, 2, 3, 33, 6, 7, 21, 22, 23, 26, 29, 12, 13, 35, 16, 14, 19, 15, 28, 20, 30, 25, 11, 17, 18, 32, 31, and 36. In one embodiment, the bacterial composition comprises a purified bacterial strain containing a 16S rDNA sequence having at least 97% sequence identity with the nucleic acid sequences represented as SEQ ID NOs: 27, 10, 8, 9, 4, 5, 24, 1, 2, 3, 33, 6, 7, 21, 22, 23, 26, 29, 12, 13, 35, 16, 14, 19, 15, 28, 20, 30, 25, 11, 17, 18, 32, 31, and 36. In one embodiment, the bacterial composition essentially consists of a purified bacterial strain containing a 16S rDNA sequence having at least 97% sequence identity with the nucleic acid sequences shown as SEQ ID NOs: 27, 10, 8, 9, 4, 5, 24, 1, 2, 3, 33, 6, 7, 21, 22, 23, 26, 29, 12, 13, 35, 16, 14, 19, 15, 28, 20, 30, 25, 11, 17, 18, 32, 31, and 36. In one embodiment, the bacterial consortium is LBP-12 (see, for example, Figure 35).

[0222] In one aspect, the present disclosure provides a composition comprising purified bacterial strains associated with the following species: Collinsella aerofaciens, Bifidobacterium pseudocatenulatum, Bifidobacterium adolescentis, Bifidobacterium longum, Bacteroides ovatus, Bacteroides thetaiotaomicron, Bacteroides xylanisolvens, Bacteroides caccae, Bacteroides cellulosilyticus, Bacteroides faecis, Bacteroides uniformis, Bacteroides vulgatus, Odoribacter splanchnicus, Parabacteroides distasonis, Parabacteroides merdae, Alistipes putredinis, Alistipes shahii, Clostridium citroniae, Clostridium clostridioforme, Clostridium innocuum, Erysipelatoclostridium ramosum, Erysipelotrichaceae bacterium 6_1_45, Eubacterium hallii, Eubacterium rectale, Blautia obeum, Blautia producta, Coprococcus comes, Dorea longicatena, Escherichia coli, and Fusobacterium mortiferum.

[0223] In one aspect, the present disclosure provides a composition comprising purified bacterial strains associated with the following species: Collinsella aerofaciens, Bifidobacterium pseudocatenulatum, Bifidobacterium adolescentis, Bifidobacterium longum, Bacteroides ovatus, Bacteroides thetaiotaomicron, Bacteroides xylanisolvens, Bacteroides caccae, Bacteroides cellulosilyticus, Bacteroides faecis, Bacteroides uniformis, Bacteroides vulgatus, Odoribacter splanchnicus, Parabacteroides distasonis, Parabacteroides merdae, Alistipes putredinis, Alistipes shahii, Clostridium citroniae, Clostridium clostridioforme, Clostridium innocuum, Erysipelatoclostridium ramosum, Erysipelotrichaceae bacterium 6_1_45, Eubacterium hallii, Eubacterium rectale, Blautia obeum, Blautia producta, Coprococcus comes, Dorea longicatena, Escherichia coli, and Fusobacterium mortiferum.

[0224] In one aspect, the present disclosure relates to the following species Collinsella aerofaciens, Bifidobacterium pseudocatenulatum, Bifidobacterium adolescentis, Bifidobacterium longum, Bacteroides ovatus, Bacteroides thetaiotaomicron, Bacteroides xylanisolvens, Bacteroides caccae, Bacteroides cellulosilyticus, Bacteroides faecis, Bacteroides uniformis, Bacteroides vulgatus, Odoribacter splanchnicus, Parabacteroides distasonis, Parabacteroides merdae, Alistipes putredinis, Alistipes shahii, Clostridium citroniae, Clostridium clostridioforme, Clostridium innocuum, Erysipelatoclostridium ramosum, Erysipelotrichaceae bacterium The present invention provides compositions essentially consisting of purified bacterial strains related to 6_1_45, Eubacterium hallii, Eubacterium rectale, Blautia obeum, Blautia producta, Coprococcus comes, Dorea longicatena, Escherichia coli, and Fusobacterium mortiferum. In some embodiments, as used herein, “essentially consisting of” refers to compositions that do not contain any additional therapeutically active bacterial strains.

[0225] In one embodiment, the bacterial composition comprises a purified bacterial strain containing a 16S rDNA sequence having at least 97% sequence identity with the nucleic acid sequences represented as SEQ ID NOs: 27, 10, 8, 9, 4, 5, 24, 1, 2, 3, 6, 7, 1, 2, 3, 6, 7, 28, 20, 25, 11, 17, 18, 36, and 34. In one embodiment, the bacterial composition comprises a purified bacterial strain containing a 16S rDNA sequence having at least 97% sequence identity with the nucleic acid sequences represented as SEQ ID NOs: 27, 10, 8, 9, 4, 5, 24, 1, 2, 3, 6, 7, 21, 22, 23, 26, 29, 12, 13, 14, 19, 15, 28, 20, 25, 11, 17, 18, 36, and 34. In one embodiment, the bacterial composition essentially consists of a purified bacterial strain containing a 16S rDNA sequence having at least 97% sequence identity with the nucleic acid sequence shown as SEQ ID NOs: 27, 10, 8, 9, 4, 5, 24, 1, 2, 3, 6, 7, 21, 22, 23, 26, 29, 12, 13, 14, 19, 15, 28, 20, 25, 11, 17, 18, 36, and 34. In one embodiment, the bacterial consortium is LBP-13 (see, for example, Figure 35).

[0226] In one embodiment, the present disclosure provides a composition comprising purified bacterial strains relating to the following species: Bifidobacterium longum, Bacteroides ovatus, Bacteroides xylanisolvens, Bacteroides cellulosilyticus, Bacteroides faecis, Bacteroides uniformis, Bacteroides vulgatus, Odoribacter splanchnicus, Parabacteroides distasonis, Alistipes putredinis, Clostridium citroniae, Clostridium clostridioforme, Clostridium innocuum, Erysipelatoclostridium ramosum, Eubacterium hallii, Eubacterium rectale, Blautia obeum, Blautia producta, Dorea longicatena, Escherichia coli, and Fusobacterium mortiferum.

[0227] In one embodiment, the present disclosure provides a composition comprising purified bacterial strains relating to the following species: Bifidobacterium longum, Bacteroides ovatus, Bacteroides xylanisolvens, Bacteroides cellulosilyticus, Bacteroides faecis, Bacteroides uniformis, Bacteroides vulgatus, Odoribacter splanchnicus, Parabacteroides distasonis, Alistipes putredinis, Clostridium citroniae, Clostridium clostridioforme, Clostridium innocuum, Erysipelatoclostridium ramosum, Eubacterium hallii, Eubacterium rectale, Blautia obeum, Blautia producta, Dorea longicatena, Escherichia coli, and Fusobacterium mortiferum.

[0228] In one embodiment, the present disclosure provides a composition essentially consisting of purified bacterial strains relating to the following species: Bifidobacterium longum, Bacteroides ovatus, Bacteroides xylanisolvens, Bacteroides cellulosilyticus, Bacteroides faecis, Bacteroides uniformis, Bacteroides vulgatus, Odoribacter splanchnicus, Parabacteroides distasonis, Alistipes putredinis, Clostridium citroniae, Clostridium clostridioforme, Clostridium innocuum, Erysipelatoclostridium ramosum, Eubacterium hallii, Eubacterium rectale, Blautia obeum, Blautia producta, Dorea longicatena, Escherichia coli, and Fusobacterium mortiferum. In some embodiments, as used herein, “essentially consisting of” refers to a composition that does not contain any additional therapeutically active bacterial strains.

[0229] In one embodiment, the bacterial composition comprises a purified bacterial strain containing a 16S rDNA sequence having at least 97% sequence identity with the nucleic acid sequence shown as SEQ ID NOs: 9, 4, 24, 2, 3, 6, 7, 21, 22, 26, 12, 13, 14, 19, 28, 20, 25, 11, 18, 36, and 34. In one embodiment, the bacterial composition comprises a purified bacterial strain containing a 16S rDNA sequence having at least 97% sequence identity with the nucleic acid sequence shown as SEQ ID NOs: 9, 4, 24, 2, 3, 6, 7, 21, 22, 26, 12, 13, 14, 19, 28, 20, 25, 11, 18, 36, and 34. In one embodiment, the bacterial composition essentially consists of a purified bacterial strain containing a 16S rDNA sequence having at least 97% sequence identity with the nucleic acid sequence shown as SEQ ID NOs: 9, 4, 24, 2, 3, 6, 7, 21, 22, 26, 12, 13, 14, 19, 28, 20, 25, 11, 18, 36, and 34. In one embodiment, the bacterial consortium is LBP-14 (see, for example, Figure 35).

[0230] In one aspect, the present disclosure relates to the following species: Bacteroides ovatus, Bacteroides thetaiotaomicron, Bacteroides xylanisolvens, Bacteroides caccae, Bacteroides cellulosilyticus, Bacteroides faecis, Bacteroides uniformis, Bacteroides vulgatus, Parabacteroides merdae, Alistipes putredinis, Alistipes shahii, Clostridium citroniae, Clostridium clostridioforme, Clostridium innocuum, Erysipelatoclostridium ramosum, Erysipelotrichaceae bacterium 6_1_45, Eubacterium hallii, Eubacterium rectale, Blautia obeum, Blautia producta, Coprococcus comes, Dorea longicatena, Escherichia coli, and Fusobacterium The present invention provides a composition containing a purified bacterial strain related to Mortiferum.

[0231] In one aspect, the present disclosure relates to the following species: Bacteroides ovatus, Bacteroides thetaiotaomicron, Bacteroides xylanisolvens, Bacteroides caccae, Bacteroides cellulosilyticus, Bacteroides faecis, Bacteroides uniformis, Bacteroides vulgatus, Parabacteroides merdae, Alistipes putredinis, Alistipes shahii, Clostridium citroniae, Clostridium clostridioforme, Clostridium innocuum, Erysipelatoclostridium ramosum, Erysipelotrichaceae bacterium 6_1_45, Eubacterium hallii, Eubacterium rectale, Blautia obeum, Blautia producta, Coprococcus comes, Dorea longicatena, Escherichia coli, and Fusobacterium The present invention provides a composition comprising purified bacterial strains related to Mortiferum.

[0232] In one aspect, the present disclosure relates to the following species: Bacteroides ovatus, Bacteroides thetaiotaomicron, Bacteroides xylanisolvens, Bacteroides caccae, Bacteroides cellulosilyticus, Bacteroides faecis, Bacteroides uniformis, Bacteroides vulgatus, Parabacteroides merdae, Alistipes putredinis, Alistipes shahii, Clostridium citroniae, Clostridium clostridioforme, Clostridium innocuum, Erysipelatoclostridium ramosum, Erysipelotrichaceae bacterium 6_1_45, Eubacterium hallii, Eubacterium rectale, Blautia obeum, Blautia producta, Coprococcus comes, Dorea longicatena, Escherichia coli, and Fusobacterium The present invention provides compositions essentially derived from purified bacterial strains related to Mortiferum. In some embodiments, as used herein, “essentially derived from” refers to compositions that do not contain any additional therapeutically active bacterial strains.

[0233] In one embodiment, the bacterial composition comprises a purified bacterial strain containing a 16S rDNA sequence having at least 97% sequence identity with the nucleic acid sequences represented as SEQ ID NOs: 4, 5, 24, 1, 2, 3, 6, 7, 26, 29, 12, 13, 14, 19, 15, 28, 20, 25, 11, 17, 18, 36, and 34. In one embodiment, the bacterial composition comprises a purified bacterial strain containing a 16S rDNA sequence having at least 97% sequence identity with the nucleic acid sequences represented as SEQ ID NOs: 4, 5, 24, 1, 2, 3, 6, 7, 26, 29, 12, 13, 14, 19, 15, 28, 20, 25, 11, 17, 18, 36, and 34. In one embodiment, the bacterial composition essentially consists of a purified bacterial strain containing a 16S rDNA sequence having at least 97% sequence identity with the nucleic acid sequences represented as SEQ ID NOs: 4, 5, 24, 1, 2, 3, 6, 7, 26, 29, 12, 13, 14, 19, 15, 28, 20, 25, 11, 17, 18, 36, and 34. In one embodiment, the bacterial consortium is LBP-15 (see, for example, Figure 35).

[0234] In one aspect, the present disclosure relates to the following species Collinsella aerofaciens, Bifidobacterium pseudocatenulatum, Bifidobacterium adolescentis, Bifidobacterium longum, Bacteroides ovatus, Bacteroides thetaiotaomicron, Bacteroides xylanisolvens, Bacteroides caccae, Bacteroides cellulosilyticus, Bacteroides faecis, Bacteroides fragilis, Bacteroides uniformis, Bacteroides vulgatus, Odoribacter splanchnicus, Parabacteroides distasonis, Parabacteroides merdae, Alistipes putredinis, Alistipes shahii, Clostridium bifermentans, Clostridium sordellii, Clostridium innocuum, Erysipelatoclostridium ramosum, Erysipelotrichaceae bacterium The present invention provides a composition comprising purified bacterial strains related to 6_1_45, Phascolarctobacterium faecium, Escherichia coli, and Fusobacterium mortiferum.

[0235] In one aspect, the present disclosure relates to the following species Collinsella aerofaciens, Bifidobacterium pseudocatenulatum, Bifidobacterium adolescentis, Bifidobacterium longum, Bacteroides ovatus, Bacteroides thetaiotaomicron, Bacteroides xylanisolvens, Bacteroides caccae, Bacteroides cellulosilyticus, Bacteroides faecis, Bacteroides fragilis, Bacteroides uniformis, Bacteroides vulgatus, Odoribacter splanchnicus, Parabacteroides distasonis, Parabacteroides merdae, Alistipes putredinis, Alistipes shahii, Clostridium bifermentans, Clostridium sordellii, Clostridium innocuum, Erysipelatoclostridium ramosum, Erysipelotrichaceae bacterium The present invention provides a composition comprising purified bacterial strains related to 6_1_45, Phascolarctobacterium faecium, Escherichia coli, and Fusobacterium mortiferum.

[0236] In one aspect, the present disclosure relates to the following species Collinsella aerofaciens, Bifidobacterium pseudocatenulatum, Bifidobacterium adolescentis, Bifidobacterium longum, Bacteroides ovatus, Bacteroides thetaiotaomicron, Bacteroides xylanisolvens, Bacteroides caccae, Bacteroides cellulosilyticus, Bacteroides faecis, Bacteroides fragilis, Bacteroides uniformis, Bacteroides vulgatus, Odoribacter splanchnicus, Parabacteroides distasonis, Parabacteroides merdae, Alistipes putredinis, Alistipes shahii, Clostridium bifermentans, Clostridium sordellii, Clostridium innocuum, Erysipelatoclostridium ramosum, Erysipelotrichaceae bacterium 6_1_45 provides compositions essentially consisting of purified bacterial strains related to Phascolarctobacterium faecium, Escherichia coli, and Fusobacterium mortiferum. In some embodiments, as used herein, “essentially consisting of” refers to compositions that do not contain any additional therapeutically active bacterial strains.

[0237] In one embodiment, the bacterial composition comprises a purified bacterial strain containing a 16S rDNA sequence having at least 97% sequence identity with the nucleic acid sequences represented as SEQ ID NOs: 27, 10, 8, 9, 4, 5, 24, 1, 2, 3, 24, 1, 2, 3, 29, 35, 16, 14, 19, 15, 31, 36, and 34. In one embodiment, the bacterial composition comprises a purified bacterial strain containing a 16S rDNA sequence having at least 97% sequence identity with the nucleic acid sequences represented as SEQ ID NOs: 27, 10, 8, 9, 4, 5, 24, 1, 2, 3, 33, 6, 7, 21, 22, 23, 26, 29, 35, 16, 14, 19, 15, 31, 36, and 34. In one embodiment, the bacterial composition essentially consists of a purified bacterial strain containing a 16S rDNA sequence having at least 97% sequence identity with the nucleic acid sequence represented as SEQ ID NOs: 27, 10, 8, 9, 4, 5, 24, 1, 2, 3, 33, 6, 7, 21, 22, 23, 26, 29, 35, 16, 14, 19, 15, 31, 36, and 34. In one embodiment, the bacterial consortium is LBP-16 (see, for example, Figure 35).

[0238] In one embodiment, the present disclosure provides a composition comprising purified bacterial strains relating to the following species: Bacteroides ovatus, Bacteroides thetaiotaomicron, Bacteroides xylanisolvens, Bacteroides caccae, Bacteroides cellulosilyticus, Bacteroides faecis, Bacteroides uniformis, Bacteroides vulgatus, Alistipes putredinis, Alistipes shahii, Clostridium citroniae, Clostridium clostridioforme, Clostridium innocuum, Erysipelatoclostridium ramosum, Erysipelotrichaceae bacterium 6_1_45, Eubacterium hallii, Eubacterium rectale, Blautia obeum, Blautia producta, Coprococcus comes, Dorea longicatena, and Escherichia coli.

[0239] In one embodiment, the present disclosure provides a composition comprising purified bacterial strains relating to the following species: Bacteroides ovatus, Bacteroides thetaiotaomicron, Bacteroides xylanisolvens, Bacteroides caccae, Bacteroides cellulosilyticus, Bacteroides faecis, Bacteroides uniformis, Bacteroides vulgatus, Alistipes putredinis, Alistipes shahii, Clostridium citroniae, Clostridium clostridioforme, Clostridium innocuum, Erysipelatoclostridium ramosum, Erysipelotrichaceae bacterium 6_1_45, Eubacterium hallii, Eubacterium rectale, Blautia obeum, Blautia producta, Coprococcus comes, Dorea longicatena, and Escherichia coli.

[0240] In one embodiment, the present disclosure provides a composition essentially consisting of purified bacterial strains relating to the following species: Bacteroides ovatus, Bacteroides thetaiotaomicron, Bacteroides xylanisolvens, Bacteroides caccae, Bacteroides cellulosilyticus, Bacteroides faecis, Bacteroides uniformis, Bacteroides vulgatus, Alistipes putredinis, Alistipes shahii, Clostridium citroniae, Clostridium clostridioforme, Clostridium innocuum, Erysipelatoclostridium ramosum, Erysipelotrichaceae bacterium 6_1_45, Eubacterium hallii, Eubacterium rectale, Blautia obeum, Blautia producta, Coprococcus comes, Dorea longicatena, and Escherichia coli. In some embodiments, as used herein, “essentially consisting of” refers to a composition that does not contain any additional therapeutically active bacterial strains.

[0241] In one embodiment, the bacterial composition comprises a purified bacterial strain containing a 16S rDNA sequence having at least 97% sequence identity with the nucleic acid sequences represented as SEQ ID NOs: 4, 5, 24, 1, 2, 3, 6, 7, 26, 29, 12, 13, 14, 19, 15, 28, 20, 25, 11, 17, 18, and 36. In one embodiment, the bacterial composition comprises a purified bacterial strain containing a 16S rDNA sequence having at least 97% sequence identity with the nucleic acid sequences represented as SEQ ID NOs: 4, 5, 24, 1, 2, 3, 6, 7, 26, 29, 12, 13, 14, 19, 15, 28, 20, 25, 11, 17, 18, and 36. In one embodiment, the bacterial composition essentially consists of a purified bacterial strain containing a 16S rDNA sequence having at least 97% sequence identity with the nucleic acid sequences shown as SEQ ID NOs: 4, 5, 24, 1, 2, 3, 6, 7, 26, 29, 12, 13, 14, 19, 15, 28, 20, 25, 11, 17, 18, and 36. In one embodiment, the bacterial consortium is LBP-17 (see, for example, Figure 35).

[0242] In one embodiment, the present disclosure provides a composition comprising purified bacterial strains relating to the following species: Bacteroides ovatus, Bacteroides thetaiotaomicron, Bacteroides xylanisolvens, Bacteroides caccae, Bacteroides cellulosilyticus, Bacteroides faecis, Bacteroides uniformis, Bacteroides vulgatus, Alistipes putredinis, Alistipes shahii, Clostridium citroniae, Clostridium clostridioforme, Clostridium innocuum, Erysipelatoclostridium ramosum, Erysipelotrichaceae bacterium 6_1_45, Eubacterium hallii, Eubacterium rectale, Blautia obeum, Blautia producta, Coprococcus comes, and Dorea longicatena.

[0243] In one embodiment, the present disclosure provides a composition comprising purified bacterial strains relating to the following species: Bacteroides ovatus, Bacteroides thetaiotaomicron, Bacteroides xylanisolvens, Bacteroides caccae, Bacteroides cellulosilyticus, Bacteroides faecis, Bacteroides uniformis, Bacteroides vulgatus, Alistipes putredinis, Alistipes shahii, Clostridium citroniae, Clostridium clostridioforme, Clostridium innocuum, Erysipelatoclostridium ramosum, Erysipelotrichaceae bacterium 6_1_45, Eubacterium hallii, Eubacterium rectale, Blautia obeum, Blautia producta, Coprococcus comes, and Dorea longicatena.

[0244] In one embodiment, the present disclosure provides a composition essentially consisting of purified bacterial strains relating to the following species: Bacteroides ovatus, Bacteroides thetaiotaomicron, Bacteroides xylanisolvens, Bacteroides caccae, Bacteroides cellulosilyticus, Bacteroides faecis, Bacteroides uniformis, Bacteroides vulgatus, Alistipes putredinis, Alistipes shahii, Clostridium citroniae, Clostridium clostridioforme, Clostridium innocuum, Erysipelatoclostridium ramosum, Erysipelotrichaceae bacterium 6_1_45, Eubacterium hallii, Eubacterium rectale, Blautia obeum, Blautia producta, Coprococcus comes, and Dorea longicatena. In some embodiments, as used herein, “essentially consisting of” refers to a composition that does not contain any additional therapeutically active bacterial strains.

[0245] In one embodiment, the bacterial composition comprises a purified bacterial strain containing a 16S rDNA sequence having at least 97% sequence identity with the nucleic acid sequences shown as SEQ ID NOs: 4, 5, 24, 1, 2, 3, 6, 7, 26, 29, 12, 13, 14, 19, 15, 28, 20, 25, 11, 17, and 18. In one embodiment, the bacterial composition comprises a purified bacterial strain containing a 16S rDNA sequence having at least 97% sequence identity with the nucleic acid sequences shown as SEQ ID NOs: 4, 5, 24, 1, 2, 3, 6, 7, 26, 29, 12, 13, 14, 19, 15, 28, 20, 25, 11, 17, and 18. In one embodiment, the bacterial composition essentially consists of a purified bacterial strain containing a 16S rDNA sequence having at least 97% sequence identity with the nucleic acid sequences shown as SEQ ID NOs: 4, 5, 24, 1, 2, 3, 6, 7, 26, 29, 12, 13, 14, 19, 15, 28, 20, 25, 11, 17, and 18. In one embodiment, the bacterial consortium is LBP-18 (see, for example, Figure 35).

[0246] In one embodiment, the present disclosure provides a composition comprising purified bacterial strains relating to the following species: Bacteroides ovatus, Bacteroides thetaiotaomicron, Bacteroides xylanisolvens, Bacteroides caccae, Bacteroides cellulosilyticus, Bacteroides faecis, Bacteroides uniformis, Bacteroides vulgatus, Alistipes putredinis, Alistipes shahii, Clostridium clostridioforme, Clostridium innocuum, Erysipelatoclostridium ramosum, Erysipelotrichaceae bacterium 6_1_45, Eubacterium hallii, Blautia obeum, Blautia producta, Coprococcus comes, Escherichia coli, and Fusobacterium mortiferum.

[0247] In one embodiment, the present disclosure provides a composition comprising purified bacterial strains relating to the following species: Bacteroides ovatus, Bacteroides thetaiotaomicron, Bacteroides xylanisolvens, Bacteroides caccae, Bacteroides cellulosilyticus, Bacteroides faecis, Bacteroides uniformis, Bacteroides vulgatus, Alistipes putredinis, Alistipes shahii, Clostridium clostridioforme, Clostridium innocuum, Erysipelatoclostridium ramosum, Erysipelotrichaceae bacterium 6_1_45, Eubacterium hallii, Blautia obeum, Blautia producta, Coprococcus comes, Escherichia coli, and Fusobacterium mortiferum.

[0248] In one embodiment, the present disclosure provides compositions essentially consisting of purified bacterial strains relating to the following species: Bacteroides ovatus, Bacteroides thetaiotaomicron, Bacteroides xylanisolvens, Bacteroides caccae, Bacteroides cellulosilyticus, Bacteroides faecis, Bacteroides uniformis, Bacteroides vulgatus, Alistipes putredinis, Alistipes shahii, Clostridium clostridioforme, Clostridium innocuum, Erysipelatoclostridium ramosum, Erysipelotrichaceae bacterium 6_1_45, Eubacterium hallii, Blautia obeum, Blautia producta, Coprococcus comes, Escherichia coli, and Fusobacterium mortiferum. In some embodiments, as used herein, “essentially consisting of” means compositions that do not contain any additional therapeutically active bacterial strains.

[0249] In one embodiment, the bacterial composition comprises a purified bacterial strain containing a 16S rDNA sequence having at least 97% sequence identity with the nucleic acid sequences represented as SEQ ID NOs: 4, 5, 24, 1, 2, 3, 6, 7, 26, 29, 13, 14, 19, 15, 28, 25, 11, 17, 34, and 36. In one embodiment, the bacterial composition comprises a purified bacterial strain containing a 16S rDNA sequence having at least 97% sequence identity with the nucleic acid sequences represented as SEQ ID NOs: 4, 5, 24, 1, 2, 3, 6, 7, 26, 29, 13, 14, 19, 15, 28, 25, 11, 17, 34, and 36. In one embodiment, the bacterial composition essentially consists of a purified bacterial strain containing a 16S rDNA sequence having at least 97% sequence identity with the nucleic acid sequences shown as SEQ ID NOs: 4, 5, 24, 1, 2, 3, 6, 7, 26, 29, 13, 14, 19, 15, 28, 25, 11, 17, 34, and 36. In one embodiment, the bacterial consortium is LBP-19 (see, for example, Figure 35).

[0250] In one aspect, the present disclosure provides a method for treating bacterial infections caused by the following species: Collinsella aerofaciens, Bifidobacterium pseudocatenulatum, Bifidobacterium adolescentis, Bifidobacterium longum, Bacteroides ovatus, Bacteroides thetaiotaomicron, Bacteroides xylanisolvens, Bacteroides caccae, Bacteroides cellulosilyticus, Bacteroides faecis, Bacteroides fragilis, Bacteroides uniformis, Bacteroides vulgatus, Odoribacter splanchnicus, Parabacteroides distasonis, Parabacteroides merdae, Alistipes putredinis, Alistipes shahii, Clostridium citroniae, Clostridium clostridioforme, Clostridium bifermentans, Clostridium sordellii, Clostridium innocuum, Erysipelatoclostridium ramosum, Erysipelotrichaceae bacterium 6_1_45, Eubacterium hallii, Eubacterium rectale, Anaerostipes caccae, Blautia obeum, Blautia producta, Coprococcus comes, Dorea longicatena, Agathobaculum butyriciproducens, and Phascolarctobacterium faecium related to the purified bacteria to provide a composition containing.

[0251] In one aspect, the present disclosure provides a method for treating bacterial infections caused by the following species: Collinsella aerofaciens, Bifidobacterium pseudocatenulatum, Bifidobacterium adolescentis, Bifidobacterium longum, Bacteroides ovatus, Bacteroides thetaiotaomicron, Bacteroides xylanisolvens, Bacteroides caccae, Bacteroides cellulosilyticus, Bacteroides faecis, Bacteroides fragilis, Bacteroides uniformis, Bacteroides vulgatus, Odoribacter splanchnicus, Parabacteroides distasonis, Parabacteroides merdae, Alistipes putredinis, Alistipes shahii, Clostridium citroniae, Clostridium clostridioforme, Clostridium bifermentans, Clostridium sordellii, Clostridium innocuum, Erysipelatoclostridium ramosum, Erysipelotrichaceae bacterium 6_1_45, Eubacterium hallii, Eubacterium rectale, Anaerostipes caccae, Blautia obeum, Blautia producta, Coprococcus comes, Dorea longicatena, Agathobaculum butyriciproducens, and Phascolarctobacterium faecium related to the composition of purified bacteria.

[0252] In one aspect, the present disclosure relates to the following species Collinsella aerofaciens, Bifidobacterium pseudocatenulatum, Bifidobacterium adolescentis, Bifidobacterium longum, Bacteroides ovatus, Bacteroides thetaiotaomicron, Bacteroides xylanisolvens, Bacteroides caccae, Bacteroides cellulosilyticus, Bacteroides faecis, Bacteroides fragilis, Bacteroides uniformis, Bacteroides vulgatus, Odoribacter splanchnicus, Parabacteroides distasonis, Parabacteroides merdae, Alistipes putredinis, Alistipes shahii, Clostridium citroniae, Clostridium clostridioforme, Clostridium bifermentans, Clostridium sordellii, Clostridium The present invention provides compositions essentially consisting of purified bacterial strains related to innocuum, Erysipelatoclostridium ramosum, Erysipelotrichaceae bacterium 6145, Eubacterium hallii, Eubacterium rectale, Anaerostipes caccae, Blautia obeum, Blautia producta, Coprococcus comes, Dorea longicatena, Agathobaculum butyriciproducens, and Phascolarctobacterium faecium. In some embodiments, as used herein, “essentially consisting of” refers to compositions that do not contain any additional therapeutically active bacterial strains.

[0253] In one embodiment, the bacterial composition comprises a purified bacterial strain containing a 16S rDNA sequence having at least 97% sequence identity with the nucleic acid sequences represented as SEQ ID NOs: 27, 10, 8, 9, 4, 5, 24, 1, 2, 3, 33, 6, 7, 21, 22, 23, 26, 29, 12, 13, 35, 16, 14, 19, 15, 28, 20, 30, 25, 11, 17, 18, 32, and 31. In one embodiment, the bacterial composition comprises a purified bacterial strain containing a 16S rDNA sequence having at least 97% sequence identity with the nucleic acid sequences represented as SEQ ID NOs: 27, 10, 8, 9, 4, 5, 24, 1, 2, 3, 33, 6, 7, 21, 22, 23, 26, 29, 12, 13, 35, 16, 14, 19, 15, 28, 20, 30, 25, 11, 17, 18, 32, and 31. In one embodiment, the bacterial composition essentially consists of a purified bacterial strain containing a 16S rDNA sequence having at least 97% sequence identity with the nucleic acid sequences shown as SEQ ID NOs: 27, 10, 8, 9, 4, 5, 24, 1, 2, 3, 33, 6, 7, 21, 22, 23, 26, 29, 12, 13, 35, 16, 14, 19, 15, 28, 20, 30, 25, 11, 17, 18, 32, and 31. In one embodiment, the bacterial consortium is LBP-20 (see, for example, Figure 35).

[0254] In one aspect, the present disclosure provides a method for producing a bacterial culture of the following species: Collinsella aerofaciens, Bifidobacterium pseudocatenulatum, Bifidobacterium adolescentis, Bifidobacterium longum, Bacteroides ovatus, Bacteroides thetaiotaomicron, Bacteroides xylanisolvens, Bacteroides caccae, Bacteroides cellulosilyticus, Bacteroides faecis, Bacteroides uniformis, Bacteroides vulgatus, Odoribacter splanchnicus, Parabacteroides distasonis, Parabacteroides merdae, Alistipes putredinis, Alistipes shahii, Clostridium citroniae, Clostridium clostridioforme, Clostridium innocuum, Erysipelatoclostridium ramosum, Erysipelotrichaceae bacterium 6_1_45, Eubacterium hallii, Eubacterium rectale, Anaerostipes caccae, Blautia obeum, Blautia producta, Coprococcus comes, Dorea longicatena, Agathobaculum butyriciproducens, Phascolarctobacterium faecium, Escherichia coli, and Fusobacterium mortiferum related to the purified bacteria strains to provide a composition.

[0255] In one aspect, the present disclosure provides a method for producing a bacterial culture of the following species: Collinsella aerofaciens, Bifidobacterium pseudocatenulatum, Bifidobacterium adolescentis, Bifidobacterium longum, Bacteroides ovatus, Bacteroides thetaiotaomicron, Bacteroides xylanisolvens, Bacteroides caccae, Bacteroides cellulosilyticus, Bacteroides faecis, Bacteroides uniformis, Bacteroides vulgatus, Odoribacter splanchnicus, Parabacteroides distasonis, Parabacteroides merdae, Alistipes putredinis, Alistipes shahii, Clostridium citroniae, Clostridium clostridioforme, Clostridium innocuum, Erysipelatoclostridium ramosum, Erysipelotrichaceae bacterium 6_1_45, Eubacterium hallii, Eubacterium rectale, Anaerostipes caccae, Blautia obeum, Blautia producta, Coprococcus comes, Dorea longicatena, Agathobaculum butyriciproducens, Phascolarctobacterium faecium, Escherichia coli, and Fusobacterium mortiferum related to a purified bacterial strain composition.

[0256] In one aspect, the present disclosure relates to the following species Collinsella aerofaciens, Bifidobacterium pseudocatenulatum, Bifidobacterium adolescentis, Bifidobacterium longum, Bacteroides ovatus, Bacteroides thetaiotaomicron, Bacteroides xylanisolvens, Bacteroides caccae, Bacteroides cellulosilyticus, Bacteroides faecis, Bacteroides uniformis, Bacteroides vulgatus, Odoribacter splanchnicus, Parabacteroides distasonis, Parabacteroides merdae, Alistipes putredinis, Alistipes shahii, Clostridium citroniae, Clostridium clostridioforme, Clostridium innocuum, Erysipelatoclostridium ramosum, Erysipelotrichaceae bacterium The present invention provides compositions essentially consisting of purified bacterial strains related to 6_1_45, Eubacterium hallii, Eubacterium rectale, Anaerostipes caccae, Blautia obeum, Blautia producta, Coprococcus comes, Dorea longicatena, Agathobaculum butyriciproducens, Phascolarctobacterium faecium, Escherichia coli, and Fusobacterium mortiferum. In some embodiments, as used herein, “essentially consisting of” refers to compositions that do not contain any additional therapeutically active bacterial strains.

[0257] In one embodiment, the bacterial composition comprises a purified bacterial strain containing a 16S rDNA sequence having at least 97% sequence identity with the nucleic acid sequences represented as SEQ ID NOs: 27, 10, 8, 9, 4, 5, 24, 1, 2, 3, 33, 6, 7, 21, 22, 23, 26, 29, 12, 13, 14, 19, 15, 28, 20, 30, 25, 11, 17, 18, 32, 31, 36, and 34. In one embodiment, the bacterial composition consists of a purified bacterial strain containing a 16S rDNA sequence having at least 97% sequence identity with the nucleic acid sequences represented as SEQ ID NOs: 27, 10, 8, 9, 4, 5, 24, 1, 2, 3, 33, 6, 7, 21, 22, 23, 26, 29, 12, 13, 14, 19, 15, 28, 20, 30, 25, 11, 17, 18, 32, 31, 36, and 34. In one embodiment, the bacterial composition essentially consists of a purified bacterial strain containing a 16S rDNA sequence having at least 97% sequence identity with the nucleic acid sequences shown as SEQ ID NOs: 27, 10, 8, 9, 4, 5, 24, 1, 2, 3, 33, 6, 7, 21, 22, 23, 26, 29, 12, 13, 14, 19, 15, 28, 20, 30, 25, 11, 17, 18, 32, 31, 36, and 34. In one embodiment, the bacterial consortium is LBP-21 (see, for example, Figure 35).

[0258] In one aspect, the present disclosure relates to the following species: Collinsella aerofaciens, Bifidobacterium adolescentis, Bifidobacterium longum, Bacteroides ovatus, Bacteroides thetaiotaomicron, Bacteroides xylanisolvens, Bacteroides cellulosilyticus, Bacteroides uniformis, Bacteroides vulgatus, Parabacteroides distasonis, Alistipes putredinis, Clostridium citroniae, Clostridium clostridioforme, Clostridium innocuum, Erysipelatoclostridium ramosum, Erysipelotrichaceae bacterium 6_1_45, Eubacterium hallii, Eubacterium rectale, Anaerostipes caccae, Blautia obeum, Blautia producta, Coprococcus comes, Dorea The present invention provides a composition comprising purified bacterial strains related to longicatena, Agathobaculum butyriciproducens, Phascolarctobacterium faecium, Escherichia coli, and Fusobacterium mortiferum.

[0259] In one aspect, the present disclosure relates to the following species: Collinsella aerofaciens, Bifidobacterium adolescentis, Bifidobacterium longum, Bacteroides ovatus, Bacteroides thetaiotaomicron, Bacteroides xylanisolvens, Bacteroides cellulosilyticus, Bacteroides uniformis, Bacteroides vulgatus, Parabacteroides distasonis, Alistipes putredinis, Clostridium citroniae, Clostridium clostridioforme, Clostridium innocuum, Erysipelatoclostridium ramosum, Erysipelotrichaceae bacterium 6_1_45, Eubacterium hallii, Eubacterium rectale, Anaerostipes caccae, Blautia obeum, Blautia producta, Coprococcus comes, Dorea The present invention provides a composition comprising purified bacterial strains related to longicatena, Agathobaculum butyriciproducens, Phascolarctobacterium faecium, Escherichia coli, and Fusobacterium mortiferum.

[0260] In one aspect, the present disclosure relates to the following species: Collinsella aerofaciens, Bifidobacterium adolescentis, Bifidobacterium longum, Bacteroides ovatus, Bacteroides thetaiotaomicron, Bacteroides xylanisolvens, Bacteroides cellulosilyticus, Bacteroides uniformis, Bacteroides vulgatus, Parabacteroides distasonis, Alistipes putredinis, Clostridium citroniae, Clostridium clostridioforme, Clostridium innocuum, Erysipelatoclostridium ramosum, Erysipelotrichaceae bacterium 6_1_45, Eubacterium hallii, Eubacterium rectale, Anaerostipes caccae, Blautia obeum, Blautia producta, Coprococcus comes, Dorea The present invention provides compositions essentially consisting of purified bacterial strains related to longicatena, Agathobaculum butyriciproducens, Phascolarctobacterium faecium, Escherichia coli, and Fusobacterium mortiferum. In some embodiments, as used herein, “essentially consisting of” refers to compositions that do not contain any additional therapeutically active bacterial strains.

[0261] In one embodiment, the bacterial composition comprises a purified bacterial strain containing a 16S rDNA sequence having at least 97% sequence identity with the nucleic acid sequence represented as SEQ ID NOs: 27, 8, 9, 4, 5, 24, 2, 6, 7, 22, 26, 12, 6, 7, 22, 26, 12, 13, 14, 22, 26, 28, 20, 30, 25, 11, 17, 18, 32, 31, 36, and 34. In one embodiment, the bacterial composition essentially consists of a purified bacterial strain containing a 16S rDNA sequence having at least 97% sequence identity with the nucleic acid sequence shown as SEQ ID NOs: 27, 8, 9, 4, 5, 24, 2, 6, 7, 22, 26, 12, 13, 14, 19, 15, 28, 20, 30, 25, 11, 17, 18, 32, 31, 36, and 34. In one embodiment, the bacterial consortium is LBP-22 (see, for example, Figure 35).

[0262] In one aspect, the present disclosure relates to the following species Collinsella aerofaciens, Bifidobacterium longum, Bacteroides ovatus, Bacteroides thetaiotaomicron, Bacteroides xylanisolvens, Bacteroides cellulosilyticus, Bacteroides uniformis, Bacteroides vulgatus, Parabacteroides distasonis, Alistipes putredinis, Clostridium citroniae, Clostridium clostridioforme, Clostridium innocuum, Erysipelatoclostridium ramosum, Erysipelotrichaceae bacterium 6_1_45, Eubacterium hallii, Anaerostipes caccae, Blautia obeum, Blautia producta, Dorea longicatena, Agathobaculum butyriciproducens, Phascolarctobacterium The present invention provides a composition containing purified bacterial strains related to Faecium, Escherichia coli, and Fusobacterium mortiferum.

[0263] In one aspect, the present disclosure relates to the following species Collinsella aerofaciens, Bifidobacterium longum, Bacteroides ovatus, Bacteroides thetaiotaomicron, Bacteroides xylanisolvens, Bacteroides cellulosilyticus, Bacteroides uniformis, Bacteroides vulgatus, Parabacteroides distasonis, Alistipes putredinis, Clostridium citroniae, Clostridium clostridioforme, Clostridium innocuum, Erysipelatoclostridium ramosum, Erysipelotrichaceae bacterium 6_1_45, Eubacterium hallii, Anaerostipes caccae, Blautia obeum, Blautia producta, Dorea longicatena, Agathobaculum butyriciproducens, Phascolarctobacterium The present invention provides a composition comprising purified bacterial strains related to Faecium, Escherichia coli, and Fusobacterium mortiferum.

[0264] In one aspect, the present disclosure relates to the following species Collinsella aerofaciens, Bifidobacterium longum, Bacteroides ovatus, Bacteroides thetaiotaomicron, Bacteroides xylanisolvens, Bacteroides cellulosilyticus, Bacteroides uniformis, Bacteroides vulgatus, Parabacteroides distasonis, Alistipes putredinis, Clostridium citroniae, Clostridium clostridioforme, Clostridium innocuum, Erysipelatoclostridium ramosum, Erysipelotrichaceae bacterium 6_1_45, Eubacterium hallii, Anaerostipes caccae, Blautia obeum, Blautia producta, Dorea longicatena, Agathobaculum butyriciproducens, Phascolarctobacterium The present invention provides compositions essentially consisting of purified bacterial strains related to Faecium, Escherichia coli, and Fusobacterium mortiferum. In some embodiments, as used herein, “essentially consisting of” refers to compositions that do not contain any additional therapeutically active bacterial strains.

[0265] In one embodiment, the bacterial composition comprises a purified bacterial strain containing a 16S rDNA sequence having at least 97% sequence identity with the nucleic acid sequences represented as SEQ ID NOs: 27, 9, 4, 5, 24, 2, 6, 7, 22, 26, 12, 13, 14, 19, 15, 28, 30, 25, 11, 18, 32, 31, 36, and 24. In one embodiment, the bacterial composition comprises a purified bacterial strain containing a 16S rDNA sequence having at least 97% sequence identity with the nucleic acid sequences represented as SEQ ID NOs: 27, 9, 4, 5, 24, 2, 6, 7, 22, 26, 12, 13, 14, 19, 15, 28, 30, 25, 11, 18, 32, 31, 36, and 24. In one embodiment, the bacterial composition essentially consists of a purified bacterial strain containing a 16S rDNA sequence having at least 97% sequence identity with the nucleic acid sequences represented as SEQ ID NOs: 27, 9, 4, 5, 24, 2, 6, 7, 22, 26, 12, 13, 14, 19, 15, 28, 30, 25, 11, 18, 32, 31, 36, and 24. In one embodiment, the bacterial consortium is LBP-23 (see, for example, Figure 35).

[0266] In one aspect, the present disclosure relates to the following species Collinsella aerofaciens, Bifidobacterium longum, Bacteroides ovatus, Bacteroides thetaiotaomicron, Bacteroides xylanisolvens, Bacteroides caccae, Bacteroides cellulosilyticus, Bacteroides fragilis, Bacteroides uniformis, Bacteroides vulgatus, Odoribacter splanchnicus, Parabacteroides distasonis, Alistipes putredinis, Alistipes shahii, Clostridium citroniae, Clostridium clostridioforme, Erysipelatoclostridium ramosum, Erysipelotrichaceae bacterium 6_1_45, Anaerostipes caccae, Blautia obeum, Blautia producta, Coprococcus comes, Dorea The present invention provides a composition comprising purified bacterial strains related to longicatena, Agathobaculum butyriciproducens, Phascolarctobacterium faecium, Escherichia coli, and Fusobacterium mortiferum.

[0267] In one aspect, the present disclosure relates to the following species Collinsella aerofaciens, Bifidobacterium longum, Bacteroides ovatus, Bacteroides thetaiotaomicron, Bacteroides xylanisolvens, Bacteroides caccae, Bacteroides cellulosilyticus, Bacteroides fragilis, Bacteroides uniformis, Bacteroides vulgatus, Odoribacter splanchnicus, Parabacteroides distasonis, Alistipes putredinis, Alistipes shahii, Clostridium citroniae, Clostridium clostridioforme, Erysipelatoclostridium ramosum, Erysipelotrichaceae bacterium 6_1_45, Anaerostipes caccae, Blautia obeum, Blautia producta, Coprococcus comes, Dorea The present invention provides a composition comprising purified bacterial strains related to longicatena, Agathobaculum butyriciproducens, Phascolarctobacterium faecium, Escherichia coli, and Fusobacterium mortiferum.

[0268] In one aspect, the present disclosure relates to the following species Collinsella aerofaciens, Bifidobacterium longum, Bacteroides ovatus, Bacteroides thetaiotaomicron, Bacteroides xylanisolvens, Bacteroides caccae, Bacteroides cellulosilyticus, Bacteroides fragilis, Bacteroides uniformis, Bacteroides vulgatus, Odoribacter splanchnicus, Parabacteroides distasonis, Alistipes putredinis, Alistipes shahii, Clostridium citroniae, Clostridium clostridioforme, Erysipelatoclostridium ramosum, Erysipelotrichaceae bacterium 6_1_45, Anaerostipes caccae, Blautia obeum, Blautia producta, Coprococcus comes, Dorea The present invention provides compositions essentially consisting of purified bacterial strains related to longicatena, Agathobaculum butyriciproducens, Phascolarctobacterium faecium, Escherichia coli, and Fusobacterium mortiferum. In some embodiments, as used herein, “essentially consisting of” refers to compositions that do not contain any additional therapeutically active bacterial strains.

[0269] In one embodiment, the bacterial composition comprises a purified bacterial strain containing a 16S rDNA sequence having at least 97% sequence identity with the nucleic acid sequence shown as SEQ ID NOs: 27, 9, 4, 5, 24, 1, 2, 33, 6, 7, 21, 22, 26, 29, 12, 13, 19, 15, 30, 25, 11, 17, 18, 32, 31, 36, and 34. In one embodiment, the bacterial composition comprises a purified bacterial strain containing a 16S rDNA sequence having at least 97% sequence identity with the nucleic acid sequence shown as SEQ ID NOs: 27, 9, 4, 5, 24, 1, 2, 33, 6, 7, 21, 22, 26, 29, 12, 13, 19, 15, 30, 25, 11, 17, 18, 32, 31, 36, and 34. In one embodiment, the bacterial composition essentially consists of a purified bacterial strain containing a 16S rDNA sequence having at least 97% sequence identity with the nucleic acid sequence shown as SEQ ID NOs: 27, 9, 4, 5, 24, 1, 2, 33, 6, 7, 21, 22, 26, 29, 12, 13, 19, 15, 30, 25, 11, 17, 18, 32, 31, 36, and 34. In one embodiment, the bacterial consortium is LBP-24 (see, for example, Figure 35).

[0270] In one aspect, the present disclosure provides a composition comprising purified bacterial strains associated with the following species: Collinsella aerofaciens, Bifidobacterium pseudocatenulatum, Bifidobacterium adolescentis, Bifidobacterium longum, Bacteroides ovatus, Bacteroides xylanisolvens, Bacteroides vulgatus, Odoribacter splanchnicus, Parabacteroides distasonis, Parabacteroides merdae, Alistipes putredinis, Alistipes shahii, Clostridium citroniae, Clostridium clostridioforme, Clostridium bifermentans, Clostridium sordellii, Clostridium innocuum, Erysipelatoclostridium ramosum, Erysipelotrichaceae bacterium 6_1_45, Eubacterium hallii, Eubacterium rectale, Anaerostipes caccae, Blautia obeum, Blautia producta, Coprococcus comes, Dorea longicatena, Agathobaculum butyriciproducens, Phascolarctobacterium faecium, Escherichia coli, and Fusobacterium mortiferum.

[0271] In one aspect, the present disclosure provides a composition comprising purified bacterial strains associated with the following species: Collinsella aerofaciens, Bifidobacterium pseudocatenulatum, Bifidobacterium adolescentis, Bifidobacterium longum, Bacteroides ovatus, Bacteroides xylanisolvens, Bacteroides vulgatus, Odoribacter splanchnicus, Parabacteroides distasonis, Parabacteroides merdae, Alistipes putredinis, Alistipes shahii, Clostridium citroniae, Clostridium clostridioforme, Clostridium bifermentans, Clostridium sordellii, Clostridium innocuum, Erysipelatoclostridium ramosum, Erysipelotrichaceae bacterium 6_1_45, Eubacterium hallii, Eubacterium rectale, Anaerostipes caccae, Blautia obeum, Blautia producta, Coprococcus comes, Dorea longicatena, Agathobaculum butyriciproducens, Phascolarctobacterium faecium, Escherichia coli, and Fusobacterium mortiferum.

[0272] In one aspect, the present disclosure relates to the following species Collinsella aerofaciens, Bifidobacterium pseudocatenulatum, Bifidobacterium adolescentis, Bifidobacterium longum, Bacteroides ovatus, Bacteroides xylanisolvens, Bacteroides vulgatus, Odoribacter splanchnicus, Parabacteroides distasonis, Parabacteroides merdae, Alistipes putredinis, Alistipes shahii, Clostridium citroniae, Clostridium clostridioforme, Clostridium bifermentans, Clostridium sordellii, Clostridium innocuum, Erysipelatoclostridium ramosum, Erysipelotrichaceae bacterium 6_1_45, Eubacterium hallii, Eubacterium rectale, Anaerostipes The present invention provides compositions comprising purified bacterial strains related to caccae, Blautia obeum, Blautia producta, Coprococcus comes, Dorea longicatena, Agathobaculum butyriciproducens, Phascolarctobacterium faecium, Escherichia coli, and Fusobacterium mortiferum. The present invention provides compositions essentially derived from purified bacterial strains related to [the aforementioned organisms]. In some embodiments, as used herein, "essentially derived from" refers to compositions that do not contain any additional therapeutically active bacterial strains.

[0273] In one embodiment, the bacterial composition comprises a purified bacterial strain containing a 16S rDNA sequence having at least 97% sequence identity with the nucleic acid sequences represented as SEQ ID NOs: 27, 10, 8, 9, 4, 24, 7, 21, 22, 23, 26, 29, 11, 17, 18, 32, 31, 36, and 34. In one embodiment, the bacterial composition comprises a purified bacterial strain containing a 16S rDNA sequence having at least 97% sequence identity with the nucleic acid sequences represented as SEQ ID NOs: 27, 10, 8, 9, 4, 24, 7, 21, 22, 23, 26, 29, 12, 13, 35, 16, 14, 19, 15, 28, 20, 30, 25, 11, 17, 18, 32, 31, 36, and 34. In one embodiment, the bacterial composition essentially comprises a purified bacterial strain containing a 16S rDNA sequence having at least 97% sequence identity with the nucleic acid sequence shown as SEQ ID NOs: 27, 10, 8, 9, 4, 24, 7, 21, 22, 23, 26, 29, 12, 13, 35, 16, 14, 19, 15, 28, 20, 30, 25, 11, 17, 18, 32, 31, 36, and 34. In one embodiment, the bacterial consortium is LBP-25 (see, for example, Figure 35).

[0274] In one aspect, the present disclosure relates to the following species: Bifidobacterium longum, Bacteroides ovatus, Bacteroides thetaiotamicron, Bacteroides xylanisolvens, Bacteroides caccae, Bacteroides cellulosilyticus, Bacteroides faecis, Bacteroides fragilis, Bacteroides uniformis, Bacteroides vulgatus, Parabacteroides distasonis, Parabacteroides merdae, Alistipes putredinis, Alistipes shahii, Clostridium citroniae, Clostridium clostridioforme, Clostridium bifermentans, Clostridium sordellii, Clostridium innocuum, Erysipelatoclostridium ramosum, Erysipelotrichaceae bacterium 6_1_45, Anaerostipes caccae, Blautia The present invention provides a composition comprising purified bacterial strains related to obeum, Blautia producta, Dorea longicatena, Agathobaculum butyriciproducens, Phascolarctobacterium faecium, Escherichia coli, and Fusobacterium mortiferum.

[0275] In one aspect, the present disclosure relates to the following species: Bifidobacterium longum, Bacteroides ovatus, Bacteroides thetaiotamicron, Bacteroides xylanisolvens, Bacteroides caccae, Bacteroides cellulosilyticus, Bacteroides faecis, Bacteroides fragilis, Bacteroides uniformis, Bacteroides vulgatus, Parabacteroides distasonis, Parabacteroides merdae, Alistipes putredinis, Alistipes shahii, Clostridium citroniae, Clostridium clostridioforme, Clostridium bifermentans, Clostridium sordellii, Clostridium innocuum, Erysipelatoclostridium ramosum, Erysipelotrichaceae bacterium 6_1_45, Anaerostipes caccae, Blautia The present invention provides a composition comprising purified bacterial strains related to obeum, Blautia producta, Dorea longicatena, Agathobaculum butyriciproducens, Phascolarctobacterium faecium, Escherichia coli, and Fusobacterium mortiferum.

[0276] In one aspect, the present disclosure relates to the following species: Bifidobacterium longum, Bacteroides ovatus, Bacteroides thetaiotamicron, Bacteroides xylanisolvens, Bacteroides caccae, Bacteroides cellulosilyticus, Bacteroides faecis, Bacteroides fragilis, Bacteroides uniformis, Bacteroides vulgatus, Parabacteroides distasonis, Parabacteroides merdae, Alistipes putredinis, Alistipes shahii, Clostridium citroniae, Clostridium clostridioforme, Clostridium bifermentans, Clostridium sordellii, Clostridium innocuum, Erysipelatoclostridium ramosum, Erysipelotrichaceae bacterium 6_1_45, Anaerostipes caccae, Blautia In some embodiments providing compositions essentially consisting of purified bacterial strains related to obeum, Blautia producta, Dorea longicatena, Agathobaculum butyriciproducens, Phascolarctobacterium faecium, Escherichia coli, and Fusobacterium mortiferum, "essentially consisting of" as used herein refers to compositions that do not contain any additional therapeutically active bacterial strains.

[0277] In one embodiment, the bacterial composition comprises a purified bacterial strain containing a 16S rDNA sequence having at least 97% sequence identity with the nucleic acid sequence represented as SEQ ID NOs: 9, 4, 5, 24, 1, 2, 3, 33, 6, 7, 22, 23, 26, 29, 12, 13, 35, 16, 14, 19, 15, 30, 25, 11, 18, 32, 31, 36, and 34. In one embodiment, the bacterial composition comprises a purified bacterial strain containing a 16S rDNA sequence having at least 97% sequence identity with the nucleic acid sequence represented as SEQ ID NOs: 9, 4, 5, 24, 1, 2, 3, 33, 6, 7, 22, 23, 26, 29, 12, 13, 35, 16, 14, 19, 15, 30, 25, 11, 18, 32, 31, 36, and 34. In one embodiment, the bacterial composition essentially consists of a purified bacterial strain containing a 16S rDNA sequence having at least 97% sequence identity with the nucleic acid sequence represented as SEQ ID NOs: 9, 4, 5, 24, 1, 2, 3, 33, 6, 7, 22, 23, 26, 29, 12, 13, 35, 16, 14, 19, 15, 30, 25, 11, 18, 32, 31, 36, and 34. In one embodiment, the bacterial consortium is LBP-26 (see, for example, Figure 35).

[0278] In one aspect, the present disclosure relates to the following species: Bifidobacterium longum, Bacteroides ovatus, Bacteroides xylanisolvens, Bacteroides caccae, Bacteroides vulgatus, Odoribacter splanchnicus, Parabacteroides distasonis, Alistipes putredinis, Alistipes shahii, Clostridium citroniae, Clostridium clostridioforme, Erysipelatoclostridium ramosum, Erysipelotrichaceae bacterium 6_1_45, Anaerostipes caccae, Blautia obeum, Blautia producta, Coprococcus comes, Dorea longicatena, Agathobaculum butyriciproducens, Phascolarctobacterium faecium, Escherichia coli, and Fusobacterium The present invention provides a composition containing a purified bacterial strain related to Mortiferum.

[0279] In one aspect, the present disclosure relates to the following species: Bifidobacterium longum, Bacteroides ovatus, Bacteroides xylanisolvens, Bacteroides caccae, Bacteroides vulgatus, Odoribacter splanchnicus, Parabacteroides distasonis, Alistipes putredinis, Alistipes shahii, Clostridium citroniae, Clostridium clostridioforme, Erysipelatoclostridium ramosum, Erysipelotrichaceae bacterium 6_1_45, Anaerostipes caccae, Blautia obeum, Blautia producta, Coprococcus comes, Dorea longicatena, Agathobaculum butyriciproducens, Phascolarctobacterium faecium, Escherichia coli, and Fusobacterium The present invention provides a composition comprising purified bacterial strains related to Mortiferum.

[0280] In one aspect, the present disclosure relates to the following species: Bifidobacterium longum, Bacteroides ovatus, Bacteroides xylanisolvens, Bacteroides caccae, Bacteroides vulgatus, Odoribacter splanchnicus, Parabacteroides distasonis, Alistipes putredinis, Alistipes shahii, Clostridium citroniae, Clostridium clostridioforme, Erysipelatoclostridium ramosum, Erysipelotrichaceae bacterium 6_1_45, Anaerostipes caccae, Blautia obeum, Blautia producta, Coprococcus comes, Dorea longicatena, Agathobaculum butyriciproducens, Phascolarctobacterium faecium, Escherichia coli, and Fusobacterium The present invention provides compositions essentially derived from purified bacterial strains related to Mortiferum. In some embodiments, as used herein, “essentially derived from” refers to compositions that do not contain any additional therapeutically active bacterial strains.

[0281] In one embodiment, the bacterial composition comprises a purified bacterial strain containing a 16S rDNA sequence having at least 97% sequence identity with the nucleic acid sequence represented as SEQ ID NOs: 9, 4, 5, 24, 1, 7, 21, 22, 26, 29, 12, 13, 19, 15, 30, 25, 11, 17, 18, 32, 31, 36, and 34. In one embodiment, the bacterial composition comprises a purified bacterial strain containing a 16S rDNA sequence having at least 97% sequence identity with the nucleic acid sequence represented as SEQ ID NOs: 9, 4, 5, 24, 1, 7, 21, 22, 26, 29, 12, 13, 19, 15, 30, 25, 11, 17, 18, 32, 31, 36, and 34. In one embodiment, the bacterial composition essentially consists of a purified bacterial strain containing a 16S rDNA sequence having at least 97% sequence identity with the nucleic acid sequence represented as SEQ ID NOs: 9, 4, 5, 24, 1, 7, 21, 22, 26, 29, 12, 13, 19, 15, 30, 25, 11, 17, 18, 32, 31, 36, and 34. In one embodiment, the bacterial consortium is LBP-27 (see, for example, Figure 35).

[0282] In one aspect, the present disclosure relates to the following species Collinsella aerofaciens, Bifidobacterium longum, Bacteroides ovatus, Bacteroides thetaiotamicron, Bacteroides xylanisolvens, Bacteroides caccae, Bacteroides cellulosilyticus, Bacteroides ovatus, Bacteroides vulgatus, Odoribacter splanchnicus, Parabacteroides distasonis, Alistipes putredinis, Alistipes shahii, Clostridium citroniae, Clostridium clostridioforme, Erysipelatoclostridium ramosum, Erysipelotrichaceae bacterium 6_1_45, Anaerostipes caccae, Blautia obeum, Blautia producta, Coprococcus comes, Dorea longicatena, Agathobaculum The present invention provides a composition comprising purified bacterial strains related to butyriciproducens, Phascolarctobacterium faecium, Escherichia coli, and Fusobacterium mortiferum.

[0283] In one aspect, the present disclosure relates to the following species Collinsella aerofaciens, Bifidobacterium longum, Bacteroides ovatus, Bacteroides thetaiotamicron, Bacteroides xylanisolvens, Bacteroides caccae, Bacteroides cellulosilyticus, Bacteroides ovatus, Bacteroides vulgatus, Odoribacter splanchnicus, Parabacteroides distasonis, Alistipes putredinis, Alistipes shahii, Clostridium citroniae, Clostridium clostridioforme, Erysipelatoclostridium ramosum, Erysipelotrichaceae bacterium 6_1_45, Anaerostipes caccae, Blautia obeum, Blautia producta, Coprococcus comes, Dorea longicatena, Agathobaculum The present invention provides a composition comprising purified bacterial strains related to butyriciproducens, Phascolarctobacterium faecium, Escherichia coli, and Fusobacterium mortiferum.

[0284] In one aspect, the present disclosure relates to the following species Collinsella aerofaciens, Bifidobacterium longum, Bacteroides ovatus, Bacteroides thetaiotamicron, Bacteroides xylanisolvens, Bacteroides caccae, Bacteroides cellulosilyticus, Bacteroides ovatus, Bacteroides vulgatus, Odoribacter splanchnicus, Parabacteroides distasonis, Alistipes putredinis, Alistipes shahii, Clostridium citroniae, Clostridium clostridioforme, Erysipelatoclostridium ramosum, Erysipelotrichaceae bacterium 6_1_45, Anaerostipes caccae, Blautia obeum, Blautia producta, Coprococcus comes, Dorea longicatena, Agathobaculum The present invention provides compositions essentially consisting of purified bacterial strains related to butyriciproducens, Phascolarctobacterium faecium, Escherichia coli, and Fusobacterium mortiferum. In some embodiments, as used herein, “essentially consisting of” refers to compositions that do not contain any additional therapeutically active bacterial strains.

[0285] In one embodiment, the bacterial composition comprises a purified bacterial strain containing a 16S rDNA sequence having at least 97% sequence identity with the nucleic acid sequences represented as SEQ ID NOs: 27, 9, 4, 5, 24, 1, 2, 6, 7, 21, 22, 26, 29, 12, 13, 19, 15, 30, 25, 11, 17, 18, 32, 31, 36, and 34. In one embodiment, the bacterial composition comprises a purified bacterial strain containing a 16S rDNA sequence having at least 97% sequence identity with the nucleic acid sequences represented as SEQ ID NOs: 27, 9, 4, 5, 24, 1, 2, 6, 7, 21, 22, 26, 29, 12, 13, 19, 15, 30, 25, 11, 17, 18, 32, 31, 36, and 34. In one embodiment, the bacterial composition essentially consists of a purified bacterial strain containing a 16S rDNA sequence having at least 97% sequence identity with the nucleic acid sequences shown as SEQ ID NOs: 27, 9, 4, 5, 24, 1, 2, 6, 7, 21, 22, 26, 29, 12, 13, 19, 15, 30, 25, 11, 17, 18, 32, 31, 36, and 34. In one embodiment, the bacterial consortium is LBP-28 (see, for example, Figure 35).

[0286] In one aspect, the present disclosure relates to the following species Collinsella aerofaciens, Bifidobacterium longum, Bacteroides ovatus, Bacteroides xylanisolvens, Bacteroides vulgatus, Odoribacter splanchnicus, Parabacteroides distasonis, Alistipes putredinis, Alistipes shahii, Clostridium citroniae, Clostridium clostridioforme, Erysipelatoclostridium ramosum, Erysipelotrichaceae bacterium 6_1_45, Anaerostipes caccae, Blautia obeum, Blautia producta, Coprococcus comes, Dorea longicatena, Agathobaculum butyriciproducens, Phascolarctobacterium faecium, Escherichia coli, and Fusobacterium The present invention provides a composition containing a purified bacterial strain related to Mortiferum.

[0287] In one aspect, the present disclosure relates to the following species Collinsella aerofaciens, Bifidobacterium longum, Bacteroides ovatus, Bacteroides xylanisolvens, Bacteroides vulgatus, Odoribacter splanchnicus, Parabacteroides distasonis, Alistipes putredinis, Alistipes shahii, Clostridium citroniae, Clostridium clostridioforme, Erysipelatoclostridium ramosum, Erysipelotrichaceae bacterium 6_1_45, Anaerostipes caccae, Blautia obeum, Blautia producta, Coprococcus comes, Dorea longicatena, Agathobaculum butyriciproducens, Phascolarctobacterium faecium, Escherichia coli, and Fusobacterium The present invention provides a composition comprising purified bacterial strains related to Mortiferum.

[0288] In one aspect, the present disclosure relates to the following species Collinsella aerofaciens, Bifidobacterium longum, Bacteroides ovatus, Bacteroides xylanisolvens, Bacteroides vulgatus, Odoribacter splanchnicus, Parabacteroides distasonis, Alistipes putredinis, Alistipes shahii, Clostridium citroniae, Clostridium clostridioforme, Erysipelatoclostridium ramosum, Erysipelotrichaceae bacterium 6_1_45, Anaerostipes caccae, Blautia obeum, Blautia producta, Coprococcus comes, Dorea longicatena, Agathobaculum butyriciproducens, Phascolarctobacterium faecium, Escherichia coli, and Fusobacterium The present invention provides compositions essentially derived from purified bacterial strains related to Mortiferum. In some embodiments, as used herein, “essentially derived from” refers to compositions that do not contain any additional therapeutically active bacterial strains.

[0289] In one embodiment, the bacterial composition comprises a purified bacterial strain containing a 16S rDNA sequence having at least 97% sequence identity with the nucleic acid sequences represented as SEQ ID NOs: 27, 9, 4, 24, 7, 21, 22, 26, 29, 12, 13, 19, 15, 30, 25, 11, 17, 18, 32, 31, 36, and 34. In one embodiment, the bacterial composition comprises a purified bacterial strain containing a 16S rDNA sequence having at least 97% sequence identity with the nucleic acid sequences represented as SEQ ID NOs: 27, 9, 4, 24, 7, 21, 22, 26, 29, 12, 13, 19, 15, 30, 25, 11, 17, 18, 32, 31, 36, and 34. In one embodiment, the bacterial composition essentially consists of a purified bacterial strain containing a 16S rDNA sequence having at least 97% sequence identity with the nucleic acid sequence shown as SEQ ID NOs: 27, 9, 4, 24, 7, 21, 22, 26, 29, 12, 13, 19, 15, 30, 25, 11, 17, 18, 32, 31, 36, and 34. In one embodiment, the bacterial consortium is LBP-29 (see, for example, Figure 35).

[0290] In one embodiment, the present disclosure provides a composition comprising purified bacterial strains relating to the following species: Collinsella aerofaciens, Bifidobacterium longum, Bacteroides ovatus, Bacteroides xylanisolvens, Odoribacter splanchnicus, Alistipes putredinis, Alistipes shahii, Clostridium clostridioforme, Erysipelatoclostridium ramosum, Erysipelotrichaceae bacterium 6_1_45, Anaerostipes caccae, Blautia obeum, Blautia producta, Coprococcus comes, Dorea longicatena, Agathobaculum butyriciproducens, Phascolarctobacterium faecium, Escherichia coli, and Fusobacterium mortiferum.

[0291] In one embodiment, the present disclosure provides a composition comprising purified bacterial strains relating to the following species: Collinsella aerofaciens, Bifidobacterium longum, Bacteroides ovatus, Bacteroides xylanisolvens, Odoribacter splanchnicus, Alistipes putredinis, Alistipes shahii, Clostridium clostridioforme, Erysipelatoclostridium ramosum, Erysipelotrichaceae bacterium 6_1_45, Anaerostipes caccae, Blautia obeum, Blautia producta, Coprococcus comes, Dorea longicatena, Agathobaculum butyriciproducens, Phascolarctobacterium faecium, Escherichia coli, and Fusobacterium mortiferum.

[0292] In one embodiment, the present disclosure provides a composition essentially consisting of purified bacterial strains relating to the following species: Collinsella aerofaciens, Bifidobacterium longum, Bacteroides ovatus, Bacteroides xylanisolvens, Odoribacter splanchnicus, Alistipes putredinis, Alistipes shahii, Clostridium clostridioforme, Erysipelatoclostridium ramosum, Erysipelotrichaceae bacterium 6_1_45, Anaerostipes caccae, Blautia obeum, Blautia producta, Coprococcus comes, Dorea longicatena, Agathobaculum butyriciproducens, Phascolarctobacterium faecium, Escherichia coli, and Fusobacterium mortiferum. In some embodiments, as used herein, “essentially consisting of” refers to a composition that does not contain any additional therapeutically active bacterial strains.

[0293] In one embodiment, the bacterial composition comprises a purified bacterial strain containing a 16S rDNA sequence having at least 97% sequence identity with the nucleic acid sequences represented as SEQ ID NOs: 27, 9, 4, 24, 21, 26, 13, 19, 15, 30, 25, 11, 17, 18, 32, 36, and 34. In one embodiment, the bacterial composition comprises a purified bacterial strain containing a 16S rDNA sequence having at least 97% sequence identity with the nucleic acid sequences represented as SEQ ID NOs: 27, 9, 4, 24, 21, 26, 13, 19, 15, 30, 25, 11, 17, 18, 32, 36, and 34. In one embodiment, the bacterial composition essentially consists of a purified bacterial strain containing a 16S rDNA sequence having at least 97% sequence identity with the nucleic acid sequence shown as SEQ ID NOs: 27, 9, 4, 24, 21, 26, 13, 19, 15, 30, 25, 11, 17, 18, 32, 36, and 34. In one embodiment, the bacterial consortium is LBP-30 (see, for example, Figure 35).

[0294] In one aspect, the present disclosure relates to the following species Collinsella aerofaciens, Bifidobacterium adolescentis, Bifidobacterium longum, Bacteroides ovatus, Bacteroides faecis, Bacteroides fragilis, Bacteroides vulgatus, Odoribacter splanchnicus, Alistipes putredinis, Clostridium citroniae, Clostridium clostridioforme, Clostridium bifermentans, Clostridium sordellii, Clostridium innocuum, Erysipelatoclostridium ramosum, Erysipelotrichaceae bacterium 6_1_45, Anaerostipes caccae, Blautia obeum, Blautia producta, Dorea longicatena, Agathobaculum butyriciproducens, Phascolarctobacterium The present invention provides a composition containing purified bacterial strains related to Faecium, Escherichia coli, and Fusobacterium mortiferum.

[0295] In one aspect, the present disclosure relates to the following species Collinsella aerofaciens, Bifidobacterium adolescentis, Bifidobacterium longum, Bacteroides ovatus, Bacteroides faecis, Bacteroides fragilis, Bacteroides vulgatus, Odoribacter splanchnicus, Alistipes putredinis, Clostridium citroniae, Clostridium clostridioforme, Clostridium bifermentans, Clostridium sordellii, Clostridium innocuum, Erysipelatoclostridium ramosum, Erysipelotrichaceae bacterium 6_1_45, Anaerostipes caccae, Blautia obeum, Blautia producta, Dorea longicatena, Agathobaculum butyriciproducens, Phascolarctobacterium The present invention provides a composition comprising purified bacterial strains related to Faecium, Escherichia coli, and Fusobacterium mortiferum.

[0296] In one aspect, the present disclosure relates to the following species Collinsella aerofaciens, Bifidobacterium adolescentis, Bifidobacterium longum, Bacteroides ovatus, Bacteroides faecis, Bacteroides fragilis, Bacteroides vulgatus, Odoribacter splanchnicus, Alistipes putredinis, Clostridium citroniae, Clostridium clostridioforme, Clostridium bifermentans, Clostridium sordellii, Clostridium innocuum, Erysipelatoclostridium ramosum, Erysipelotrichaceae bacterium 6_1_45, Anaerostipes caccae, Blautia obeum, Blautia producta, Dorea longicatena, Agathobaculum butyriciproducens, Phascolarctobacterium The present invention provides compositions essentially consisting of purified bacterial strains related to Faecium, Escherichia coli, and Fusobacterium mortiferum. In some embodiments, as used herein, “essentially consisting of” refers to compositions that do not contain any additional therapeutically active bacterial strains.

[0297] In one embodiment, the bacterial composition comprises a purified bacterial strain containing 16S rDNA having at least 97% sequence identity with the nucleic acid sequences represented as SEQ ID NOs: 27, 8, 9, 4, 3, 33, 7, 21, 26, 21, 26, 12, 13, 35, 16, 14, 19, 15, 28, 30, 25, 11, 18, 32, 31, 36, and 34. In one embodiment, the bacterial composition comprises a purified bacterial strain containing 16S rDNA having at least 97% sequence identity with the nucleic acid sequences represented as SEQ ID NOs: 27, 8, 9, 4, 3, 33, 7, 21, 26, 12, 13, 35, 16, 14, 19, 15, 28, 30, 25, 11, 18, 32, 31, 36, and 34. In one embodiment, the bacterial composition essentially consists of a purified bacterial strain containing 16S rDNA having at least 97% sequence identity with the nucleic acid sequences shown as SEQ ID NOs: 27, 8, 9, 4, 3, 33, 7, 21, 26, 12, 13, 35, 16, 14, 19, 15, 28, 30, 25, 11, 18, 32, 31, 36, and 34. In one embodiment, the bacterial consortium is LBP-31 (see, for example, Figure 35).

[0298] In one embodiment, the present disclosure provides a composition comprising purified bacterial strains relating to the following species: Collinsella aerofaciens, Bifidobacterium longum, Bacteroides ovatus, Bacteroides faecis, Bacteroides vulgatus, Odoribacter splanchnicus, Alistipes putredinis, Clostridium citroniae, Clostridium clostridioforme, Erysipelatoclostridium ramosum, Erysipelotrichaceae bacterium 6_1_45, Anaerostipes caccae, Blautia obeum, Blautia producta, Dorea longicatena, Agathobaculum butyriciproducens, Phascolarctobacterium faecium, Escherichia coli, and Fusobacterium mortiferum.

[0299] In one embodiment, the present disclosure provides a composition comprising purified bacterial strains relating to the following species: Collinsella aerofaciens, Bifidobacterium longum, Bacteroides ovatus, Bacteroides faecis, Bacteroides vulgatus, Odoribacter splanchnicus, Alistipes putredinis, Clostridium citroniae, Clostridium clostridioforme, Erysipelatoclostridium ramosum, Erysipelotrichaceae bacterium 6_1_45, Anaerostipes caccae, Blautia obeum, Blautia producta, Dorea longicatena, Agathobaculum butyriciproducens, Phascolarctobacterium faecium, Escherichia coli, and Fusobacterium mortiferum.

[0300] In one embodiment, the present disclosure provides a composition essentially consisting of purified bacterial strains relating to the following species: Collinsella aerofaciens, Bifidobacterium longum, Bacteroides ovatus, Bacteroides faecis, Bacteroides vulgatus, Odoribacter splanchnicus, Alistipes putredinis, Clostridium citroniae, Clostridium clostridioforme, Erysipelatoclostridium ramosum, Erysipelotrichaceae bacterium 6_1_45, Anaerostipes caccae, Blautia obeum, Blautia producta, Dorea longicatena, Agathobaculum butyriciproducens, Phascolarctobacterium faecium, Escherichia coli, and Fusobacterium mortiferum. In some embodiments, as used herein, “essentially consisting of” refers to a composition that does not contain any additional therapeutically active bacterial strains.

[0301] In one embodiment, the bacterial composition comprises a purified bacterial strain containing a 16S rDNA sequence having at least 97% sequence identity with the nucleic acid sequence shown as SEQ ID NOs: 27, 9, 4, 3, 7, 21, 26, 12, 13, 19, 15, 30, 25, 11, 18, 32, 31, 36, and 34. In one embodiment, the bacterial composition comprises a purified bacterial strain containing a 16S rDNA sequence having at least 97% sequence identity with the nucleic acid sequence shown as SEQ ID NOs: 27, 9, 4, 3, 7, 21, 26, 12, 13, 19, 15, 30, 25, 11, 18, 32, 31, 36, and 34. In one embodiment, the bacterial composition essentially consists of a purified bacterial strain containing a 16S rDNA sequence having at least 97% sequence identity with the nucleic acid sequence shown as SEQ ID NOs: 27, 9, 4, 3, 7, 21, 26, 12, 13, 19, 15, 30, 25, 11, 18, 32, 31, 36, and 34. In one embodiment, the bacterial consortium is LBP-32 (see, for example, Figure 35).

[0302] In one embodiment, the present disclosure provides a composition comprising purified bacterial strains relating to the following species: Collinsella aerofaciens, Bifidobacterium longum, Bacteroides ovatus, Bacteroides vulgatus, Parabacteroides distasonis, Alistipes putredinis, Clostridium citroniae, Clostridium clostridioforme, Erysipelatoclostridium ramosum, Erysipelotrichaceae bacterium 6_1_45, Anaerostipes caccae, Blautia obeum, Blautia producta, Agathobaculum butyriciproducens, Phascolarctobacterium faecium, Escherichia coli, and Fusobacterium mortiferum.

[0303] In one embodiment, the present disclosure provides a composition comprising purified bacterial strains related to the following species: Collinsella aerofaciens, Bifidobacterium longum, Bacteroides ovatus, Bacteroides vulgatus, Parabacteroides distasonis, Alistipes putredinis, Clostridium citroniae, Clostridium clostridioforme, Erysipelatoclostridium ramosum, Erysipelotrichaceae bacterium 6_1_45, Anaerostipes caccae, Blautia obeum, Blautia producta, Agathobaculum butyriciproducens, Phascolarctobacterium faecium, Escherichia coli, and Fusobacterium mortiferum.

[0304] In one embodiment, the present disclosure provides compositions essentially consisting of purified bacterial strains relating to the following species: Collinsella aerofaciens, Bifidobacterium longum, Bacteroides ovatus, Bacteroides vulgatus, Parabacteroides distasonis, Alistipes putredinis, Clostridium citroniae, Clostridium clostridioforme, Erysipelatoclostridium ramosum, Erysipelotrichaceae bacterium 6_1_45, Anaerostipes caccae, Blautia obeum, Blautia producta, Agathobaculum butyriciproducens, Phascolarctobacterium faecium, Escherichia coli, and Fusobacterium mortiferum. In some embodiments, as used herein, “essentially consisting of” means compositions that do not contain any additional therapeutically active bacterial strains.

[0305] In one embodiment, the bacterial composition comprises a purified bacterial strain containing a 16S rDNA sequence having at least 97% sequence identity with the nucleic acid sequences represented as SEQ ID NOs: 27, 9, 4, 7, 22, 26, 12, 13, 19, 15, 30, 25, 11, 32, 31, 36, and 34. In one embodiment, the bacterial composition comprises a purified bacterial strain containing a 16S rDNA sequence having at least 97% sequence identity with the nucleic acid sequences represented as SEQ ID NOs: 27, 9, 4, 7, 22, 26, 12, 13, 19, 15, 30, 25, 11, 32, 31, 36, and 34. In one embodiment, the bacterial composition essentially consists of a purified bacterial strain containing a 16S rDNA sequence having at least 97% sequence identity with the nucleic acid sequence shown as SEQ ID NOs: 27, 9, 4, 7, 22, 26, 12, 13, 19, 15, 30, 25, 11, 32, 31, 36, and 34. In one embodiment, the bacterial consortium is LBP-33 (see, for example, Figure 35).

[0306] In one embodiment, the present disclosure provides a composition comprising purified bacterial strains relating to the following species: Collinsella aerofaciens, Bifidobacterium longum, Bacteroides ovatus, Bacteroides vulgatus, Alistipes putredinis, Clostridium citroniae, Clostridium clostridioforme, Erysipelatoclostridium ramosum, Erysipelotrichaceae bacterium 6_1_45, Blautia obeum, Blautia producta, Dorea longicatena, Phascolarctobacterium faecium, Escherichia coli, and Fusobacterium mortiferum.

[0307] In one embodiment, the present disclosure provides a composition comprising purified bacterial strains relating to the following species: Collinsella aerofaciens, Bifidobacterium longum, Bacteroides ovatus, Bacteroides vulgatus, Alistipes putredinis, Clostridium citroniae, Clostridium clostridioforme, Erysipelatoclostridium ramosum, Erysipelotrichaceae bacterium 6_1_45, Blautia obeum, Blautia producta, Dorea longicatena, Phascolarctobacterium faecium, Escherichia coli, and Fusobacterium mortiferum.

[0308] In one embodiment, the present disclosure provides compositions essentially consisting of purified bacterial strains relating to the following species: Collinsella aerofaciens, Bifidobacterium longum, Bacteroides ovatus, Bacteroides vulgatus, Alistipes putredinis, Clostridium citroniae, Clostridium clostridioforme, Erysipelatoclostridium ramosum, Erysipelotrichaceae bacterium 6_1_45, Blautia obeum, Blautia producta, Dorea longicatena, Phascolarctobacterium faecium, Escherichia coli, and Fusobacterium mortiferum. In some embodiments, as used herein, “essentially consisting of” means compositions that do not contain any additional therapeutically active bacterial strains.

[0309] In one embodiment, the bacterial composition comprises a purified bacterial strain containing a 16S rDNA sequence having at least 97% sequence identity with the nucleic acid sequence shown as SEQ ID NOs: 27, 9, 4, 7, 26, 12, 13, 19, 15, 25, 11, 18, 31, 36, and 34. In one embodiment, the bacterial composition comprises a purified bacterial strain containing a 16S rDNA sequence having at least 97% sequence identity with the nucleic acid sequence shown as SEQ ID NOs: 27, 9, 4, 7, 26, 12, 13, 19, 15, 25, 11, 18, 31, 36, and 34. In one embodiment, the bacterial composition essentially consists of a purified bacterial strain containing a 16S rDNA sequence having at least 97% sequence identity with the nucleic acid sequence shown as SEQ ID NOs: 27, 9, 4, 7, 26, 12, 13, 19, 15, 25, 11, 18, 31, 36, and 34. In one embodiment, the bacterial consortium is LBP-34 (see, for example, Figure 35).

[0310] In one embodiment, the disclosure provides a composition comprising one or more purified bacterial strains belonging to the phylum Bacteroidetes and one or more purified bacterial strains selected from the group consisting of Escherichia species (e.g., Escherichia species 3_2_53FAA) and Fusobacterium species (e.g., Fusobacterium mortiferum). In one embodiment, the present disclosure provides a composition essentially comprising one or more purified bacterial strains belonging to the phylum Bacteroidetes and one or more purified bacterial strains selected from the group consisting of Escherichia species (e.g., Escherichia species 3_2_53FAA) and Fusobacterium species (e.g., Fusobacterium mortiferum).

[0311] In one embodiment, the disclosure provides a composition comprising one or more purified bacterial strains belonging to the phylum Bacteroidetes and one or more purified bacterial strains from among Escherichia species such as E. coli (e.g., Escherichia species 3_2_53FAA). In one embodiment, the disclosure provides a composition comprising one or more purified bacterial strains belonging to the phylum Bacteroidetes and one or more purified bacterial strains from among Escherichia species such as E. coli (e.g., Escherichia species 3_2_53FAA). In one embodiment, the disclosure provides a composition essentially comprising one or more purified bacterial strains belonging to the phylum Bacteroidetes and one or more purified bacterial strains from among Escherichia species such as E. coli (e.g., Escherichia species 3_2_53FAA).

[0312] In one embodiment, the disclosure provides a composition comprising one or more purified bacterial strains belonging to the phylum Bacteroidetes and one or more purified bacterial strains of the Fusobacterium species (e.g., Fusobacterium mortiferum). In one embodiment, the disclosure provides a composition comprising one or more purified bacterial strains belonging to the phylum Bacteroidetes and one or more purified bacterial strains of the Fusobacterium species (e.g., Fusobacterium mortiferum). In one embodiment, the disclosure provides a composition essentially comprising one or more purified bacterial strains belonging to the phylum Bacteroidetes and one or more purified bacterial strains of the Fusobacterium species (e.g., Fusobacterium mortiferum). In some embodiments, as used herein, “essentially comprising” means a composition that does not contain any additional therapeutically active bacterial strains.

[0313] In some embodiments, the compositions described herein comprise one or more purified bacterial strains belonging to the phylum Bacteroidetes. Bacteroidetes are Gram-negative, non-spore-forming, rod-shaped bacteria. While Bacteroidetes can be opportunistic pathogens, many Bacteroidetes species coexist symbiotically with the mouse and human gastrointestinal tract, degrading host proteins and complex sugar polymers. Decreased Bacteroidetes abundance may be associated with obesity and irritable bowel syndrome, while increased Bacteroidetes abundance may be associated with type 1 and type 2 diabetes. The phylum Bacteroidetes includes the classes Bacteroidia (e.g., Bacteroidales), Balneolia (e.g., Balneolales), Chitinophagia (e.g., Chitinophagales), Cytophagia (e.g., Cytophagales), Flavobacteriia (e.g., Flavobacteriales), Rhodothermia (e.g., Rhodothermales), and Sphingobacteria (e.g., Sphingobacteriales).

[0314] In some embodiments, one or more bacterial strains of the phylum Bacteroidetes belong to the class Bacteroidales. In some embodiments, one or more bacterial strains of the phylum Bacteroidetes belong to the family Bacteroidaceae.

[0315] In some embodiments, one or more bacterial strains of the phylum Bacteroidetes produce short-chain fatty acids (SCFAs), such as any SCFA described herein. In some embodiments, one or more bacterial strains of the phylum Bacteroidetes produce butyrate. In some embodiments, Bacteroidetes bacteria that are butyrate-producing strains include Collinsella aerofaciens, Bacteroides ovatus, Bacteroides thetaiotamicron, Bacteroides xylanisolvens, Bacteroides caccae, Bacteroides cellulosilyticus, Bacteroides faecis, Bacteroides fragilis, Bacteroides uniformis, Bacteroides vulgatus, Odoribacter splanchnicus, Parabacteroides distasonis, Parabacteroides merdae, Alistipes putredinis, and Alistipes shahii.

[0316] In one embodiment, the disclosure relates to purified bacterial strains belonging to the Escherichia species (e.g., Escherichia species 3_2_53FAA), Fusobacterium species (e.g., Fusobacterium mortiferum), and Bacteroides ovatus, Bacteroides thetaiotamicron, Bacteroides xylanisolvens, Bacteroides caccae, Bacteroides cellulosilyticus, Bacteroides faecis, Bacteroides fragilis, Bacteroides uniformis, Bacteroides vulgatus, Odoribacter splanchnicus, Parabacteroides distasonis, Parabacteroides merdae, Alistipes putredinis, and Alistipes The present invention provides a composition comprising one or more purified bacterial strains (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20) selected from the group consisting of shahii.

[0317] In one embodiment, the disclosure relates to purified bacterial strains belonging to the Escherichia species (e.g., Escherichia species 3_2_53FAA), Fusobacterium species (e.g., Fusobacterium mortiferum), and Bacteroides ovatus, Bacteroides thetaiotamicron, Bacteroides xylanisolvens, Bacteroides caccae, Bacteroides cellulosilyticus, Bacteroides faecis, Bacteroides fragilis, Bacteroides uniformis, Bacteroides vulgatus, Odoribacter splanchnicus, Parabacteroides distasonis, Parabacteroides merdae, Alistipes putredinis, and Alistipes The present invention provides a composition comprising one or more purified bacterial strains (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20) selected from the group consisting of shahii.

[0318] In one embodiment, the disclosure includes purified bacterial strains belonging to the Escherichia species (e.g., Escherichia species 3_2_53FAA) and the Fusobacterium species (e.g., Fusobacterium mortiferum), as well as Bacteroides ovatus, Bacteroides thetaiotamicron, Bacteroides xylanisolvens, Bacteroides caccae, Bacteroides cellulosilyticus, Bacteroides faecis, Bacteroides fragilis, Bacteroides uniformis, Bacteroides vulgatus, Odoribacter splanchnicus, Parabacteroides distasonis, Parabacteroides merdae, Alistipes putredinis, and Alistipes The present invention provides a composition essentially consisting of one or more purified bacterial strains (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20) selected from the group consisting of shahii. In some embodiments, as used herein, “essentially consisting of” means a composition that does not contain any additional therapeutically active bacterial strains.

[0319] In one embodiment, the bacterial composition comprises a purified bacterial strain containing a 16S rDNA sequence having at least 97% sequence identity with the nucleic acid sequence shown as Sequence ID No. 36, a purified bacterial strain containing a 16S rDNA sequence having at least 97% sequence identity with the nucleic acid sequence shown as Sequence ID No. 34, and one or more purified bacterial strains containing a 16S rDNA sequence having at least 97% sequence identity with the nucleic acid sequences shown as Sequence IDs No. 1-7, 21-24, 26, 29, and 33.

[0320] In one embodiment, the bacterial composition comprises a purified bacterial strain containing a 16S rDNA sequence having at least 97% sequence identity with the nucleic acid sequence shown as Sequence ID No. 36, a purified bacterial strain containing a 16S rDNA sequence having at least 97% sequence identity with the nucleic acid sequence shown as Sequence ID No. 34, and one or more purified bacterial strains containing a 16S rDNA sequence having at least 97% sequence identity with the nucleic acid sequences shown as Sequence IDs No. 1-7, 21-24, 26, 29, and 33.

[0321] In one embodiment, the bacterial composition essentially comprises a purified bacterial strain containing a 16S rDNA sequence having at least 97% sequence identity with the nucleic acid sequence shown as Sequence ID No. 36, a purified bacterial strain containing a 16S rDNA sequence having at least 97% sequence identity with the nucleic acid sequence shown as Sequence ID No. 34, and one or more purified bacterial strains containing a 16S rDNA sequence having at least 97% sequence identity with the nucleic acid sequences shown as Sequence IDs No. 1-7, 21-24, 26, 29, and 33.

[0322] In one embodiment, the present disclosure provides a composition comprising a purified bacterial strain belonging to the Escherichia species (e.g., Escherichia species 3_2_53FAA) and one or more purified bacterial strains (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20) selected from the group consisting of Bacteroides ovatus, Bacteroides thetaiotamicron, Bacteroides xylanisolvens, Bacteroides caccae, Bacteroides cellulosilyticus, Bacteroides faecis, Bacteroides fragilis, Bacteroides uniformis, Bacteroides vulgatus, Odoribacter splanchnicus, Parabacteroides distasonis, Parabacteroides merdae, Alistipes putredinis, and Alistipes shahii.

[0323] In one embodiment, the present disclosure provides a composition comprising a purified bacterial strain belonging to the Escherichia species (e.g., Escherichia species 3_2_53FAA) and one or more purified bacterial strains (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20) selected from the group consisting of Bacteroides ovatus, Bacteroides thetaiotamicron, Bacteroides xylanisolvens, Bacteroides caccae, Bacteroides cellulosilyticus, Bacteroides faecis, Bacteroides fragilis, Bacteroides uniformis, Bacteroides vulgatus, Odoribacter splanchnicus, Parabacteroides distasonis, Parabacteroides merdae, Alistipes putredinis, and Alistipes shahii.

[0324] In one embodiment, the disclosure includes purified bacterial strains belonging to the Escherichia species (e.g., Escherichia species 3_2_53FAA), and Bacteroides ovatus, Bacteroides thetaiotamicron, Bacteroides xylanisolvens, Bacteroides caccae, Bacteroides cellulosilyticus, Bacteroides faecis, Bacteroides fragilis, Bacteroides uniformis, Bacteroides vulgatus, Odoribacter splanchnicus, Parabacteroides distasonis, Parabacteroides merdae, Alistipes putredinis, and Alistipes The present invention provides a composition essentially consisting of one or more purified bacterial strains (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20) selected from the group consisting of shahii. In some embodiments, as used herein, “essentially consisting of” means a composition that does not contain any additional therapeutically active bacterial strains.

[0325] In one embodiment, the bacterial composition comprises a purified bacterial strain containing a 16S rDNA sequence having at least 97% sequence identity with the nucleic acid sequence shown as Sequence ID No. 36, and one or more purified bacterial strains containing a 16S rDNA sequence having at least 97% sequence identity with the nucleic acid sequences shown as Sequence ID Nos. 1-7, 21-24, 26, 29, and 33.

[0326] In one embodiment, the bacterial composition comprises a purified bacterial strain containing a 16S rDNA sequence having at least 97% sequence identity with the nucleic acid sequence shown as Sequence ID No. 36, and one or more purified bacterial strains containing a 16S rDNA sequence having at least 97% sequence identity with the nucleic acid sequences shown as Sequence ID Nos. 1-7, 21-24, 26, 29, and 33.

[0327] In one embodiment, the bacterial composition essentially consists of a purified bacterial strain containing a 16S rDNA sequence having at least 97% sequence identity with the nucleic acid sequence shown as Sequence ID No. 36, and one or more purified bacterial strains containing a 16S rDNA sequence having at least 97% sequence identity with the nucleic acid sequences shown as Sequence ID Nos. 1-7, 21-24, 26, 29, and 33.

[0328] In one embodiment, the present disclosure provides a composition comprising a purified bacterial strain belonging to the Fusobacterium species (e.g., Fusobacterium mortiferum) and one or more purified bacterial strains (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20) selected from the group consisting of Bacteroides ovatus, Bacteroides thetaiotamicron, Bacteroides xylanisolvens, Bacteroides caccae, Bacteroides cellulosilyticus, Bacteroides faecis, Bacteroides fragilis, Bacteroides uniformis, Bacteroides vulgatus, Odoribacter splanchnicus, Parabacteroides distasonis, Parabacteroides merdae, Alistipes putredinis, and Alistipes shahii.

[0329] In one embodiment, the present disclosure provides a composition comprising a purified bacterial strain belonging to the Fusobacterium species (e.g., Fusobacterium mortiferum) and one or more purified bacterial strains (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20) selected from the group consisting of Bacteroides ovatus, Bacteroides thetaiotamicron, Bacteroides xylanisolvens, Bacteroides caccae, Bacteroides cellulosilyticus, Bacteroides faecis, Bacteroides fragilis, Bacteroides uniformis, Bacteroides vulgatus, Odoribacter splanchnicus, Parabacteroides distasonis, Parabacteroides merdae, Alistipes putredinis, and Alistipes shahii.

[0330] In one embodiment, the present disclosure provides a composition comprising a purified bacterial strain belonging to the Fusobacterium species (e.g., Fusobacterium mortiferum) and one or more purified bacterial strains (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20) selected from the group consisting of Bacteroides ovatus, Bacteroides thetaiotamicron, Bacteroides xylanisolvens, Bacteroides caccae, Bacteroides cellulosilyticus, Bacteroides faecis, Bacteroides fragilis, Bacteroides uniformis, Bacteroides vulgatus, Odoribacter splanchnicus, Parabacteroides distasonis, Parabacteroides merdae, Alistipes putredinis, and Alistipes shahii. In some embodiments, as used herein, “essentially consisting of” refers to a composition that does not contain any additional therapeutically active bacterial strains.

[0331] In one embodiment, the bacterial composition comprises a purified bacterial strain containing a 16S rDNA sequence having at least 97% sequence identity with the nucleic acid sequence shown as Sequence ID No. 34, and one or more purified bacterial strains containing a 16S rDNA sequence having at least 97% sequence identity with the nucleic acid sequences shown as Sequence ID Nos. 1-7, 21-24, 26, 29, and 33.

[0332] In one embodiment, the bacterial composition comprises a purified bacterial strain containing a 16S rDNA sequence having at least 97% sequence identity with the nucleic acid sequence shown as Sequence ID No. 34, and one or more purified bacterial strains containing a 16S rDNA sequence having at least 97% sequence identity with the nucleic acid sequences shown as Sequence ID Nos. 1-7, 21-24, 26, 29, and 33.

[0333] In one embodiment, the bacterial composition essentially consists of a purified bacterial strain containing a 16S rDNA sequence having at least 97% sequence identity with the nucleic acid sequence shown as Sequence ID No. 34, and one or more purified bacterial strains containing a 16S rDNA sequence having at least 97% sequence identity with the nucleic acid sequences shown as Sequence ID Nos. 1-7, 21-24, 26, 29, and 33.

[0334] In one embodiment, the disclosure includes purified bacterial strains belonging to the Escherichia species (e.g., E. coli (e.g., Escherichia species 3_2_53FAA)), purified bacterial strains belonging to the Fusobacterium species (e.g., Fusobacterium mortiferum), and Collinsella aerofaciens, Bacteroides ovatus, Bacteroides thetaiotamicron, Bacteroides xylanisolvens, Bacteroides caccae, Bacteroides cellulosilyticus, Bacteroides faecis, Bacteroides fragilis, Bacteroides uniformis, Bacteroides vulgatus, Odoribacter splanchnicus, Parabacteroides distasonis, Parabacteroides merdae, Alistipes putredinis, Alistipes shahii, Bifidobacterium pseudocatenulatum, and Bifidobacterium. The present invention provides a composition comprising one or more purified bacterial strains selected from the group consisting of adolescentis, Bifidobacterium longum, Clostridium citroniae, Clostridium clostridioforme, Clostridium bifermentans, Clostridium sordelli, Clostridium innocuum, Erysipelatoclostridium ramosum, Erysipelotrichaceae bacterium 6145, Eubacterium hallii, Eubacterium rectale, Anaerostipes caccae, Blautia obeum, Blautia producta, Coprococcus comes, Dorea longicatena, Agathobaculum butyriciproducens, and Phascolarctobacterium faecis.See PCT International Publication WO2019 / 118515, which is incorporated in its entirety herein by reference.

[0335] In one embodiment, the disclosure includes purified bacterial strains belonging to the Escherichia species (e.g., E. coli (e.g., Escherichia species 3_2_53FAA)), purified bacterial strains belonging to the Fusobacterium species (e.g., Fusobacterium mortiferum), and Collinsella aerofaciens, Bacteroides ovatus, Bacteroides thetaiotamicron, Bacteroides xylanisolvens, Bacteroides caccae, Bacteroides cellulosilyticus, Bacteroides faecis, Bacteroides fragilis, Bacteroides uniformis, Bacteroides vulgatus, Odoribacter splanchnicus, Parabacteroides distasonis, Parabacteroides merdae, Alistipes putredinis, Alistipes shahii, Bifidobacterium pseudocatenulatum, and Bifidobacterium. The present invention provides a composition comprising one or more purified bacterial strains selected from the group consisting of adolescentis, Bifidobacterium longum, Clostridium citroniae, Clostridium clostridioforme, Clostridium bifermentans, Clostridium sordelli, Clostridium innocuum, Erysipelatoclostridium ramosum, Erysipelotrichaceae bacterium 6_1_45, Eubacterium hallii, Eubacterium rectale, Anaerostipes caccae, Blautia obeum, Blautia producta, Coprococcus comes, Dorea longicatena, Agathobaculum butyriciproducens, and Phascolarctobacterium faecis.

[0336] In one embodiment, the disclosure includes purified bacterial strains belonging to the Escherichia species (e.g., E. coli (e.g., Escherichia species 3_2_53FAA)), purified bacterial strains belonging to the Fusobacterium species (e.g., Fusobacterium mortiferum), and Collinsella aerofaciens, Bacteroides ovatus, Bacteroides thetaiotamicron, Bacteroides xylanisolvens, Bacteroides caccae, Bacteroides cellulosilyticus, Bacteroides faecis, Bacteroides fragilis, Bacteroides uniformis, Bacteroides vulgatus, Odoribacter splanchnicus, Parabacteroides distasonis, Parabacteroides merdae, Alistipes putredinis, Alistipes shahii, Bifidobacterium pseudocatenulatum, and Bifidobacterium. The present invention provides a composition essentially consisting of one or more purified bacterial strains selected from the group consisting of adolescentis, Bifidobacterium longum, Clostridium citroniae, Clostridium clostridioforme, Clostridium bifermentans, Clostridium sordelli, Clostridium innocuum, Erysipelatoclostridium ramosum, Erysipelotrichaceae bacterium 6145, Eubacterium hallii, Eubacterium rectale, Anaerostipes caccae, Blautia obeum, Blautia producta, Coprococcus comes, Dorea longicatena, Agathobaculum butyriciproducens, and Phascolarctobacterium faecis.

[0337] In one embodiment, the bacterial composition comprises a purified bacterial strain containing a 16S rDNA sequence having at least 97% sequence identity with the nucleic acid sequence shown as Sequence ID No. 36, a purified bacterial strain containing a 16S rDNA sequence having at least 97% sequence identity with the nucleic acid sequence shown as Sequence ID No. 34, and one or more purified bacterial strains containing 16S rDNA sequences having at least 97% sequence identity with the nucleic acid sequences shown as Sequence IDs No. 1 to 33 and 35.

[0338] In one embodiment, the bacterial composition comprises a purified bacterial strain containing a 16S rDNA sequence having at least 97% sequence identity with the nucleic acid sequence shown as Sequence ID No. 36, a purified bacterial strain containing a 16S rDNA sequence having at least 97% sequence identity with the nucleic acid sequence shown as Sequence ID No. 34, and one or more purified bacterial strains containing 16S rDNA sequences having at least 97% sequence identity with the nucleic acid sequences shown as Sequence IDs No. 1 to 33 and 35.

[0339] In one embodiment, the bacterial composition essentially comprises a purified bacterial strain containing a 16S rDNA sequence having at least 97% sequence identity with the nucleic acid sequence shown as Sequence ID No. 36, a purified bacterial strain containing a 16S rDNA sequence having at least 97% sequence identity with the nucleic acid sequence shown as Sequence ID No. 34, and one or more purified bacterial strains containing a 16S rDNA sequence having at least 97% sequence identity with the nucleic acid sequences shown as Sequence IDs No. 1 to 33 and 35.

[0340] It should be understood that any of the compositions described herein may contain multiple strains of a particular bacterial species. For example, in some embodiments, a composition may contain two strains of Parabacteroides distasonis and / or two strains of Parabacteroides merdae.

[0341] The disclosure also relates to Collinsella aerofaciens, Bacteroides ovatus, Bacteroides thetaiotamicron, Bacteroides xylanisolvens, Bacteroides caccae, Bacteroides cellulosilyticus, Bacteroides faecis, Bacteroides fragilis, Bacteroides uniformis, Bacteroides vulgatus, Odoribacter splanchnicus, Parabacteroides distasonis, Parabacteroides merdae, Alistipes putredinis, Alistipes shahii, Bifidobacterium pseudocatenulatum, Bifidobacterium adolescentis, Bifidobacterium longum, Clostridium citroniae, Clostridium clostridioforme, Clostridium bolteae, Clostridium bifermentans, Clostridium sordellii, Clostridium The composition includes bacterial strains having close sequence identity or homology to and / or contained therein in the species innocuum, Erysipelatoclostridium ramosum, Erysipelotrichaceae bacterium 6_1_45, Eubacterium hallii, Eubacterium rectale, Anaerostipes caccae, Blautia obeum, Blautia producta, Coprococcus comes, Dorea longicatena, Agathobaculum butyriciproducens, Phascolarctobacterium faecis, Escherichia species 3_2_53FAA, and Fusobacterium mortiferum.

[0342] In some embodiments, the compositions disclosed herein include two or more bacterial strains. In some embodiments, the compositions described herein include at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, at least 10, at least 11, at least 12, at least 13, at least 14, at least 15, at least 16, at least 17, at least 18, at least 19, or at least 20, at least 21, at least 22, at least 23, at least 24, at least 25, at least 26, at least 27, at least 28, at least 29, at least 30, at least 31, at least 32, at least 33, at least 34, at least 35, at least 36, or more bacterial strains (e.g., purified bacterial strains).

[0343] In some embodiments, the composition does not contain Fusobacterium mortiferum. In some embodiments, the composition does not contain bacterial strains considered to pose a potential clinical risk. In some embodiments, the composition does not contain C. bifermentans, B. fragilis, and / or C. sordellii. In some embodiments, the composition does not contain bacterial strains belonging to the family Eubacteriaceae, Eubacterium hallii, and / or Eubacterium rectale.

[0344] It should be understood that the terms “bacteria” and “bacterial strain” as used herein are interchangeable. Compositions described herein that include multiple purified bacterial strains may also be referred to as “live bacterial products.”

[0345] In one embodiment, the disclosure provides a viable bacterial product referred to as "33-mixB" (see Figures 3 and 5). As shown in Figure 5, the live bacterial product 33-mixB contains the following species Collinsella aerofaciens, Bacteroides ovatus, Bacteroides thetaiotamicron, Bacteroides xylanisolvens, Bacteroides caccae, Bacteroides cellulosilyticus, Bacteroides faecis, Bacteroides uniformis, Bacteroides vulgatus, Odoribacter splanchnicus, Parabacteroides distasonis, Parabacteroides merdae, Alistipes putredinis, Alistipes shahii, Bifidobacterium pseudocatenulatum, Bifidobacterium adolescentis, Bifidobacterium longum, Clostridium citroniae, Clostridium clostridioforme, Clostridium innocuum, Erysipelatoclostridium ramosum, Erysipelotrichaceae bacterium 6_1_45, Eubacterium hallii, Eubacterium rectale, Anaerostipes caccae, Blautia obeum, Blautia producta, Coprococcus comes, Dorea longicatena, Agathobaculum butyriciproducens, Phascolarctobacterium faecis, Escherichia species 3_2_53FAA, and Fusobacterium Contains 33 bacterial strains related to P. mortiferum.

[0346] In some embodiments, the composition comprises Collinsella aerofaciens, Bacteroides ovatus, Bacteroides thetaiotamicron, Bacteroides xylanisolvens, Bacteroides caccae, Bacteroides cellulosilyticus, Bacteroides faecis, Bacteroides uniformis, Bacteroides vulgatus, Odoribacter splanchnicus, Parabacteroides distasonis, Parabacteroides merdae, Alistipes putredinis, Alistipes shahii, Bifidobacterium pseudocatenulatum, Bifidobacterium adolescentis, Bifidobacterium longum, Clostridium citroniae, Clostridium clostridioforme, Clostridium innocuum, Erysipelatoclostridium ramosum, Erysipelotrichaceae bacterium 6_1_45, Eubacterium It includes two or more bacterial species (e.g., two, three, four, five, or more) selected from the group consisting of hallii, Eubacterium rectale, Anaerostipes caccae, Blautia obeum, Blautia producta, Coprococcus comes, Dorea longicatena, Agathobaculum butyriciproducens, Phascolarctobacterium faecis, Escherichia species 3_2_53FAA, and Fusobacterium mortiferum.

[0347] In some embodiments, the composition comprises Collinsella aerofaciens, Bacteroides ovatus, Bacteroides thetaiotamicron, Bacteroides xylanisolvens, Bacteroides caccae, Bacteroides cellulosilyticus, Bacteroides faecis, Bacteroides uniformis, Bacteroides vulgatus, Odoribacter splanchnicus, Parabacteroides distasonis, Parabacteroides merdae, Alistipes putredinis, Alistipes shahii, Bifidobacterium pseudocatenulatum, Bifidobacterium adolescentis, Bifidobacterium longum, Clostridium citroniae, Clostridium clostridioforme, Clostridium innocuum, Erysipelatoclostridium ramosum, Erysipelotrichaceae bacterium 6_1_45, Eubacterium It consists of two or more bacterial species (e.g., two, three, four, five, or more) selected from the group consisting of hallii, Eubacterium rectale, Anaerostipes caccae, Blautia obeum, Blautia producta, Coprococcus comes, Dorea longicatena, Agathobaculum butyriciproducens, Phascolarctobacterium faecis, Escherichia species 3_2_53FAA, and Fusobacterium mortiferum.

[0348] In some embodiments, the composition comprises the following 33 bacterial species: Collinsella aerofaciens, Bacteroides ovatus, Bacteroides thetaiotamicron, Bacteroides xylanisolvens, Bacteroides caccae, Bacteroides cellulosilyticus, Bacteroides faecis, Bacteroides uniformis, Bacteroides vulgatus, Odoribacter splanchnicus, Parabacteroides distasonis, Parabacteroides merdae, Alistipes putredinis, Alistipes shahii, Bifidobacterium pseudocatenulatum, Bifidobacterium adolescentis, Bifidobacterium longum, Clostridium citroniae, Clostridium clostridioforme, Clostridium innocuum, Erysipelatoclostridium ramosum, Erysipelotrichaceae bacterium 6_1_45, Eubacterium hallii, Eubacterium rectale, Anaerostipes caccae, Blautia obeum, Blautia producta, Coprococcus comes, Dorea longicatena, Agathobaculum butyriciproducens, Phascolarctobacterium faecis, Escherichia species 3_2_53FAA, and Fusobacterium mortiferum.

[0349] In some embodiments, the composition comprises the following 33 bacterial species: Collinsella aerofaciens, Bacteroides ovatus, Bacteroides thetaiotamicron, Bacteroides xylanisolvens, Bacteroides caccae, Bacteroides cellulosilyticus, Bacteroides faecis, Bacteroides uniformis, Bacteroides vulgatus, Odoribacter splanchnicus, Parabacteroides distasonis, Parabacteroides merdae, Alistipes putredinis, Alistipes shahii, Bifidobacterium pseudocatenulatum, Bifidobacterium adolescentis, Bifidobacterium longum, Clostridium citroniae, Clostridium clostridioforme, Clostridium innocuum, Erysipelatoclostridium ramosum, Erysipelotrichaceae bacterium 6_1_45, Eubacterium hallii, Eubacterium rectale, Anaerostipes caccae, Blautia obeum, Blautia producta, Coprococcus comes, Dorea longicatena, Agathobaculum butyriciproducens, Phascolarctobacterium faecis, Escherichia species 3_2_53FAA, and Fusobacterium mortiferum.

[0350] In some embodiments, the composition essentially consists of the following 33 bacterial species: Collinsella aerofaciens, Bacteroides ovatus, Bacteroides thetaiotamicron, Bacteroides xylanisolvens, Bacteroides caccae, Bacteroides cellulosilyticus, Bacteroides faecis, Bacteroides uniformis, Bacteroides vulgatus, Odoribacter splanchnicus, Parabacteroides distasonis, Parabacteroides merdae, Alistipes putredinis, Alistipes shahii, Bifidobacterium pseudocatenulatum, Bifidobacterium adolescentis, Bifidobacterium longum, Clostridium citroniae, Clostridium clostridioforme, Clostridium innocuum, Erysipelatoclostridium ramosum, Erysipelotrichaceae bacterium 6_1_45, Eubacterium hallii, Eubacterium rectale, Anaerostipes caccae, Blautia obeum, Blautia producta, Coprococcus comes, Dorea longicatena, Agathobaculum butyriciproducens, Phascolarctobacterium faecis, Escherichia species 3_2_53FAA, and Fusobacterium mortiferum. In some embodiments, as used herein, “essentially consisting of” refers to a composition that does not contain any additional therapeutically active bacterial strains.

[0351] In one embodiment, the bacterial composition comprises two or more (e.g., two, three, four, five, or more) purified bacterial strains, each containing a 16S rDNA sequence having at least 97% sequence identity with a nucleic acid sequence selected from SEQ ID NOs: 1 to 36. In one embodiment, the bacterial composition comprises two or more (e.g., two, three, four, five, or more) purified bacterial strains, each containing a 16S rDNA sequence having at least 97% sequence identity with a nucleic acid sequence selected from SEQ ID NOs: 1 to 36. In one embodiment, the bacterial composition essentially consists of two or more (e.g., two, three, four, five, or more) purified bacterial strains, each containing a 16S rDNA sequence having at least 97% sequence identity with a nucleic acid sequence selected from SEQ ID NOs: 1 to 36.

[0352] In one embodiment, the bacterial composition comprises 33 bacterial strains, each containing a 16S rDNA sequence having at least 97% sequence identity with a nucleic acid sequence selected from SEQ ID NOs: 1-15, 17-32, 34, and 36. In one embodiment, the bacterial composition comprises 33 bacterial strains, each containing a 16S rDNA sequence having at least 97% sequence identity with a nucleic acid sequence selected from SEQ ID NOs: 1-15, 17-32, 34, and 36. In one embodiment, the bacterial composition essentially consists of 33 bacterial strains, each containing a 16S rDNA sequence having at least 97% sequence identity with a nucleic acid sequence selected from SEQ ID NOs: 1-15, 17-32, 34, and 36.

[0353] In one embodiment, the disclosure provides a viable bacterial product referred to as “27-mix” (see Figures 3 and 5). As shown in Figure 5, the 27-mix of live bacterial products contains 27 bacterial strains related to the following species: Collinsella aerofaciens, Bacteroides ovatus, Bacteroides thetaiotamicron, Bacteroides xylanisolvens, Bacteroides cellulosilyticus, Bacteroides uniformis, Bacteroides vulgatus, Parabacteroides distasonis, Alistipes putredinis, Alistipes shahii, Bifidobacterium adolescentis, Bifidobacterium longum, Clostridium citroniae, Clostridium clostridioforme, Clostridium innocuum, Erysipelatoclostridium ramosum, Erysipelotrichaceae bacterium 6145, Eubacterium rectale, Anaerostipes caccae, Blautia obeum, Blautia producta, Coprococcus comes, Dorea longicatena, Agathobaculum butyriciproducens, Phascolarctobacterium faecis, Escherichia species 3_2_53FAA, and Fusobacterium mortiferum.

[0354] In some embodiments, the composition comprises Collinsella aerofaciens, Bacteroides ovatus, Bacteroides thetaiotamicron, Bacteroides xylanisolvens, Bacteroides cellulosilyticus, Bacteroides uniformis, Bacteroides vulgatus, Parabacteroides distasonis, Alistipes putredinis, Alistipes shahii, Bifidobacterium adolescentis, Bifidobacterium longum, Clostridium citroniae, Clostridium clostridioforme, Clostridium innocuum, Erysipelatoclostridium ramosum, Erysipelotrichaceae bacterium 6_1_45, Eubacterium rectale, Anaerostipes caccae, Blautia obeum, Blautia producta, Coprococcus comes, Dorea longicatena, Agathobaculum It includes two or more bacterial species (e.g., two, three, four, five, or more) selected from the group consisting of butyriciproducens, Phascolarctobacterium faecis, Escherichia species 3_2_53FAA, and Fusobacterium mortiferum.

[0355] In some embodiments, the composition comprises the following 27 bacterial species: Collinsella aerofaciens, Bacteroides ovatus, Bacteroides thetaiotamicron, Bacteroides xylanisolvens, Bacteroides cellulosilyticus, Bacteroides uniformis, Bacteroides vulgatus, Parabacteroides distasonis, Alistipes putredinis, Alistipes shahii, Bifidobacterium adolescentis, Bifidobacterium longum, Clostridium citroniae, Clostridium clostridioforme, Clostridium innocuum, Erysipelatoclostridium ramosum, Erysipelotrichaceae bacterium 6_1_45, Eubacterium rectale, Anaerostipes caccae, Blautia obeum, Blautia producta, Coprococcus comes, Dorea longicatena, Agathobaculum butyriciproducens, Phascolarctobacterium faecis, Escherichia species 3_2_53FAA, and Fusobacterium mortiferum.

[0356] In some embodiments, the composition comprises the following 27 bacterial species: Collinsella aerofaciens, Bacteroides ovatus, Bacteroides thetaiotamicron, Bacteroides xylanisolvens, Bacteroides cellulosilyticus, Bacteroides uniformis, Bacteroides vulgatus, Parabacteroides distasonis, Alistipes putredinis, Alistipes shahii, Bifidobacterium adolescentis, Bifidobacterium longum, Clostridium citroniae, Clostridium clostridioforme, Clostridium innocuum, Erysipelatoclostridium ramosum, Erysipelotrichaceae bacterium 6_1_45, Eubacterium rectale, Anaerostipes caccae, Blautia obeum, Blautia producta, Coprococcus comes, Dorea longicatena, Agathobaculum butyriciproducens, Phascolarctobacterium faecis, Escherichia species 3_2_53FAA, and Fusobacterium mortiferum.

[0357] In some embodiments, the composition essentially consists of the following 27 bacterial species: Collinsella aerofaciens, Bacteroides ovatus, Bacteroides thetaiotamicron, Bacteroides xylanisolvens, Bacteroides cellulosilyticus, Bacteroides uniformis, Bacteroides vulgatus, Parabacteroides distasonis, Alistipes putredinis, Alistipes shahii, Bifidobacterium adolescentis, Bifidobacterium longum, Clostridium citroniae, Clostridium clostridioforme, Clostridium innocuum, Erysipelatoclostridium ramosum, Erysipelotrichaceae bacterium 6145, Eubacterium rectale, Anaerostipes caccae, Blautia obeum, Blautia producta, Coprococcus comes, Dorea Longicatena, Agathobaculum butyriciproducens, Phascolarctobacterium faecis, Escherichia species 3_2_53FAA, and Fusobacterium mortiferum. In some embodiments, as used herein, “essentially consisting of” refers to a composition that does not contain any additional therapeutically active bacterial strains.

[0358] In one embodiment, the bacterial composition comprises two or more (e.g., 2, 3, 4, 5, or more) purified bacterial strains, each containing a 16S rDNA sequence having at least 97% sequence identity with a nucleic acid sequence selected from SEQ ID NOs: 2, 4-9, 11-15, 17-20, 22, 24-27, 29-34, and 36. In one embodiment, the bacterial composition comprises two or more (e.g., 2, 3, 4, 5, or more) purified bacterial strains, each containing a 16S rDNA sequence having at least 97% sequence identity with a nucleic acid sequence selected from SEQ ID NOs: 2, 4-9, 11-15, 17-20, 22, 24-27, 29-34, and 36. In one embodiment, the bacterial composition essentially consists of two or more (e.g., 2, 3, 4, 5, or more) purified bacterial strains, each containing a nucleic acid sequence selected from Sequence IDs 2, 4-9, 11-15, 17-20, 22, 24-27, 29-34, and 36, and a 16S rDNA sequence having at least 97% sequence identity.

[0359] In one embodiment, the bacterial composition comprises 27 bacterial strains, each containing a 16S rDNA sequence having at least 97% sequence identity with a nucleic acid sequence selected from SEQ ID NOs: 2, 4-9, 11-15, 17-20, 22, 24-27, 29-34, and 36. In one embodiment, the bacterial composition comprises 27 bacterial strains, each containing a 16S rDNA sequence having at least 97% sequence identity with a nucleic acid sequence selected from SEQ ID NOs: 2, 4-9, 11-15, 17-20, 22, 24-27, 29-34, and 36. In one embodiment, the bacterial composition essentially consists of 27 bacterial strains, each containing a 16S rDNA sequence having at least 97% sequence identity with a nucleic acid sequence selected from SEQ ID NOs: 2, 4-9, 11-15, 17-20, 22, 24-27, 29-34, and 36.

[0360] In one embodiment, the disclosure provides a viable bacterial product referred to as “23-mix” (see Figures 3 and 5). As shown in Figure 5, the 23-mix of bacterial products contains 23 bacterial strains related to the following species: Bacteroides ovatus, Bacteroides thetaiotamicron, Bacteroides xylanisolvens, Bacteroides caccae, Bacteroides cellulosilyticus, Bacteroides faecis, Bacteroides uniformis, Bacteroides vulgatus, Alistipes putredinis, Alistipes shahii, Clostridium citroniae, Clostridium clostridioforme, Clostridium innocuum, Erysipelatoclostridium ramosum, Erysipelotrichaceae bacterium 6_1_45, Eubacterium hallii, Eubacterium rectale, Blautia obeum, Blautia producta, Coprococcus comes, Dorea longicatena, Escherichia sp. 3_2_53FAA, and Fusobacterium mortiferum.

[0361] In some embodiments, the compositions contain Bacteroides ovatus, Bacteroides thetaiotamicron, Bacteroides xylanisolvens, Bacteroides caccae, Bacteroides cellulosilyticus, Bacteroides faecis, Bacteroides uniformis, Bacteroides vulgatus, Alistipes putredinis, Alistipes shahii, Clostridium citroniae, Clostridium clostridioforme, Clostridium innocuum, Erysipelotrichaceae bacterium 6_1_45, Eubacterium hallii, Eubacterium rectale, Blautia obeum, Blautia producta, Coprococcus comes, Dorea longicatena, Escherichia species 3_2_53FAA, and Fusobacterium It includes two or more bacterial species (e.g., two, three, four, five, or more) selected from the group consisting of mortiferum.

[0362] The following strains include: Bacteroides ovatus, Bacteroides thetaiotamicron, and Bacteroides xylanisolvens、Bacteroides caccae、Bacteroides cellulosilyticus、Bacteroides faecis、Bacteroides uniformis、Bacteroides vulgatus、Alistipes putredinis、Alistipes shahii、Clostridium citroniae、Clostridium clostridioforme、Clostridium innocuum、Erysipelatoclostridium ramosum、Erysipelotrichaceae bacterium 6_1_45、Eubacterium hallii、Eubacterium rectale、Blautia obeum、Blautia producta、Coprococcus comes、Dorea longicatena, Escherichia, 3_2_53FAA, and Fusobacterium mortiferum.

[0363] It contains the following 23 generic strains: Bacteroides ovatus, Bacteroides thetaiotamicron, and Bacteroides xylanisolvens、Bacteroides caccae、Bacteroides cellulosilyticus、Bacteroides faecis、Bacteroides uniformis、Bacteroides vulgatus、Alistipes putredinis、Alistipes shahii、Clostridium citroniae、Clostridium clostridioforme、Clostridium innocuum、Erysipelatoclostridium ramosum、Erysipelotrichaceae bacterium 6_1_45、Eubacterium hallii、Eubacterium rectale、Blautia obeum、Blautia producta、Coprococcus comes、Dorea longicatena, Escherichia, 3_2_53FAA, and Fusobacterium mortiferum.

[0364] In some embodiments, the composition essentially consists of the following 23 bacterial strains: Bacteroides ovatus, Bacteroides thetaiotamicron, Bacteroides xylanisolvens, Bacteroides caccae, Bacteroides cellulosilyticus, Bacteroides faecis, Bacteroides uniformis, Bacteroides vulgatus, Alistipes putredinis, Alistipes shahii, Clostridium citroniae, Clostridium clostridioforme, Clostridium innocuum, Erysipelatoclostridium ramosum, Erysipelotrichaceae bacterium 6_1_45, Eubacterium hallii, Eubacterium rectale, Blautia obeum, Blautia producta, Coprococcus comes, Dorea longicatena, Escherichia species 3_2_53FAA, and Fusobacterium Mortiferum. In some embodiments, as used herein, “essentially consisting of” refers to a composition that does not contain any additional therapeutically active bacterial strains.

[0365] In one embodiment, the bacterial composition comprises two or more (e.g., two, three, four, five, or more) purified bacterial strains, each containing a 16S rDNA sequence having at least 97% sequence identity with a nucleic acid sequence selected from SEQ ID NOs: 1-7, 11-15, 17-20, 24-26, 28, 29, 34, and 36. In one embodiment, the bacterial composition comprises two or more (e.g., two, three, four, five, or more) purified bacterial strains, each containing a 16S rDNA sequence having at least 97% sequence identity with a nucleic acid sequence selected from SEQ ID NOs: 1-7, 11-15, 17-20, 24-26, 28, 29, 34, and 36. In one embodiment, the bacterial composition essentially consists of two or more (e.g., two, three, four, five, or more) purified bacterial strains, each containing a 16S rDNA sequence having at least 97% sequence identity with a nucleic acid sequence selected from SEQ ID NOs: 1-7, 11-15, 17-20, 24-26, 28, 29, 34, and 36.

[0366] In one embodiment, the bacterial composition comprises 23 bacterial strains, each containing a 16S rDNA sequence having at least 97% sequence identity with a nucleic acid sequence selected from SEQ ID NOs: 1-7, 11-15, 17-20, 24-26, 28, 29, 34, and 36. In one em...

Claims

1. A pharmaceutical composition for use in a method for inhibiting the colonization of pathogenic bacteria belonging to the species Klebsiella pneumoniae in a target area, wherein the pharmaceutical composition is as follows: (i) bacterial strains belonging to the species Bacteroides ovatus; (ii) Bacterial strains belonging to the species Bacteroides vulgatus; (iii) A bacterial strain belonging to the species Bifidobacterium longum; (iv) A bacterial strain belonging to the species Blautia coccoides; (v) Bacterial strains belonging to the species Clostridium citroniae; (vi) Bacterial strains belonging to the species Clostridium clostridioforme; (vii) A bacterial strain belonging to the species Clostridium innocuum; (viiii) A bacterial strain belonging to the species Dorea longicatena; (ix) A bacterial strain belonging to the species Erysipelatoclostridium ramosum; (x) A bacterial strain belonging to the species Blautia obeum; (xi) A bacterial strain belonging to the species Alistipes putredinis; (xii) A bacterial strain belonging to the species Collinsella aerofaciens; (xiiii) A bacterial strain belonging to the species Phascolarctobacterium faecium; (xiv) bacterial strains belonging to species Fusobacterium mortiferum; and (xv) Bacterial strains belonging to the species Escherichia coli Includes, The combinations of (i) to (xv) inhibit the replication and / or survival of pathogenic bacteria belonging to the species Klebsiella pneumoniae. The pharmaceutical product is characterized by not including (a) a bacterial strain belonging to the species Bacteroides fragilis, not including (b) a bacterial strain belonging to the species Paraclostridium bifermentans, and / or (c) a bacterial strain belonging to the species Clostridium sordellii.

2. A pharmaceutical composition for use in a method for inhibiting the colonization of pathogenic bacteria belonging to the species Klebsiella pneumoniae in a target area, wherein the pharmaceutical composition is as follows: (i) A bacterial strain containing a 16S rDNA sequence having at least 97% sequence identity with the nucleic acid sequence of Sequence ID No. 4; (ii) A bacterial strain containing a 16S rDNA sequence having at least 97% sequence identity with the nucleic acid sequence of Sequence ID No. 7; (iii) A bacterial strain containing a 16S rDNA sequence having at least 97% sequence identity with the nucleic acid sequence of Sequence ID No. 9; (iv) A bacterial strain containing a 16S rDNA sequence having at least 97% sequence identity with the nucleic acid sequence of Sequence ID No. 11; (v) A bacterial strain containing a 16S rDNA sequence having at least 97% sequence identity with the nucleic acid sequence of Sequence ID No. 12; (vi) A bacterial strain containing a 16S rDNA sequence having at least 97% sequence identity with the nucleic acid sequence of Sequence ID No. 13; (vii) A bacterial strain containing a 16S rDNA sequence having at least 97% sequence identity with the nucleic acid sequence of Sequence ID No. 15; (viiii) A bacterial strain containing a 16S rDNA sequence having at least 97% sequence identity with the nucleic acid sequence of Sequence ID No. 18; (ix) A bacterial strain containing a 16S rDNA sequence having at least 97% sequence identity with the nucleic acid sequence of Sequence ID No. 19; (x) A bacterial strain containing a 16S rDNA sequence having at least 97% sequence identity with the nucleic acid sequence of Sequence ID No. 25; (xi) A bacterial strain containing a 16S rDNA sequence having at least 97% sequence identity with the nucleic acid sequence of Sequence ID No. 26; (xi) A bacterial strain containing a 16S rDNA sequence having at least 97% sequence identity with the nucleic acid sequence of Sequence ID No. 27; (xiiii) A bacterial strain containing a 16S rDNA sequence having at least 97% sequence identity with the nucleic acid sequence of Sequence ID No. 31; (xiv) A bacterial strain containing a 16S rDNA sequence having at least 97% sequence identity with the nucleic acid sequence of Sequence ID No. 34; and (xv) A bacterial strain containing a 16S rDNA sequence having at least 97% sequence identity with the nucleic acid sequence of Sequence ID No.

36. Includes, The combinations of (i) to (xv) inhibit the replication and / or survival of pathogenic bacteria belonging to the species Klebsiella pneumoniae. The pharmaceutical product is characterized by (a) not including a bacterial strain containing a 16S rDNA sequence having at least 97% sequence identity with the nucleic acid sequence of Sequence ID No. 33, (b) not including a bacterial strain containing a 16S rDNA sequence having at least 97% sequence identity with the nucleic acid sequence of Sequence ID No. 35, and / or (c) not including a bacterial strain containing a 16S rDNA sequence having at least 97% sequence identity with the nucleic acid sequence of Sequence ID No.

16.

3. (i) The bacterial strain contains a 16S rDNA sequence that has at least 99% sequence identity with the nucleic acid sequence of Sequence ID No. 4; The bacterial strain (ii) contains a 16S rDNA sequence that has at least 99% sequence identity with the nucleic acid sequence of Sequence ID No. 7; The bacterial strain (iii) contains a 16S rDNA sequence that has at least 99% sequence identity with the nucleic acid sequence of Sequence ID No. 9; The bacterial strain (iv) contains a 16S rDNA sequence that has at least 99% sequence identity with the nucleic acid sequence of Sequence ID No. 11; (v) The bacterial strain contains a 16S rDNA sequence that has at least 99% sequence identity with the nucleic acid sequence of Sequence ID No. 12; (vi) is a bacterial strain that contains a 16S rDNA sequence having at least 99% sequence identity with the nucleic acid sequence of Sequence ID No. 13; The bacterial strain (vii) contains a 16S rDNA sequence that has at least 99% sequence identity with the nucleic acid sequence of Sequence ID No. 15; The bacterial strain (viiii) contains a 16S rDNA sequence that has at least 99% sequence identity with the nucleic acid sequence of Sequence ID No. 18; The bacterial strain (ix) contains a 16S rDNA sequence that has at least 99% sequence identity with the nucleic acid sequence of Sequence ID No. 19; The bacterial strain (x) contains a 16S rDNA sequence that has at least 99% sequence identity with the nucleic acid sequence of Sequence ID No. 25; The bacterial strain (xi) contains a 16S rDNA sequence that has at least 99% sequence identity with the nucleic acid sequence of Sequence ID No. 26; The bacterial strain (xii) contains a 16S rDNA sequence that has at least 99% sequence identity with the nucleic acid sequence of Sequence ID No. 27; The bacterial strain (xiii) contains a 16S rDNA sequence that has at least 99% sequence identity with the nucleic acid sequence of Sequence ID No. 31; The bacterial strain (xiv) contains a 16S rDNA sequence that has at least 99% sequence identity with the nucleic acid sequence of Sequence ID No. 34; and The pharmaceutical product according to claim 2, wherein the bacterial strain (xv) contains a 16S rDNA sequence having at least 99% sequence identity with the nucleic acid sequence of Sequence ID No.

36.

4. The pharmaceutical product according to any one of claims 1 to 3, wherein the bacterial strain is freeze-dried.

5. The pharmaceutical product according to any one of claims 1 to 4, wherein one or more bacterial strains are of the spore type.

6. The pharmaceutical product according to any one of claims 1 to 5, wherein the pharmaceutical product comprises a bacterial strain originating from two or more human donors.

7. The pharmaceutical product according to any one of claims 1 to 6, wherein the bacterial strain is present in a plurality of pharmaceutical compositions comprising pharmaceutically acceptable excipients.

8. The pharmaceutical composition according to claim 7, wherein the pharmaceutical composition is formulated for oral delivery.

9. The pharmaceutical composition according to claim 7, wherein the pharmaceutical composition is formulated for rectal delivery.

10. A pharmaceutical composition formulated for delivery to the intestines, according to any one of claims 7 to 9.

11. The pharmaceutical composition according to any one of claims 7 to 10, wherein the pharmaceutical composition is formulated for delivery to the colon.

12. The pharmaceutical composition according to any one of claims 7 to 11, wherein the pharmaceutical composition comprises a pH-sensitive composition comprising one or more enteric-coated polymers.

13. The pharmaceutical product according to any one of claims 1 to 12, wherein the colonization by pathogenic bacteria is colonization in the target intestine.

14. The pharmaceutical product according to any one of claims 1 to 13, wherein the pathogenic bacterium is a pathogenic symbiont.

15. The pharmaceutical product according to claim 14, wherein a pathogenic symbiotic organism induces a Th1 immune response in a target.

Images